<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Parenteral versus oral iron therapy for adults and children with chronic kidney disease - O'Lone, EL - 2019 | Cochrane Library</title> <meta content="Parenteral versus oral iron therapy for adults and children with chronic kidney disease - O'Lone, EL - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007857.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Parenteral versus oral iron therapy for adults and children with chronic kidney disease - O'Lone, EL - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007857.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007857.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Parenteral versus oral iron therapy for adults and children with chronic kidney disease" name="citation_title"/> <meta content="Emma L O'Lone" name="citation_author"/> <meta content="The University of Sydney" name="citation_author_institution"/> <meta content="Elisabeth M Hodson" name="citation_author"/> <meta content="The Children's Hospital at Westmead" name="citation_author_institution"/> <meta content="elisabeth.hodson@health.nsw.gov.au" name="citation_author_email"/> <meta content="Ionut Nistor" name="citation_author"/> <meta content='"Grigore T. Popa" University of Medicine and Pharmacy' name="citation_author_institution"/> <meta content="Davide Bolignano" name="citation_author"/> <meta content="CNR ‐ Italian National Council of Research" name="citation_author_institution"/> <meta content="Angela C Webster" name="citation_author"/> <meta content="Jonathan C Craig" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD007857.pub3" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/02/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007857.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007857.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007857.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Anemia, Iron-Deficiency [blood, *therapy]; Blood Transfusion [statistics &amp; numerical data]; Cause of Death; Ferritins [blood]; Hemoglobin A [metabolism]; Injections, Intravenous; Iron Compounds [*administration &amp; dosage, adverse effects]; Kidney Failure, Chronic [blood, *complications]; Randomized Controlled Trials as Topic; Transferrin [metabolism]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007857.pub3&amp;doi=10.1002/14651858.CD007857.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="77cjsSG8";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007857\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007857\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007857\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007857\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","ru","pt","ms","ja","fr","zh_HANT","hr","fa","hu"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007857.pub3",title:"Parenteral versus oral iron therapy for adults and children with chronic kidney disease",firstPublishedDate:"Feb 21, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=77cjsSG8&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007857.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007857.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007857.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007857.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007857.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007857.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007857.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007857.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007857.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007857.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11606 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007857.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/full#CD007857-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/full#CD007857-sec-0094"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/full#CD007857-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/full#CD007857-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/full#CD007857-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/full#CD007857-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/full#CD007857-sec-0070"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/full#CD007857-sec-0088"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/appendices#CD007857-sec-0099"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/table_n/CD007857StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/table_n/CD007857StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Parenteral versus oral iron therapy for adults and children with chronic kidney disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/information#CD007857-cr-0002">Emma L O'Lone</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/information#CD007857-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Elisabeth M Hodson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/information#CD007857-cr-0004">Ionut Nistor</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/information#CD007857-cr-0005">Davide Bolignano</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/information#CD007857-cr-0006">Angela C Webster</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007857.pub3/information#CD007857-cr-0007">Jonathan C Craig</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/information/en#CD007857-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 February 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007857.pub3">https://doi.org/10.1002/14651858.CD007857.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007857-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007857-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007857-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007857-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007857-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007857-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007857-abs-0001" lang="en"> <section id="CD007857-sec-0001"> <h3 class="title" id="CD007857-sec-0001">Background</h3> <p>The anaemia seen in chronic kidney disease (CKD) may be exacerbated by iron deficiency. Iron can be provided through different routes, with advantages and drawbacks of each route. It remains unclear whether the potential harms and additional costs of intravenous (IV) compared with oral iron are justified. This is an update of a review first published in 2012. </p> </section> <section id="CD007857-sec-0002"> <h3 class="title" id="CD007857-sec-0002">Objectives</h3> <p>To determine the benefits and harms of IV iron supplementation compared with oral iron for anaemia in adults and children with CKD, including participants on dialysis, with kidney transplants and CKD not requiring dialysis. </p> </section> <section id="CD007857-sec-0003"> <h3 class="title" id="CD007857-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Register of Studies up to 7 December 2018 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal, and ClinicalTrials.gov. </p> </section> <section id="CD007857-sec-0004"> <h3 class="title" id="CD007857-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) and quasi‐RCTs in which IV and oral routes of iron administration were compared in adults and children with CKD. </p> </section> <section id="CD007857-sec-0005"> <h3 class="title" id="CD007857-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed study eligibility, risk of bias, and extracted data. Results were reported as risk ratios (RR) with 95% confidence intervals (CI) for dichotomous outcomes. For continuous outcomes the mean difference (MD) was used or standardised mean difference (SMD) if different scales had been used. Statistical analyses were performed using the random‐effects model. Subgroup analysis and univariate meta‐regression were performed to investigate between study differences. The certainty of the evidence was assessed using GRADE. </p> </section> <section id="CD007857-sec-0006"> <h3 class="title" id="CD007857-sec-0006">Main results</h3> <p>We included 39 studies (3852 participants), 11 of which were added in this update. A low risk of bias was attributed to 20 (51%) studies for sequence generation, 14 (36%) studies for allocation concealment, 22 (56%) studies for attrition bias and 20 (51%) for selective outcome reporting. All studies were at a high risk of performance bias. However, all studies were considered at low risk of detection bias because the primary outcome in all studies was laboratory‐based and unlikely to be influenced by lack of blinding. </p> <p>There is insufficient evidence to suggest that IV iron compared with oral iron makes any difference to death (all causes) (11 studies, 1952 participants: RR 1.12, 95% CI 0.64, 1.94) (absolute effect: 33 participants per 1000 with IV iron versus 31 per 1000 with oral iron), the number of participants needing to start dialysis (4 studies, 743 participants: RR 0.81, 95% CI 0.41, 1.61) or the number needing blood transfusions (5 studies, 774 participants: RR 0.86, 95% CI 0.55, 1.34) (absolute effect: 87 per 1,000 with IV iron versus 101 per 1,000 with oral iron). These analyses were assessed as having low certainty evidence. It is uncertain whether IV iron compared with oral iron reduces cardiovascular death because the certainty of this evidence was very low (3 studies, 206 participants: RR 1.71, 95% CI 0.41 to 7.18). Quality of life was reported in five studies with four reporting no difference between treatment groups and one reporting improvement in participants treated with IV iron. </p> <p>IV iron compared with oral iron may increase the numbers of participants, who experience allergic reactions or hypotension (15 studies, 2607 participants: RR 3.56, 95% CI 1.88 to 6.74) (absolute harm: 24 per 1000 with IV iron versus 7 per 1000) but may reduce the number of participants with all gastrointestinal adverse effects (14 studies, 1986 participants: RR 0.47, 95% CI 0.33 to 0.66) (absolute benefit: 150 per 1000 with IV iron versus 319 per 1000). These analyses were assessed as having low certainty evidence. </p> <p>IV iron compared with oral iron may increase the number of participants who achieve target haemoglobin (13 studies, 2206 participants: RR 1.71, 95% CI 1.43 to 2.04) (absolute benefit: 542 participants per 1,000 with IV iron versus 317 per 1000 with oral iron), increased haemoglobin (31 studies, 3373 participants: MD 0.72 g/dL, 95% CI 0.39 to 1.05); ferritin (33 studies, 3389 participants: MD 224.84 µg/L, 95% CI 165.85 to 283.83) and transferrin saturation (27 studies, 3089 participants: MD 7.69%, 95% CI 5.10 to 10.28), and may reduce the dose required of erythropoietin‐stimulating agents (ESAs) (11 studies, 522 participants: SMD ‐0.72, 95% CI ‐1.12 to ‐0.31) while making little or no difference to glomerular filtration rate (8 studies, 1052 participants: 0.83 mL/min, 95% CI ‐0.79 to 2.44). All analyses were assessed as having low certainty evidence. There were moderate to high degrees of heterogeneity in these analyses but in meta‐regression, definite reasons for this could not be determined. </p> </section> <section id="CD007857-sec-0007"> <h3 class="title" id="CD007857-sec-0007">Authors' conclusions</h3> <p>The included studies provide low certainty evidence that IV iron compared with oral iron increases haemoglobin, ferritin and transferrin levels in CKD participants, increases the number of participants who achieve target haemoglobin and reduces ESA requirements. However, there is insufficient evidence to determine whether IV iron compared with oral iron influences death (all causes), cardiovascular death and quality of life though most studies reported only short periods of follow‐up. Adverse effects were reported in only 50% of included studies. We therefore suggest that further studies that focus on patient‐centred outcomes with longer follow‐up periods are needed to determine if the use of IV iron is justified on the basis of reductions in ESA dose and cost, improvements in patient quality of life, and with few serious adverse effects. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007857-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007857-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD007857-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD007857-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007857-abs-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007857-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD007857-abs-0015">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/hu#CD007857-abs-0018">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ja#CD007857-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007857-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD007857-abs-0009">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007857-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007857-abs-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD007857-abs-0014">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007857-abs-0005" lang="en"> <h3>Iron treatment for adults and children with reduced kidney function</h3> <p><b>What is the issue?</b> </p> <p>Anaemia (reduction in the number of circulating red blood cells) often occurs in people who have kidney damage, especially those who need dialysis treatment. Anaemia can cause tiredness, reduce exercise tolerance and increase heart size. A common cause of anaemia is reduced production of a hormone, erythropoietin. Iron deficiency can make anaemia worse, and reduce the response to medications that stimulate erythropoietin production. Iron can be taken orally (by mouth) or injected intravenously (via a vein). Intravenous (IV) iron is given under supervision in hospitals. There is uncertainty about whether IV iron should be used rather than oral iron. </p> <p><b>What did we do?</b> </p> <p>We reviewed 39 studies (3852 participants) which compared IV iron supplements with oral iron in participants with chronic kidney disease. </p> <p><b>What did we find?</b> </p> <p>We found that IV iron may increase blood levels of haemoglobin and iron compared with oral iron. However, IV iron may increase the number of allergic reactions though it may reduce side effects such as constipation, diarrhoea, nausea and vomiting seen with oral iron. We did not find sufficient evidence to determine whether IV iron compared with oral iron improved quality of life, altered overall death rate or death due to heart disease. </p> <p><b>Conclusions</b> </p> <p>Although the results suggest that IV iron compared with oral iron may be more effective in raising iron and haemoglobin levels, we found insufficient data to determine if the benefits of IV iron are justified by improved quality of life or mortality despite the small risk of potentially serious allergic effects in some patients given IV iron. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007857-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007857-sec-0094"></div> <h3 class="title" id="CD007857-sec-0095">Implications for practice</h3> <section id="CD007857-sec-0095"> <p>This systematic review identified evidence to indicate that compared with oral iron therapy, IV iron therapy contributed increased ferritin and TSAT levels, reduced ESA dose required, and provided a small but significant increase in Hb. Limited patient‐centred outcomes data (death, cardiovascular disease, quality of life) were reported in the included studies. These data support the current practice of administering IV iron to in‐centre HD patients to increase iron stores, and probably, reduce both the ESA dose required, and its cost. </p> <p>While this update identified a few more studies, which addressed patient‐centred outcomes, including adverse effects, to determine if benefits exceed harms for all patients with CKD, only 11 studies reported on death (all causes), three reported on cardiovascular death and five reported on quality of life. However, because of small number of studies reporting these outcomes and low quality of evidence, the relative effects of different iron regimens on these patient‐centred outcomes remain uncertain. More studies reported on allergic reactions/hypotension (14 studies) and gastrointestinal adverse effects (13 studies), While gastrointestinal adverse effects with oral iron are common with oral iron, these effects must be balanced against the rare, but potentially life threatening adverse effects seen with IV iron. </p> <p>There are now additional large studies examining IV and oral iron in CKD participants with longer follow up periods. These confirm that IV iron compared with oral iron in CKD participants increases laboratory indices compared with oral iron, increases the number achieving target Hb without changing the rate of decline in kidney function. However, there are still no studies, which have assessed whether these benefits outweigh the disadvantages of increased numbers and durations of hospital visits for treatment. </p> </section> <h3 class="title" id="CD007857-sec-0096">Implications for research</h3> <section id="CD007857-sec-0096"> <p>Further large RCTs with longer durations of treatment and follow‐up periods are still required. These need to assess patient‐centred outcomes including death (all causes), cardiovascular death, cardiac morbidity using cardiac function tests, hospitalisations, quality of life and patient inconvenience created by hospital or clinic visits for IV iron in non‐dialysis or PD patients as well as common haematological parameters. The costs of all aspects of IV therapy must also be determined to assess overall value of IV iron, especially in non‐dialysis and PD patients. The doses of oral and IV iron should be standardised across studies in an effort to reduce the heterogeneity seen in this systematic review. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007857-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007857-sec-0036"></div> <div class="table" id="CD007857-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Patient‐centred outcomes for oral versus IV iron in adults and children with chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient‐centred outcomes for oral versus IV iron in adults and children with CKD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults and children with CKD<br/> <b>Setting:</b> Nephrology departments<br/> <b>Intervention:</b> IV iron<br/> <b>Comparison:</b> oral iron </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral iron</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IV iron</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death (all causes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1,000<br/> (19 to 58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.12<br/> (0.64 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1952 (11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 11/38 studies represented with only about 1/3 of patients.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular death</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1,000<br/> (8 to 142) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.71<br/> (0.41 to 7.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type of adverse event: allergic reactions/hypotension</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1,000<br/> (13 to 46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.56<br/> (1.88 to 6.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2607 (15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type of adverse event: all gastrointestinal adverse effects</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>319 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1,000<br/> (105 to 211) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.47<br/> (0.33 to 0.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1986 (14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type of adverse event: infection</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1,000<br/> (72 to 157) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.32<br/> (0.90 to 1.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>954 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Numbers of non‐dialysis patients needing to commence dialysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1,000<br/> (19 to 75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.81<br/> (0.41 to 1.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>743 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number requiring transfusion</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1,000<br/> (56 to 136) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.86<br/> (0.55 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>774 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>CKD:</b> chronic kidney disease; <b>IV:</b> intravenous; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for imprecision </p> <p><sup>2</sup> Downgraded one level for likely publication bias </p> <p><sup>3</sup> Downgraded one level for high heterogeneity </p> <p><sup>4</sup> Downgraded one level for publication bias </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007857-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Laboratory and pharmaceutical outcomes for adults and children with chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Laboratory and pharmaceutical outcomes for adults and children with CKD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults and children with CKD<br/> <b>Setting:</b> Nephrology departments<br/> <b>Intervention:</b> IV iron<br/> <b>Comparison:</b> oral iron </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral iron</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IV iron</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number achieving target Hb or increase ≥1 g/dL</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>317 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>542 per 1,000<br/> (453 to 646) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.71<br/> (1.43 to 2.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2206 (13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of bias (ROB) downgraded as little info on random sequence generation (RSG) and allocation concealment. Heterogeneity 60% </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hb: final or change (g/dL)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean Hb level was 0.72 g/dL higher with IV iron compared to oral iron (0.39 to 1.05 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3373 (31)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/31 are at ROB for RSG &amp;/or allocation concealment. Heterogeneity 94%</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ferritin: final or change (µg/L)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean ferritin level was 224.84 µg/L higher with IV iron compared to oral iron (165.85 to 283.83 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3389 (33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/13 are at ROB for RSG or allocation concealment. Heterogeneity 60%.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSAT: final or change (%)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean TSAT was 7.69% higher with IV iron compared to oral iron (5.1 to 10.28 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3089 (27)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/27 only are at low risk of bias and heterogeneity is 97%.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HCT (%)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean HCT was 1.18% higher with IV iron compared to oral iron (2.17 lower to 4.52 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 4 studies in this analysis, all with unknown risk of selection bias. Heterogeneity 96%. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ESA dose: final or change</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The SMD for ESA dose was 0.72 lower with IV iron compared to oral iron (0.31 to 1.12 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>522 (11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ROB downgraded as little information on RSG and Allocation concealment. Heterogeneity 77% </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>eGFR: final or change (mL/min)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>the mean eGFR was 0.83 mL/min higher with IV iron compared to oral iron (0.79 lower to 2.44 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1052 (8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Half of the studies are at ROB for RSG &amp; allocation concealment.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>CKD:</b> chronic kidney disease; <b>eGFR:</b> estimated glomerular filtration rate; <b>ESA:</b> erythrocyte‐stimulating agent; <b>Hb:</b> haemoglobin; <b>HCT:</b> haematocrit; <b>IV</b> : intravenous; <b>RR:</b> Risk ratio; <b>TSAT:</b> transferrin saturation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for risk of bias </p> <p><sup>2</sup> Downgraded one level for inconsistency </p> <p><sup>3</sup> Downgraded one level for imprecision </p> <p><sup>4</sup> Downgraded one level for likely publication bias </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007857-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007857-sec-0037"></div> <section id="CD007857-sec-0038"> <h3 class="title" id="CD007857-sec-0038">Description of the condition</h3> <p>A reduction in the number of circulating red blood cells is termed anaemia. The prevalence of anaemia in patients with chronic kidney disease (CKD) is twice that in the general population. As kidney function deteriorates, the prevalence of anaemia increases from 8.4% at CKD stage 1 to 53.4% at CKD stage 5 (<a href="./references#CD007857-bbs2-0086" title="StaufferME , FanT . Prevalence of anemia in chronic kidney disease in the United States. PLoS ONE [Electronic Resource]2014;9(1):e84943. [MEDLINE: 24392162] ">Stauffer 2014</a>). The cause of anaemia in CKD is multifactorial though largely driven by decreased kidney production of erythropoietin. Iron deficiency can exacerbate the degree of anaemia and reduce the response to erythropoietin‐stimulating agents (ESAs). Anaemia has been found to contribute to a number of pathological processes. Observational studies have shown anaemia to be associated with increased mortality (at an haemoglobin level (Hb) &lt; 11.0 g/dL) (<a href="./references#CD007857-bbs2-0065" title="KovesdyCP , TrivediBK , Kalantar‐ZadehK , AndersonJE . Association of anemia with outcomes in men with moderate and severe chronic kidney disease.. Kidney International2006;69(3):560‐4. [MEDLINE: 16395253] ">Kovesdy 2006</a>; <a href="./references#CD007857-bbs2-0067" title="LevinA , DjurdjevO , DuncanJ , RosenbaumD , WerbR . Haemoglobin at time of referral prior to dialysis predicts survival: an association of haemoglobin with long‐term outcomes. Nephrology Dialysis Transplantation2006;21(2):370‐7. [MEDLINE: 16249203] ">Levin 2006</a>), increased hospital stay (<a href="./references#CD007857-bbs2-0068" title="LiS , CollinsAJ . Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney International2004;65(2):626‐33. [MEDLINE: 14717934] ">Li 2004</a>), increased cardiovascular events (<a href="./references#CD007857-bbs2-0068" title="LiS , CollinsAJ . Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney International2004;65(2):626‐33. [MEDLINE: 14717934] ">Li 2004</a>; <a href="./references#CD007857-bbs2-0088" title="VlagopoulosPT , TighiouartH , WeinerDE , GriffithJ , PettittD , SalemDN , et al. Anemia as a risk factor for cardiovascular disease and all‐cause mortality in diabetes: the impact of chronic kidney disease. Journal of the American Society of Nephrology2005;16(11):3403‐10. [MEDLINE: 16162813] ">Vlagopoulos 2005</a>; <a href="./references#CD007857-bbs2-0089" title="WeinerDE , TighiouartH , VlagopoulosPT , GriffithJL , SalemDN , LeveyAS , et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. Journal of the American Society of Nephrology2005;16(6):1803‐10. [MEDLINE: 15857925] ">Weiner 2005</a>) and decreased quality of life (<a href="./references#CD007857-bbs2-0053" title="FukuharaS , YamazakiS , MarumoF , AkibaT , AkizawaT , FujimiS , et al. Health‐related quality of life of predialysis patients with chronic renal failure. Nephron2007;105(1):c1‐8. [MEDLINE: 17106210] ">Fukuhara 2007</a>). Limited data have also shown that an increase in Hb can improve a number of these indices (<a href="./references#CD007857-bbs2-0067" title="LevinA , DjurdjevO , DuncanJ , RosenbaumD , WerbR . Haemoglobin at time of referral prior to dialysis predicts survival: an association of haemoglobin with long‐term outcomes. Nephrology Dialysis Transplantation2006;21(2):370‐7. [MEDLINE: 16249203] ">Levin 2006</a>; <a href="./references#CD007857-bbs2-0075" title="MorenoF , Sanz‐GuajardoD , Lopez‐GomezJM , JofreR , ValderrabanoF . Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. Journal of the American Society of Nephrology2000;11(2):335‐42. [MEDLINE: 10665941] ">Moreno 2000</a>). However, a systematic review of studies assessing the effects of targeting higher Hb concentrations in patients with CKD by using higher doses of ESA showed a significantly higher risk of death (all causes) (risk ratio (RR) 1.17) and arteriovenous access thrombosis (RR 1.34) in the higher Hb target group compared with the lower Hb group (<a href="./references#CD007857-bbs2-0078" title="PhrommintikulA , HaasSJ , ElsikM , KrumH . Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta‐analysis. Lancet2007;369(9559):381‐8. [MEDLINE: 17276778] ">Phrommintikul 2007</a>). National (<a href="./references#CD007857-bbs2-0048" title="McMahonL . Haemoglobin. Nephrology2008;13(s2):S44‐56. [DOI: 10.1111/j.1440‐1797.2008.00997.x] ">CARI 2008</a>; <a href="./references#CD007857-bbs2-0074" title="MoistLM , FoleyRN , BarrettBJ , MadoreF , WhiteCT , KlarenbachSW , et al. Clinical practice guidelines for evidence‐based use of erythropoietic‐stimulating agents. Kidney International ‐ Supplement2008, (110):S12‐8. [MEDLINE: 18668116] ">Moist 2008</a>; <a href="./references#CD007857-bbs2-0077" title="National Institute of Health and Care Excellence. Chronic kidney disease: managing anaemia. www.nice.org.uk/guidance/ng8June 2015. ">NICE 2015</a>) and international guidelines (<a href="./references#CD007857-bbs2-0062" title="LocatelliF , NissensonAR , BarrettBJ , WalkerRG , WheelerDC , EckardtKU , et al. Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International2008;74(10):1237‐40. [MEDLINE: 18596731] ">KDIGO 2008</a>; <a href="./references#CD007857-bbs2-0070" title="LocatelliF , AljamaP , CanaudB , CovicA , DeFranciscoA , MacdougallIA , et al. Target haemoglobin to aim for with erythropoiesis‐stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT) Study. Nephrology Dialysis Transplantation2010;25(9):2846‐50. [MEDLINE: 20591813] ">Locatelli 2010</a>) recommend target Hb levels of between 10 g/dL to 12 g/dL for patients with CKD. The most recent guidelines (<a href="./references#CD007857-bbs2-0063" title="Kidney Disease: Improving Global Outcomes. Summary of recommendation statements. Kidney International Supplements2012;2(4):283‐7. [DOI: 10.1038/kisup.2012.41] ">KDIGO 2012</a>) suggest that the Hb in adult CKD patients should not exceed 11.5 g/dL. </p> <p>Iron is an essential mineral to maintain health. It is required in many intracellular processes including DNA synthesis, mitochondrial energy generation and enzymatic reactions. It is used in the production of myoglobin in muscles and Hb, the oxygen carrying component of the red blood cells. Determining iron deficiency in CKD can be challenging as it is often a functional deficiency caused by insufficient iron availability despite adequate body iron stores. The aetiology of iron deficiency in CKD is complex but includes reduced dietary intake and blood loss, particularly from the gastrointestinal tract, due to uraemia induced platelet dysfunction (<a href="./references#CD007857-bbs2-0057" title="HedgesSJ , DehoneySB , HooperJS , AmanzadehJ , BustiAJ . Evidence‐based treatment recommendations for uremic bleeding. Nature Clinical Practice Nephrology2007;3(3):138‐53. [MEDLINE: 17322926] ">Hedges 2007</a>). These losses are compounded in patients on haemodialysis (HD) by the use of heparin, losses from clotted dialysis lines and blood sampling, which can lead to losses of 2 litres to 5 litres of blood per year (<a href="./references#CD007857-bbs2-0080" title="SargentJA , AcchiardoSR . Iron requirements in hemodialysis. Blood purification2004;22(1):112‐23. [MEDLINE: 14732819] ">Sargent 2004</a>). Lastly, chronic inflammation and uraemia result in an upregulation and reduced clearance of hepcidin, inhibiting the release of iron from macrophages and decreasing gastrointestinal iron absorption (<a href="./references#CD007857-bbs2-0071" title="LopezA , CacoubP , MacdougallIC , Peyrin‐BirouletL . Iron deficiency anaemia. Lancet2016;387(10021):907‐16. [MEDLINE: 26314490] ">Lopez 2015</a>). </p> </section> <section id="CD007857-sec-0039"> <h3 class="title" id="CD007857-sec-0039">Description of the intervention</h3> <p>Therapeutic iron can be given orally. Four iron preparations are commonly used: ferrous sulphate, ferrous sulphate exsiccated, ferrous gluconate, and ferrous fumarate. It can be given intramuscularly in the form of iron dextran or it can be given intravenously. Six main forms of intravenous (IV) iron are currently available: iron sucrose, ferric gluconate, ferric carboxymaltose, iron isomaltoside‐1000, ferumoxytol, and iron dextran (low‐molecular‐weight forms) (<a href="./references#CD007857-bbs2-0071" title="LopezA , CacoubP , MacdougallIC , Peyrin‐BirouletL . Iron deficiency anaemia. Lancet2016;387(10021):907‐16. [MEDLINE: 26314490] ">Lopez 2015</a>). </p> <p>Oral iron frequently causes gastrointestinal side effects including heartburn, nausea, vomiting, diarrhoea, and constipation (<a href="./references#CD007857-bbs2-0071" title="LopezA , CacoubP , MacdougallIC , Peyrin‐BirouletL . Iron deficiency anaemia. Lancet2016;387(10021):907‐16. [MEDLINE: 26314490] ">Lopez 2015</a>). These events affect patient compliance and can limit total intake. Although serious adverse events related to IV forms of iron are rare, the effects can be life threatening and include pulmonary embolism, anaphylactic reaction, loss of consciousness, circulatory collapse, hypotension, dyspnoea, pruritus, hypersensitivity and urticaria (<a href="./references#CD007857-bbs2-0046" title="BailieGR . Adverse events associated with intravenous iron preparations: a comparison of reported rates. Clinical Advances in Hematology &amp; Oncology2012;10(9):600‐2. [MEDLINE: 23073127] ">Bailie 2012</a>; <a href="./references#CD007857-bbs2-0071" title="LopezA , CacoubP , MacdougallIC , Peyrin‐BirouletL . Iron deficiency anaemia. Lancet2016;387(10021):907‐16. [MEDLINE: 26314490] ">Lopez 2015</a>). The cumulative rate for all adverse events, for all IV iron preparations, is 14.1 adverse events per million units sold though it appears to be higher in products such as ferumoxytol compared with iron sucrose (<a href="./references#CD007857-bbs2-0046" title="BailieGR . Adverse events associated with intravenous iron preparations: a comparison of reported rates. Clinical Advances in Hematology &amp; Oncology2012;10(9):600‐2. [MEDLINE: 23073127] ">Bailie 2012</a>). IV iron preparations require administration under supervision and this need increases the cost of administration and is inconvenient for patients who are not receiving in‐centre HD. IV iron has also been linked to an increased risk of infection and cardiovascular disease; iron can act as a growth factor for some bacteria and free iron has been shown to impair neutrophil and T cell function as well as increase reactive oxygen species (<a href="./references#CD007857-bbs2-0052" title="FishbaneS , MathewA , VaziriND . Iron toxicity: relevance for dialysis patients. Nephrology Dialysis Transplantation2014;29(2):255‐9. [MEDLINE: 24166458] ">Fishbane 2014</a>; <a href="./references#CD007857-bbs2-0060" title="IshidaJH , JohansenKL . Iron and infection in hemodialysis patients. Seminars in Dialysis2014;27(1):26‐36. [MEDLINE: 24329610] ">Ishida 2014</a>). The majority of the literature to date supports these associations although the most recent cohort study of nearly 23,000 HD patients suggested no difference in length of stay, death or readmission for infection in those who received IV iron during admission and those who did not (<a href="./references#CD007857-bbs2-0061" title="IshidaJH , MarafinoBJ , McCullochCE , DalrympleLS , DudleyRA , GrimesBA , et al. Receipt of intravenous iron and clinical outcomes among hemodialysis patients hospitalized for infection. Clinical Journal of The American Society of Nephrology: CJASN2015;10(10):1799‐805. [MEDLINE: 26416943] ">Ishida 2015</a>). Furthermore there is increasing evidence that free iron plays a role in direct injury to kidney tissue, which could result in more rapid deterioration in kidney function (<a href="./references#CD007857-bbs2-0084" title="ShahSV , RajapurkarMM , BaligaR . The role of catalytic iron in acute kidney injury. Clinical Journal of The American Society of Nephrology: CJASN2011;6(10):2329‐31. [MEDLINE: 21979910] ">Shah 2011</a>). </p> <p>Controversies remain about the most effective and safe way to provide iron supplementation in patients with CKD (<a href="./references#CD007857-bbs2-0051" title="FishbaneS . Iron management in nondialysis‐dependent CKD. American Journal of Kidney Diseases2007;49(6):736‐43. [MEDLINE: 17533016] ">Fishbane 2007</a>; <a href="./references#CD007857-bbs2-0072" title="MacdougallIC , BircherAJ , EckardtKU , ObradorGT , PollockCA , StenvinkelP , et al. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney International2016;89(1):28‐39. [MEDLINE: 26759045] ">Macdougall 2016</a>). Current parameters used to monitor iron status include serum ferritin levels, serum iron, transferrin saturation (TSAT), per cent of hypochromic red blood cells, and reticulocyte Hb content. There is debate about the most valuable measures to assess iron status, and the setting of optimum levels of these measures in patients with CKD to increase Hb and optimise ESA response. Novel markers being developed but not yet in routine use include hepcidin, soluble transferrin receptor one and non‐transferrin bound iron (<a href="./references#CD007857-bbs2-0054" title="GawedaAE , GinzburgYZ , ChaitY , GermainMJ , AronoffGR , RachmilewitzE . Iron dosing in kidney disease: inconsistency of evidence and clinical practice. Nephrology Dialysis Transplantation2015;30(2):187‐96. [MEDLINE: 24821751] ">Gaweda 2015</a>). </p> </section> <section id="CD007857-sec-0040"> <h3 class="title" id="CD007857-sec-0040">How the intervention might work</h3> <p>Iron deficiency is the most common cause of anaemia in CKD and of hypo‐responsiveness to ESAs (<a href="./references#CD007857-bbs2-0066" title="KwackC , BalakrishnanVS . Managing erythropoietin hyporesponsiveness. Seminars in Dialysis2006;19(2):146‐51. [MEDLINE: 16551293] ">Kwack 2006</a>). ESAs accelerate erythropoiesis by increasing iron utilisation and depleting iron stores. Optimal efficacy of ESAs depends on the availability of iron to achieve and maintain target Hb levels. Patients with CKD stage 5D require higher targets for ferritin and TSAT levels to achieve increased Hb levels compared with patients whose kidney function is normal. Two studies targeting ferritin levels of 400 ng/mL or 30% to 50% TSAT resulted in significant reductions in the ESA dose required to maintain Hb levels compared with targeting a ferritin level of 200 ng/mL or TSAT levels of 20% to 30% (<a href="./references#CD007857-bbs2-0047" title="BesarabA , AminN , AhsanM , VogelSE , ZazuwaG , FrinakS , et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. Journal of the American Society of Nephrology2000;11(3):530‐8. [MEDLINE: 10703677] ">Besarab 2000</a>; <a href="./references#CD007857-bbs2-0050" title="DeVitaMV , FrumkinD , MittalS , KamranA , FishbaneS , MichelisMF . Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clinical Nephrology2003;60(5):335‐40. [MEDLINE: 14640239] ">DeVita 2003</a>). However, such high ferritin and TSAT levels increase the risk of iron overload and its associated complications. The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines (<a href="./references#CD007857-bbs2-0064" title="EckardtKU , vanWyckD . KDOQI 2007 update on hemoglobin target: recommendation and evidence base. www.kdigo.org/wp‐content/uploads/2017/01/Eckardt‐anemia‐in‐ckd‐2007.pdf (accessed 11 February 2019). ">KDOQI 2007</a>), the Canadian (<a href="./references#CD007857-bbs2-0073" title="MadoreF , WhiteCT , FoleyRN , BarrettBJ , MoistLM , KlarenbachSW , et al. Clinical Practice Guidelines for assessment and management of iron deficiency. Kidney International ‐ Supplement2008, (110):S7‐11. [MEDLINE: 18668119] ">Madore 2008</a>) and the European guidelines (<a href="./references#CD007857-bbs2-0069" title="LocatelliF , CovicA , EckardtK‐U , WiecekA , VanholderR , ERA‐EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrology Dialysis Transplantation2009;24(2):348‐54. [MEDLINE: 19037082] ">Locatelli 2009</a>) recommend serum ferritin of &gt; 200 ng/mL and TSAT &gt; 20% in patients receiving HD. <a href="./references#CD007857-bbs2-0063" title="Kidney Disease: Improving Global Outcomes. Summary of recommendation statements. Kidney International Supplements2012;2(4):283‐7. [DOI: 10.1038/kisup.2012.41] ">KDIGO 2012</a> recommend that iron can be given until TSAT &gt; 30% or serum ferritin &gt; 500 ng/mL. In patients with less severe degrees of CKD, serum ferritin levels &gt; 100 ng/mL and TSAT &gt; 20% are recommended. </p> </section> <section id="CD007857-sec-0041"> <h3 class="title" id="CD007857-sec-0041">Why it is important to do this review</h3> <p>The original study published in 2012 found strong evidence for increased ferritin and TSAT levels and a small increase in Hb with IV iron compared with oral iron. There was limited evidence that this came with a reduction in ESA use. Only half of the studies reported on adverse events. There have been several studies done over the last six years which have looked at the adverse event rate of the many preparations of IV iron and also included hard end points including all cause and cardiovascular death. At present the majority of HD patients receive IV iron and the use of IV iron in the peritoneal dialysis (PD) and CKD populations is increasing. We felt it was important to update this review to ensure that patient focused adverse events were analysed as well as providing up to date evidence on the efficacy and safety of IV iron. In this review, we aimed to explore all possible causes of heterogeneity of study results in detail by subgroup analysis and to further investigate the effects of IV iron in patients with CKD who were not on dialysis. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007857-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007857-sec-0042"></div> <p>Our objective was to determine the benefits and harms of IV iron supplementation compared with oral iron for anaemia in patients with CKD, treated with HD, PD, not receiving dialysis and post transplant. The review aimed to examine the effects of these interventions on patient centred outcomes including death, requirements for transfusion, hospitalisation, cardiac function, quality of life and change in eGFR as well as iron parameters, achieving target levels of Hb, reducing doses of ESA required, and to determine adverse effects of the therapies. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007857-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007857-sec-0043"></div> <section id="CD007857-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007857-sec-0045"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) and quasi‐RCTs (studies in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) in which oral and IV routes of administration of iron were compared in patients with CKD. </p> </section> <section id="CD007857-sec-0046"> <h4 class="title">Types of participants</h4> <section id="CD007857-sec-0047"> <h5 class="title">Inclusion criteria</h5> <p>We included adult and paediatric patients with CKD (stages 3 to 5D; glomerular filtration rate (GFR) &lt; 60 mL/min/1.73 m<sup>2</sup>). Studies in patients receiving HD, PD, or those not requiring dialysis, were included. Studies of kidney transplant patients were also included. </p> </section> <section id="CD007857-sec-0048"> <h5 class="title">Exclusion criteria</h5> <p>Studies of iron administration in patients comparing different IV or oral iron preparations and different doses of the same IV or oral preparation were excluded. Studies in patients with acute kidney injury were excluded. </p> </section> </section> <section id="CD007857-sec-0049"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD007857-list-0001"> <li> <p>We examined different IV iron supplements (including iron sucrose, dextran, ferric gluconate, ferric carboxymaltose, ferumoxytol) and oral iron preparations (including oral iron preparations which contain folic acid, vitamin C or both). </p> </li> <li> <p>We included studies using different doses and durations of IV iron compared with oral iron preparations provided that the control group received oral iron supplements only. </p> </li> </ul> </p> </section> <section id="CD007857-sec-0050"> <h4 class="title">Types of outcome measures</h4> <section id="CD007857-sec-0051"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD007857-list-0002"> <li> <p>Death (all causes)</p> </li> <li> <p>Cardiovascular death</p> </li> <li> <p>Quality of life</p> </li> </ul> </p> </section> <section id="CD007857-sec-0052"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD007857-list-0003"> <li> <p>Hb</p> <ul id="CD007857-list-0004"> <li> <p>Number achieving target Hb level</p> </li> <li> <p>Time to achieve target Hb</p> </li> <li> <p>Final or change in Hb at end of study</p> </li> <li> <p>Increase in Hb &gt; 10 g/L or other target during study</p> </li> </ul> </li> <li> <p>Iron</p> <ul id="CD007857-list-0005"> <li> <p>Number achieving target levels of iron (ferritin, TSAT, per cent of hypochromic red blood cells) </p> </li> <li> <p>Final or change in ferritin levels at the end of study</p> </li> <li> <p>Final or change in TSAT at end of study</p> </li> <li> <p>Per cent of hypochromic red blood cells</p> </li> </ul> </li> <li> <p>Erythrocyte stimulating agents (ESAs)</p> <ul id="CD007857-list-0006"> <li> <p>Reduction in required dose of ESA</p> </li> <li> <p>Number needing to increase ESA dose</p> </li> <li> <p>Number needing to decrease ESA dose or cease ESA</p> </li> </ul> </li> <li> <p>Infection</p> </li> <li> <p>Change in GFR in non‐dialysis patients</p> </li> <li> <p>Number needing transfusions</p> </li> <li> <p>Any adverse events of treatment</p> <ul id="CD007857-list-0007"> <li> <p>Adverse effects of oral iron</p> </li> <li> <p>Adverse effects of IV iron supplements including hypersensitivity reactions</p> </li> <li> <p>Number of patients needing to cease oral or IV supplements because of adverse effects</p> </li> </ul> </li> </ul> </p> <section id="CD007857-sec-0053"> <h6 class="title">Other outcomes</h6> <p> <ul id="CD007857-list-0008"> <li> <p>Haematocrit (HCT)</p> </li> <li> <p>Reticulocyte Hb concentration</p> </li> <li> <p>Numbers of non‐dialysis patients needing to commence dialysis</p> </li> <li> <p>Hospitalisation (other than for iron infusions and dialysis)</p> </li> <li> <p>Exercise tolerance</p> </li> <li> <p>Left ventricular function</p> </li> <li> <p>Sexual function</p> </li> <li> <p>Nutritional status</p> </li> <li> <p>Adherence to therapy</p> </li> <li> <p>Numbers and costs of hospitalisations/professional supervision required for IV iron supplements </p> </li> <li> <p>Iron overload (as defined by the triallists)</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD007857-sec-0054"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007857-sec-0055"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Register of Studies</a> up to 7 December 2018 through contact with the Information Specialist using search terms relevant to this review. The Register contains studies identified from the following sources. </p> <p> <ol id="CD007857-list-0009"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of kidney‐related journals and the proceedings of major kidney conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of search strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the <i>Specialised Register</i> section of information about <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Kidney and Transplant</a>. </p> <p>See <a href="./appendices#CD007857-sec-0100">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD007857-sec-0056"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD007857-list-0010"> <li> <p>Reference lists of review articles, relevant studies and clinical practice guidelines.</p> </li> <li> <p>Letters seeking information about unpublished or incomplete trials to investigators known to be involved in previous studies. </p> </li> </ol> </p> </section> </section> <section id="CD007857-sec-0057"> <h3 class="title" id="CD007857-sec-0057">Data collection and analysis</h3> <section id="CD007857-sec-0058"> <h4 class="title">Selection of studies</h4> <p>The search strategy described was used to obtain titles and abstracts of studies that were potentially relevant to the review. The titles and abstracts were screened independently by two authors, who discarded studies that were not applicable. However, studies and reviews that might include relevant data or information on studies were retained initially. Two authors independently assessed retrieved abstracts, and where necessary the full text, of these studies to determine which satisfied the inclusion criteria. </p> </section> <section id="CD007857-sec-0059"> <h4 class="title">Data extraction and management</h4> <p>Data extraction and assessment of the risk of bias were performed independently by the same authors using standardised data extraction forms. Studies reported in non‐English language journals were translated before assessment. Where more than one publication of one study existed, the publication with the most complete data was reviewed initially. Where relevant outcomes were only published in earlier versions, these data were used. Any discrepancy between published versions was highlighted. Any further information required from the original author was requested by written correspondence and any relevant information obtained in this manner was included in the review. Disagreements were resolved in consultation with a third author. </p> </section> <section id="CD007857-sec-0060"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were assessed independently by two authors using the risk of bias assessment tool (<a href="./references#CD007857-bbs2-0059" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) (<i>see</i><a href="./appendices#CD007857-sec-0101">Appendix 2</a>). </p> <p> <ul id="CD007857-list-0011"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD007857-list-0012"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> </section> <section id="CD007857-sec-0061"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (number reaching target Hb, death) results were expressed as RR with 95% confidence intervals (CI). RR with 95% CI were calculated for adverse effects. Where continuous scales of measurement were used to assess the effects of treatment (Hb level, iron parameters) the mean difference (MD) was used, or the standardised mean difference (SMD) if different scales had been used (end of study ESA dose). Either final levels or change in levels were included in meta‐analyses of continuous scales of measurement. When both measures are provided in a study, final levels were included. </p> </section> <section id="CD007857-sec-0062"> <h4 class="title">Unit of analysis issues</h4> <p>Cross‐over studies were thought likely to be inappropriate means of examining IV and oral iron because of carry over effects related to achieved Hb levels and iron parameters. Therefore, only data from the first period of cross‐over studies were included where these were reported separately, and included all or most patients who completed the first period, rather than only those who completed both treatment periods. </p> </section> <section id="CD007857-sec-0063"> <h4 class="title">Dealing with missing data</h4> <p>Where necessary, we contacted triallists to request missing patient data due to loss to follow‐up and exclusion from study analyses in an effort to conduct intention‐to‐treat analyses. Eight authors responded to our requests. Where missing dichotomous or continuous data were few, and unlikely to affect the overall results, we analysed available data. Where possible we imputed missing standard deviations and standard errors if data was presented alternatively, using methods stated in the Cochrane handbook (Higgins 2011a). </p> </section> <section id="CD007857-sec-0064"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was analysed using a Chi<sup>2</sup> test on N‐1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I<sup>2</sup> test (<a href="./references#CD007857-bbs2-0058" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). I<sup>2</sup> values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity. </p> </section> <section id="CD007857-sec-0065"> <h4 class="title">Assessment of reporting biases</h4> <p>Cochrane Kidney and Transplant's Specialised Register includes studies obtained from searching major databases, conference proceedings and prospective trial registers without language restriction in an attempt to reduce publication bias related to failure of authors to publish negative results or their inability to publish negative results in journals indexed in major databases. When sufficient studies were available, we created funnel plots and calculated Eggers' test to assess publication bias. Where multiple publications of the same study were identified, data were included from the most recent publication, and preferably, the definitive publication. However, all publications were reviewed to identify outcomes not reported in the index publication in an attempt to reduce outcome reporting bias. </p> </section> <section id="CD007857-sec-0066"> <h4 class="title">Data synthesis</h4> <p>Data were pooled using the random‐effects model for dichotomous and continuous data.</p> </section> <section id="CD007857-sec-0067"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>To explore clinical differences among studies that could influence the magnitude of the treatment effect for the outcomes of differences in ferritin, TSAT and Hb, subgroup analyses and univariate meta‐regression were performed using STATA software (StataCorp LP, Texas, USA) using restricted maximum‐likelihood to estimate between study variance. The potential sources of variability were defined a priori and were related to study rationale (CKD stage, whether aiming to increase or maintain Hb, concurrent use of erythropoietin co‐intervention, timing of initiation of erythropoietin co‐intervention), dose delivered and duration of IV and oral iron therapy, and study sponsorship. Where subgroup analysis findings suggested that more than one factor could influence the magnitude of observed differences, we planned to conduct multivariate meta‐regression. </p> <p>Underlying cause of end‐stage kidney disease (ESKD), baseline iron status, and previous iron therapy were not examined in subgroup analyses because most studies did not provide this information. All studies, except two paediatric studies, included adults of similar ages so different age groups could not be examined in subgroup analyses. Only one study (<a href="./references#CD007857-bbs2-0016" title="LiH , WangSX . Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study. Chung‐Hua i Hsueh Tsa Chih [Chinese Medical Journal]2009;89(7):457‐62. [MEDLINE: 19567093] LiH , WangSX . Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Peritoneal Dialysis International2008;28(2):149‐54. [MEDLINE: 18332450] ">Li 2008 PD</a>) included solely PD patients so it was not possible to examine different types of renal replacement therapy in subgroup analyses. </p> </section> <section id="CD007857-sec-0068"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses were performed to test decisions where inclusion of a study, with a much higher MD in Hb, might have altered meta‐analysis results. </p> <section id="CD007857-sec-0069"> <h5 class="title">'Summary of findings' tables</h5> <p>We presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD007857-bbs2-0082" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011a</a>). The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD007857-bbs2-0055" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [MEDLINE: 18436948] ">GRADE 2008</a>; <a href="./references#CD007857-bbs2-0056" title="GuyattG , OxmanA D , AklE A , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64:383‐94. [MEDLINE: 22818160] ">GRADE 2011</a>). The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD007857-bbs2-0083" title="SchünemannHJ , OxmanAD , HigginsJP , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011b</a>). We presented the following outcomes in the 'Summary of findings' tables. </p> <p> <ul id="CD007857-list-0013"> <li> <p><a href="./full#CD007857-tbl-0001">summary of findings Table for the main comparison</a> </p> <ul id="CD007857-list-0014"> <li> <p>Death (all causes)</p> </li> <li> <p>Cardiovascular death</p> </li> <li> <p>Allergic reactions/hypotension</p> </li> <li> <p>All gastrointestinal adverse effects</p> </li> <li> <p>Infection</p> </li> <li> <p>Numbers of non‐dialysis patients needing to commence dialysis</p> </li> <li> <p>Number requiring transfusion</p> </li> </ul> </li> <li> <p><a href="./full#CD007857-tbl-0002">summary of findings Table 2</a> </p> <ul id="CD007857-list-0015"> <li> <p>Number achieving target Hb or increase ≥1 g/dL</p> </li> <li> <p>Hb: final or change</p> </li> <li> <p>Ferritin: final or change</p> </li> <li> <p>TSAT: final or change</p> </li> <li> <p>HCT</p> </li> <li> <p>End of treatment or change in ESA dose</p> </li> <li> <p>eGFR end or change</p> </li> </ul> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007857-sec-0070" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007857-sec-0070"></div> <section id="CD007857-sec-0071"> <h3 class="title">Description of studies</h3> <section id="CD007857-sec-0072"> <h4 class="title">Results of the search</h4> <p>The initial study resulted in a total of 522 study reports from the Cochrane Kidney and Transplant Specialised Register to March 2010, CENTRAL (in The Cochrane Library Issue 1, 2010), MEDLINE (to October week 5, 2008) and EMBASE (to week 45, 2008). From these 522 reports, 28 studies (46 reports) were included in the systematic review while 28 studies were excluded; there were three ongoing studies. </p> <p>For the 2019 update of this review, a search of the Cochrane Kidney and Transplant Specialised Register identified 49 new reports. From these we identified 11 new included studies (31 reports) (<a href="./references#CD007857-bbs2-0002" title="AgarwalR , KusekJW , PappasMK . A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney International2015;88(4):905‐14. [DOI: 10.1038/ki.2015.163; MEDLINE: 26083656] ">Agarwal 2015 CKD</a>; <a href="./references#CD007857-bbs2-0008" title="GaillardCA , BockAH , CarreraF , EckardtK , VanWyckDB , BansalSS , et al. Hepcidin response to intravenous (IV) or oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis CKD (ND‐CKD) [abstract no: TH‐OR040]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. GaillardCA , BockAH , CarreraF , EckardtKU , VanWyckDB , BansalSS , et al. Hepcidin response to iron therapy in patients with non‐dialysis dependent CKD: an analysis of the FIND‐CKD trial. PLoS ONE [Electronic Resource]2016;11(6):e0157063. [MEDLINE: 27276035] MacdougallI , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. A model to predict haematopoietic non‐response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD): an analysis from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193‐4. [EMBASE: 72326413] MacdougallIC , BockA , CarreraF , CushwayT , MoriC , RogerS . Rationale and design of a new RCT of iron therapy in anemic non‐dialysis CKD patients: FIND‐CKD trial [abstract no: SA‐PO2402]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):660A. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. The FIND‐CKD study‐‐a randomized controlled trial of intravenous iron versus oral iron in non‐dialysis chronic kidney disease patients: background and rationale. Nephrology Dialysis Transplantation2014;29(4):843‐50. [MEDLINE: 24170814] MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. FIND‐CKD: a 56‐week randomized trial of intravenous ferric carboxymaltose versus oral iron in anemic patients with chronic kidney disease and iron deficiency [abstract no: SA‐PO1079]. Journal of the American Society of Nephrology2013;24(Abstracts):3B. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. Intravenous ferric carboxymaltose vs oral iron in anaemic patients with non‐dialysis dependent chronic kidney disease and iron deficiency: results of the randomised FIND‐CKD study [abstract no: SO049]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. MacdougallIC , BockAH , CarreraF , EckardtK , GaillardC , VanWyckD , et al. Efficacy of oral iron for treating iron deficiency in anaemic patients with non‐dialysis dependent CKD (ND‐CKD) [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii581. [EMBASE: 617290898] MacdougallIC , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. Iron administration to non‐dialysis CKD patients for one year does not cause worsening of renal function: results from the FIND‐CKD trial [abstract no: FR‐PO809]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):555A. MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Erythropoietic response to oral iron in patients with nondialysis‐dependent chronic kidney disease in the FIND‐CKD trial. Clinical Nephrology2017;88(12):301‐10. [MEDLINE: 29092739] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. FIND‐CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrology Dialysis Transplantation2014;29(11):2075‐84. [MEDLINE: 24891437] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Renal function in patients with non‐dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND‐CKD trial. BMC Nephrology2017;18(1):24. [MEDLINE: 28095881] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Hepcidin response to iron therapy in patients with non‐dialysis CKD: an analysis of the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8‐9. [EMBASE: 72206297] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Low rate of early response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD) [abstract no: TH‐PO906]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. RogerS , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. The safety of intravenous (IV) ferric carboxymaltose (FCM) in patients with non‐dialysis dependent CKD (ND‐CKD): 1‐year results from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i15‐6. [EMBASE: 72325953] RogerSD , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. IV ferric carboxymaltose (FCM) is a convenient and well‐tolerated first‐line therapy for the treatment of anaemia in patients with iron deficiency and non‐dialysis dependent chronic kidney disease (ND‐CKD): results of the randomised FIND‐CKD study [abstract no: SO048]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. RogerSD , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Intravenous (IV) ferric carboxymaltose (FCM) versus oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis dependant CKD (ND‐CKD): a safety analysis [abstract no: TH‐PO652]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):238A. ">FIND‐CKD 2014 CKD</a>; <a href="./references#CD007857-bbs2-0012" title="KalraPA , BhandariS , SaxenaS , AgarwalD , WirtzG , KletzmayrJ , et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non‐dialysis‐dependent chronic kidney disease patients with anaemia. Nephrology Dialysis Transplantation2016;31(4):646‐55. [MEDLINE: 26250435] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside 1000 (monofer) compared to oral iron sulphate in European patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii200. [EMBASE: 72206812] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside1000 (monofer) compared to oral iron sulphate in patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract no: SA‐PO1106]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B7. ">Kalra 2016 CKD</a>; <a href="./references#CD007857-bbs2-0017" title="BesarabA , CoyneD , BoltonWK , SharmaA , FotiA , BrennerL . Ferumoxytol as an intravenous iron replacement therapy: safety results from two phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO0805]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):762A. [CENTRAL: CN‐00747286] BoltonWK , BesarabA , GermainM , KovesdyCP , HutchinsonJ , KrauszA . Ferumoxytol as an IV iron replacement therapy: efficacy results from two Phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO798]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):761A. [CENTRAL: CN‐00747287] BoltonWK , FishbaneS , LiJ , MilichL , BrennerR . Increases in hemoglobin and the effect of ESA use in CKD patients treated with IV ferumoxytol [abstract]. American Journal of Kidney Diseases2009;53(4):A30. [EMBASE: 70141518] FishbaneS , BoltonWK , WinkelmayerWC , StraussW , LiZ , PereiraBJ . Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Clinical Nephrology2012;78(3):181‐8. [MEDLINE: 22874106] GermainM , BrennerL , DioguardiJ , GilbertsonD , BesarabA . Comparison of safety and efficacy of ferumoxytol in CKD subtypes: kidney transplant recipients, hemodialysis patients and non‐hemodialysis patients [abstract no: SA‐PO2530]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00747289] LuM , CohenMH , RievesD , PazdurR . FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. American Journal of Hematology2010;85(5):315‐9. [MEDLINE: 20201089] SpinowitzB , BesarabA , BoltonWK , PereiraBJ , ProvenzanoR , RaoM , et al. Ferumoxytol as intravenous iron replacement therapy in chronic kidney disease (CKD) patients not on dialysis ‐ evaluation of safety and efficacy in two phase III studies [abstract no: F‐PO026]. Journal of the American Society of Nephrology2006;17(Abstracts):342A. [CENTRAL: CN‐00644267] SpinowitzB , KauszA , MillerP , BrennerL , SinghA . Achievement of target hemoglobin with ferumoxytol versus oral iron in anemic CKD patients [abstract no: SU‐PO1031]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):814A. [CENTRAL: CN‐00688845] SpinowitzB , KrauzA , DioguardiJ , KovesdyC . Evaluation of ferumoxytol safety and efficacy in all stages of chronic kidney disease (CKD) [abstract no: 249]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00747323] ">Lu 2010 CKD</a>; <a href="./references#CD007857-bbs2-0023" title="MudgeDW , TanK , MilesR , JohnsonDW , CampbellSB , HawleyCM , et al. Intravenous versus oral iron for post‐transplant anaemia: a randomised controlled trial [abstract no: 149]. Transplantation2010;90(Suppl 1):679. [EMBASE: 71532404] MudgeDW , TanKS , MilesR , JohnsonDW , BadveSV , CampbellSB , et al. A randomized controlled trial of intravenous or oral iron for posttransplant anemia in kidney transplantation. Transplantation2012;93(8):822‐6. [MEDLINE: 22290270] MudgeDW , TanKS , MilesR , JohnsonDW , CampbellSB , HawleyCM , et al. Intravenous versus oral iron supplementation for correction of post‐transplant anaemia in renal transplant patients. BMC Nephrology2009;10:14. [MEDLINE: 19500381] ">Mudge 2009 TX</a>; <a href="./references#CD007857-bbs2-0024" title="NagarajuSP , CohnA , AkbariA , DavisJL , ZimmermanDL . Heme iron polypeptide for the treatment of iron deficiency anemia in non‐dialysis chronic kidney disease patients: a randomized controlled trial. BMC Nephrology2013;14:64. [MEDLINE: 23514036] ">Nagaraju 2013 CKD</a>; <a href="./references#CD007857-bbs2-0025" title="StraussMD . A randomized, open‐label, active‐controlled study of the safety, efficacy, and pharmacokinetics of ferumoxytol compared with oral iron for the treatment of iron deficiency anemia in pediatric subjects with chronic kidney disease. www.clinicaltrials.gov/ct2/show/NCT01155375 (first received 1 July 2010). ">NCT01155375 HD,PD,CKD</a>; <a href="./references#CD007857-bbs2-0026" title="PisaniA , RiccioE , SabbatiniM , AndreucciM , DelRioA , ViscianoB . Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrology Dialysis Transplantation2014;30(4):645‐52. [MEDLINE: 25395392] ViscianoB , NazzaroP , RiccioE , DelRioA , MozzilloGR , PisaniA . Liposomial iron for the treatment of iron deficiency anemia in non dialysis chronic kidney disease patients: a randomized controlled trial [abstract]. Nephrology Dialysis Transplantation2014;29(5 Suppl 3):iii141‐2. [EMBASE: 71491842] ViscianoB , NazzaroP , TarantinoG , TaddeiA , DelRioA , MozzilloGR , et al. Liposomial iron: a new proposal for the treatment of anaemia in chronic kidney disease [Il ferro liposomiale: una nuova proposta per il trattamento dell’anemia nei pazienti affetti da insufficenza renale cronica]. Giornale Italiano di Nefrologia2013;30(5). [MEDLINE: 24402627] ">Pisani 2014 CKD</a>; <a href="./references#CD007857-bbs2-0029" title="RagabM , MahmoudK , RagabA . Maintenance intravenous iron sucrose therapy in children under regular hemodialysis. Journal of Medical Sciences2007;7(7):1112‐6. [EMBASE: 2007615596] ">Ragab 2007 HD</a>; <a href="./references#CD007857-bbs2-0035" title="TsuchidaA , PaudyalB , PaudyalP , IshiiY , HiromuraK , NojimaY , et al. Effectiveness of oral iron to manage anemia in long‐term hemodialysis patients with the use of ultrapure dialysate. Experimental &amp; Therapeutic Medicine2010;1(5):777‐81. [EMBASE: 2010419867] ">Tsuchida 2010 HD</a>; <a href="./references#CD007857-bbs2-0039" title="WinneyRJ , SwainsonCP , ParkerA , BoneJM , RobsonJS . Iron therapy in hemodialysis patients: Oral or parenteral? [abstract]. Kidney International1977;12(1):88. [CENTRAL: CN‐00747346] ">Winney 1977 HD</a>), three new excluded studies (4 reports) and 14 additional reports of previously included studies.. The additional reports included the full publication of <a href="./references#CD007857-bbs2-0028" title="BenjaminJ . A randomized controlled trial comparing IV ferric carboxymaltose (FCM) to oral iron in anemic nondialysis dependent CKD patients (with or without erythropoiesis stimulating agent use) [abstract no: M574]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐01658222] BenjaminJ , QunibiW . Comparison of intravenous (IV) ferric carboxymaltose (FCM) to oral iron in anemic non‐dialysis dependent (NDD)‐CKD patients with or without ESA therapy [abstract no: SA‐PO2422]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):666A. QunibiW , MartinezC , SmithM , BenjaminJ , DinhQ . A randomized controlled trial comparing IV ferric carboxymaltose (FCM) to oral iron in anemic patients with non‐dialysis‐dependent CKD [abstract no: SU‐PO1030]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):814A. [CENTRAL: CN‐00689191] QunibiWY , MartinezC , SmithM , BenjaminJ , MangioneA , RogerSD . A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non‐dialysis‐dependent chronic kidney disease patients. Nephrology Dialysis Transplantation2011;26(5):1599‐607. [MEDLINE: 20929915] ">Qunibi 2011 CKD</a>. Of the 11 new included studies, four were publications of trials identified as ongoing trials in the 2010 review (<a href="./references#CD007857-bbs2-0002" title="AgarwalR , KusekJW , PappasMK . A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney International2015;88(4):905‐14. [DOI: 10.1038/ki.2015.163; MEDLINE: 26083656] ">Agarwal 2015 CKD</a>; <a href="./references#CD007857-bbs2-0012" title="KalraPA , BhandariS , SaxenaS , AgarwalD , WirtzG , KletzmayrJ , et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non‐dialysis‐dependent chronic kidney disease patients with anaemia. Nephrology Dialysis Transplantation2016;31(4):646‐55. [MEDLINE: 26250435] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside 1000 (monofer) compared to oral iron sulphate in European patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii200. [EMBASE: 72206812] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside1000 (monofer) compared to oral iron sulphate in patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract no: SA‐PO1106]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B7. ">Kalra 2016 CKD</a>; <a href="./references#CD007857-bbs2-0023" title="MudgeDW , TanK , MilesR , JohnsonDW , CampbellSB , HawleyCM , et al. Intravenous versus oral iron for post‐transplant anaemia: a randomised controlled trial [abstract no: 149]. Transplantation2010;90(Suppl 1):679. [EMBASE: 71532404] MudgeDW , TanKS , MilesR , JohnsonDW , BadveSV , CampbellSB , et al. A randomized controlled trial of intravenous or oral iron for posttransplant anemia in kidney transplantation. Transplantation2012;93(8):822‐6. [MEDLINE: 22290270] MudgeDW , TanKS , MilesR , JohnsonDW , CampbellSB , HawleyCM , et al. Intravenous versus oral iron supplementation for correction of post‐transplant anaemia in renal transplant patients. BMC Nephrology2009;10:14. [MEDLINE: 19500381] ">Mudge 2009 TX</a>; <a href="./references#CD007857-bbs2-0025" title="StraussMD . A randomized, open‐label, active‐controlled study of the safety, efficacy, and pharmacokinetics of ferumoxytol compared with oral iron for the treatment of iron deficiency anemia in pediatric subjects with chronic kidney disease. www.clinicaltrials.gov/ct2/show/NCT01155375 (first received 1 July 2010). ">NCT01155375 HD,PD,CKD</a>). The paediatric study (<a href="./references#CD007857-bbs2-0025" title="StraussMD . A randomized, open‐label, active‐controlled study of the safety, efficacy, and pharmacokinetics of ferumoxytol compared with oral iron for the treatment of iron deficiency anemia in pediatric subjects with chronic kidney disease. www.clinicaltrials.gov/ct2/show/NCT01155375 (first received 1 July 2010). ">NCT01155375 HD,PD,CKD</a>) was terminated because of challenges with enrolment with minimal data reported. Search results are shown in <a href="#CD007857-fig-0001">Figure 1</a>. One new report contained further information on two already included studies (<a href="./references#CD007857-bbs2-0015" title="LiH , WangSX . Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Blood Purification2008;26(2):151‐6. [MEDLINE: 18212498] LiH , WangSX . Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study. Chung‐Hua i Hsueh Tsa Chih [Chinese Medical Journal]2009;89(7):457‐62. [MEDLINE: 19567093] ">Li 2008 HD</a>; <a href="./references#CD007857-bbs2-0016" title="LiH , WangSX . Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study. Chung‐Hua i Hsueh Tsa Chih [Chinese Medical Journal]2009;89(7):457‐62. [MEDLINE: 19567093] LiH , WangSX . Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Peritoneal Dialysis International2008;28(2):149‐54. [MEDLINE: 18332450] ">Li 2008 PD</a>). <a href="./references#CD007857-bbs2-0031" title="BesarabA , CoyneD , BoltonWK , SharmaA , FotiA , BrennerL . Ferumoxytol as an intravenous iron replacement therapy: safety results from two phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO0805]. Journal of the American Society of Nephrology2007;18(Abstracts issue):762A. [CENTRAL: CN‐00747286] BoltonWK , BesarabA , GermainM , KovesdyCP , HutchinsonJ , KrauszA . Ferumoxytol as an IV iron replacement therapy: efficacy results from two Phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO798]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):761A. [CENTRAL: CN‐00747287] BoltonWK , FishbaneS , LiJ , MilichL , BrennerR . Increases in hemoglobin and the effect of ESA use in CKD patients treated with IV ferumoxytol [abstract]. American Journal of Kidney Diseases2009;53(4):A30. [EMBASE: 70141518] BrennerL , MillerP , RodriguezS , ParikhN , CoyneDW . Treatment of iron‐deficiency anemia with IV ferumoxytol in CKD patients: efficacy compared with oral iron across different age groups [abstract]. Blood2007;110(11). [CENTRAL: CN‐00646734] FishbaneS , BoltonWK , WinkelmayerWC , StraussW , LiZ , PereiraBJ . Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Clinical Nephrology2012;78(3):181‐8. [MEDLINE: 22874106] GermainM , BrennerL , DioguardiJ , GilbertsonD , BesarabA . Comparison of safety and efficacy of ferumoxytol in CKD subtypes: kidney transplant recipients, hemodialysis patients and non‐hemodialysis patients [abstract no: SA‐PO2530]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00747289] HorlWH . Comparing the efficacy of intravenous iron and oral iron in nondialysis patients with chronic kidney disease. Nature Clinical Practice Nephrology2008;4(10):530‐1. [EMBASE: 2008457134] LuM , CohenMH , RievesD , PazdurR . FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. American Journal of Hematology2010;85(5):315‐9. [MEDLINE: 20201089] SpinowitzB , BernardoM , NobleS , BaptistaJ , PereiraB , BrennerL . Safety and efficacy of ferumoxytol as an intravenous iron replacement therapy: results from a phase III study of chronic kidney disease (CKD) patients not on dialysis [abstract no: 30]. American Journal of Kidney Diseases2007;49(4):A32. [CENTRAL: CN‐00644268] SpinowitzB , BesarabA , BoltonWK , PereiraBJ , ProvenzanoR , RaoM , et al. Ferumoxytol as intravenous iron replacement therapy in chronic kidney disease (CKD) patients not on dialysis ‐ evaluation of safety and efficacy in two phase III studies [abstract no: F‐PO026]. Journal of the American Society of Nephrology2006;17(Abstracts):342A. [CENTRAL: CN‐00644267] SpinowitzB , KauszA , MillerP , BrennerL , SinghA . Achievement of target hemoglobin with ferumoxytol versus oral iron in anemic CKD patients [abstract no: SU‐PO1031]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):814A. [CENTRAL: CN‐00688845] SpinowitzB , KrauzA , DioguardiJ , KovesdyC . Evaluation of ferumoxytol safety and efficacy in all stages of chronic kidney disease (CKD) [abstract no: 249]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00747323] SpinowitzBS , KauszAT , BaptistaJ , NobleSD , SothinathanR , BernardoMV , et al. Ferumoxytol for treating iron deficiency anemia in CKD. Journal of the American Society of Nephrology2008;19(8):1599‐605. [MEDLINE: 18525001] ">Spinowitz 2008 CKD</a> included all nine reports, which included data for one new included study (<a href="./references#CD007857-bbs2-0017" title="BesarabA , CoyneD , BoltonWK , SharmaA , FotiA , BrennerL . Ferumoxytol as an intravenous iron replacement therapy: safety results from two phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO0805]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):762A. [CENTRAL: CN‐00747286] BoltonWK , BesarabA , GermainM , KovesdyCP , HutchinsonJ , KrauszA . Ferumoxytol as an IV iron replacement therapy: efficacy results from two Phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO798]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):761A. [CENTRAL: CN‐00747287] BoltonWK , FishbaneS , LiJ , MilichL , BrennerR . Increases in hemoglobin and the effect of ESA use in CKD patients treated with IV ferumoxytol [abstract]. American Journal of Kidney Diseases2009;53(4):A30. [EMBASE: 70141518] FishbaneS , BoltonWK , WinkelmayerWC , StraussW , LiZ , PereiraBJ . Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Clinical Nephrology2012;78(3):181‐8. [MEDLINE: 22874106] GermainM , BrennerL , DioguardiJ , GilbertsonD , BesarabA . Comparison of safety and efficacy of ferumoxytol in CKD subtypes: kidney transplant recipients, hemodialysis patients and non‐hemodialysis patients [abstract no: SA‐PO2530]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00747289] LuM , CohenMH , RievesD , PazdurR . FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. American Journal of Hematology2010;85(5):315‐9. [MEDLINE: 20201089] SpinowitzB , BesarabA , BoltonWK , PereiraBJ , ProvenzanoR , RaoM , et al. Ferumoxytol as intravenous iron replacement therapy in chronic kidney disease (CKD) patients not on dialysis ‐ evaluation of safety and efficacy in two phase III studies [abstract no: F‐PO026]. Journal of the American Society of Nephrology2006;17(Abstracts):342A. [CENTRAL: CN‐00644267] SpinowitzB , KauszA , MillerP , BrennerL , SinghA . Achievement of target hemoglobin with ferumoxytol versus oral iron in anemic CKD patients [abstract no: SU‐PO1031]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):814A. [CENTRAL: CN‐00688845] SpinowitzB , KrauzA , DioguardiJ , KovesdyC . Evaluation of ferumoxytol safety and efficacy in all stages of chronic kidney disease (CKD) [abstract no: 249]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00747323] ">Lu 2010 CKD</a>). This 2019 update contains 44 studies (101 reports). </p> <div class="figure" id="CD007857-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram of studies included in the systematic review" data-id="CD007857-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram of studies included in the systematic review</p> </div> </div> </div> </section> <section id="CD007857-sec-0073"> <h4 class="title">Included studies</h4> <p>The 11 new included studies (31 reports) provided an additional 1754 participants bringing the total to 3852 participants. Of the new studies, seven included 1653 participants with CKD, three included 75 participants on HD and one included 102 transplant patients. One study included both dialysis and non‐dialysis patients but did not specify how many patients were in each group. </p> <p>Of the 39 included studies, 38 (3832 participants) were parallel group studies, and one (20 patients) was a cross‐over study (<a href="./references#CD007857-bbs2-0033" title="StricklandID , Chaput de SaintongeDM , BoultonFE , FrancisB , RoubikovaJ , WatersJI . The therapeutic equivalence of oral and intravenous iron in renal dialysis patients. Clinical Nephrology1977;7(2):55‐7. [MEDLINE: 321170] ">Strickland 1977 HD</a>). Only three studies involved paediatric patients (<a href="./references#CD007857-bbs2-0025" title="StraussMD . A randomized, open‐label, active‐controlled study of the safety, efficacy, and pharmacokinetics of ferumoxytol compared with oral iron for the treatment of iron deficiency anemia in pediatric subjects with chronic kidney disease. www.clinicaltrials.gov/ct2/show/NCT01155375 (first received 1 July 2010). ">NCT01155375 HD,PD,CKD</a>; <a href="./references#CD007857-bbs2-0029" title="RagabM , MahmoudK , RagabA . Maintenance intravenous iron sucrose therapy in children under regular hemodialysis. Journal of Medical Sciences2007;7(7):1112‐6. [EMBASE: 2007615596] ">Ragab 2007 HD</a>; <a href="./references#CD007857-bbs2-0038" title="WaradyBA , KauszA , LernerG , BrewerED , ChadhaV , BrugnaraC , et al. Iron therapy in the pediatric hemodialysis population. Pediatric Nephrology2004;19(6):655‐61. [MEDLINE: 15064942] WaradyBA , KauszAT , LernerG , BrewerED , ChadhaV , BrugnaraC , et al. A comparison of intravenous and oral iron therapy in children receiving hemodialysis [abstract no: F‐PO789]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):221A. [CENTRAL: CN‐01657600] ">Warady 2002 HD</a>). Nineteen studies included only HD patients. <a href="./references#CD007857-bbs2-0016" title="LiH , WangSX . Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study. Chung‐Hua i Hsueh Tsa Chih [Chinese Medical Journal]2009;89(7):457‐62. [MEDLINE: 19567093] LiH , WangSX . Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Peritoneal Dialysis International2008;28(2):149‐54. [MEDLINE: 18332450] ">Li 2008 PD</a> included only patients on PD while <a href="./references#CD007857-bbs2-0020" title="MacdougallIC , UK Multicentre IV Iron Study Group. UK multicentre randomized controlled study of IV vs oral iron supplementation in dialysis patients receiving epoetin [abstract no: A1472]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):291A. [CENTRAL: CN‐00747320] ">Macdougall 1999 HD,PD</a> included both HD and PD patients. Two studies (<a href="./references#CD007857-bbs2-0004" title="AhsanN , HolmanMJ , O'BrienB , LanghoffEG , YangHC . Intravenous infusion of total is superior to oral iron in the treatment of post‐kidney transplant functional anemia [abstract no: A3131]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):672A. [CENTRAL: CN‐00676050] ">Ahsan 1997 TX</a>; <a href="./references#CD007857-bbs2-0023" title="MudgeDW , TanK , MilesR , JohnsonDW , CampbellSB , HawleyCM , et al. Intravenous versus oral iron for post‐transplant anaemia: a randomised controlled trial [abstract no: 149]. Transplantation2010;90(Suppl 1):679. [EMBASE: 71532404] MudgeDW , TanKS , MilesR , JohnsonDW , BadveSV , CampbellSB , et al. A randomized controlled trial of intravenous or oral iron for posttransplant anemia in kidney transplantation. Transplantation2012;93(8):822‐6. [MEDLINE: 22290270] MudgeDW , TanKS , MilesR , JohnsonDW , CampbellSB , HawleyCM , et al. Intravenous versus oral iron supplementation for correction of post‐transplant anaemia in renal transplant patients. BMC Nephrology2009;10:14. [MEDLINE: 19500381] ">Mudge 2009 TX</a>) evaluated patients who were in the early phase of post‐kidney transplantation. Results from these studies were pooled with studies of dialysis patients. Thirteen studies included non‐dialysis patients (CKD stages 3 to 5) while two studies (<a href="./references#CD007857-bbs2-0019" title="MacdougallIC , TuckerB , ThompsonJ , BakerIR , RaineAE . A randomised controlled study of iron supplementation in patients treated with erythropoietin [abstract]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):428. [CENTRAL: CN‐00484929] MacdougallIC , TuckerB , ThompsonJ , TomsonCR , BakerLR , RaineAE . A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney International1996;50(5):1694‐9. [MEDLINE: 8914038] MacdougallIC , TuckerB , ThompsonJ , TomsonCR , BakerLR , RaineAE . Randomised controlled study of iron supplementation in patients treated with erythropoietin [abstract]. Nephrology Dialysis Transplantation1993;8(12):1424. [CENTRAL: CN‐00260914] MacdougallIC , TuckerB , ThompsonJ , TomsonCRV , BakerLR , RaineAE . Randomised controlled study of iron supplementation in patients treated with erythropoietin [abstract]. Nephrology Dialysis Transplantation1993;8(9):960. [CENTRAL: CN‐01657602] ">Macdougall 1996 HD,PD,CKD</a>; <a href="./references#CD007857-bbs2-0025" title="StraussMD . A randomized, open‐label, active‐controlled study of the safety, efficacy, and pharmacokinetics of ferumoxytol compared with oral iron for the treatment of iron deficiency anemia in pediatric subjects with chronic kidney disease. www.clinicaltrials.gov/ct2/show/NCT01155375 (first received 1 July 2010). ">NCT01155375 HD,PD,CKD</a>) included both dialysis and non‐dialysis patients. Twelve studies were available only as abstracts or from ClinicalTrials.Gov (<a href="./references#CD007857-bbs2-0004" title="AhsanN , HolmanMJ , O'BrienB , LanghoffEG , YangHC . Intravenous infusion of total is superior to oral iron in the treatment of post‐kidney transplant functional anemia [abstract no: A3131]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):672A. [CENTRAL: CN‐00676050] ">Ahsan 1997 TX</a>; <a href="./references#CD007857-bbs2-0005" title="BroumandB , GhodsA , TaheriFM , HanjaniMR . Intravenous versus oral iron supplementation in the management of anemia in end stage renal disease [abstract]. 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6‐9; Rimini, Italy. 1998:330. [CENTRAL: CN‐00483339] ">Broumand 1998 HD</a>; <a href="./references#CD007857-bbs2-0007" title="ErtenY , OzdemirFN , GuzG , SezerS , HaberalA , KayaS , et al. Comparison of the effect of intravenous and oral iron therapies on hemodialysis patients [abstract no: M384]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):248A. [CENTRAL: CN‐01657553] ErtenY , OzdemirFN , GuzG , SezerS , HaberalA , KayaS , et al. Comparison of the effect of intravenous and oral iron therapies on hemodialysis patients [abstract]. 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6‐9; Rimini, Italy. 1998:337. [CENTRAL: CN‐00445251] ">Erten 1998 HD</a>; <a href="./references#CD007857-bbs2-0014" title="LeeheyDJ , KaskasMO , BastaniB , Ferrlecit CKD Study Group. Sodium ferric gluconate complex (SFGC) in the treatment of chronic kidney disease (CKD) patients on stable erythropoietic therapy [abstract no: F‐PO966]. Journal of the American Society of Nephrology2005;16:547A. [CENTRAL: CN‐00747316] ">Leehey 2005 CKD</a>; <a href="./references#CD007857-bbs2-0017" title="BesarabA , CoyneD , BoltonWK , SharmaA , FotiA , BrennerL . Ferumoxytol as an intravenous iron replacement therapy: safety results from two phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO0805]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):762A. [CENTRAL: CN‐00747286] BoltonWK , BesarabA , GermainM , KovesdyCP , HutchinsonJ , KrauszA . Ferumoxytol as an IV iron replacement therapy: efficacy results from two Phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO798]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):761A. [CENTRAL: CN‐00747287] BoltonWK , FishbaneS , LiJ , MilichL , BrennerR . Increases in hemoglobin and the effect of ESA use in CKD patients treated with IV ferumoxytol [abstract]. American Journal of Kidney Diseases2009;53(4):A30. [EMBASE: 70141518] FishbaneS , BoltonWK , WinkelmayerWC , StraussW , LiZ , PereiraBJ . Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Clinical Nephrology2012;78(3):181‐8. [MEDLINE: 22874106] GermainM , BrennerL , DioguardiJ , GilbertsonD , BesarabA . Comparison of safety and efficacy of ferumoxytol in CKD subtypes: kidney transplant recipients, hemodialysis patients and non‐hemodialysis patients [abstract no: SA‐PO2530]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00747289] LuM , CohenMH , RievesD , PazdurR . FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. American Journal of Hematology2010;85(5):315‐9. [MEDLINE: 20201089] SpinowitzB , BesarabA , BoltonWK , PereiraBJ , ProvenzanoR , RaoM , et al. Ferumoxytol as intravenous iron replacement therapy in chronic kidney disease (CKD) patients not on dialysis ‐ evaluation of safety and efficacy in two phase III studies [abstract no: F‐PO026]. Journal of the American Society of Nephrology2006;17(Abstracts):342A. [CENTRAL: CN‐00644267] SpinowitzB , KauszA , MillerP , BrennerL , SinghA . Achievement of target hemoglobin with ferumoxytol versus oral iron in anemic CKD patients [abstract no: SU‐PO1031]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):814A. [CENTRAL: CN‐00688845] SpinowitzB , KrauzA , DioguardiJ , KovesdyC . Evaluation of ferumoxytol safety and efficacy in all stages of chronic kidney disease (CKD) [abstract no: 249]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00747323] ">Lu 2010 CKD</a>; <a href="./references#CD007857-bbs2-0018" title="LyeWC . Ferric gluconate polymaltose complex (Ferrum) is safe and effective for intravenous use in hemodialysis (HD) patients [abstract no: A1489]. Journal of the American Society of Nephrology2000;11(Sept):284A. ">Lye 2000 HD</a>; <a href="./references#CD007857-bbs2-0020" title="MacdougallIC , UK Multicentre IV Iron Study Group. UK multicentre randomized controlled study of IV vs oral iron supplementation in dialysis patients receiving epoetin [abstract no: A1472]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):291A. [CENTRAL: CN‐00747320] ">Macdougall 1999 HD,PD</a>; <a href="./references#CD007857-bbs2-0022" title="MichaelB , TroutJR , HoelG , VolinnW , JorgensenN , DahlNV , et al. Effectiveness of continuous low‐dose intravenous ferric gluconate therapy for maintaining Hgb and decreasing epoetin requirements in hemodialysis patients [abstract no: F‐PO849]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):289A. [CENTRAL: CN‐00689934] ">Michael 2007 HD</a>; <a href="./references#CD007857-bbs2-0025" title="StraussMD . A randomized, open‐label, active‐controlled study of the safety, efficacy, and pharmacokinetics of ferumoxytol compared with oral iron for the treatment of iron deficiency anemia in pediatric subjects with chronic kidney disease. www.clinicaltrials.gov/ct2/show/NCT01155375 (first received 1 July 2010). ">NCT01155375 HD,PD,CKD</a>; <a href="./references#CD007857-bbs2-0030" title="SouzaRM , DefferrariR , KarohlC , BarrosE , ThomeF . Iron status evaluation and iron supplementation therapy in hemodialysis (HD) chronic renal failure (CRF) patients: a randomized clinical trial [abstract]. Nephrology1997;3(Suppl 1):S307. [CENTRAL: CN‐00461775] ">Souza 1997 HD</a>; <a href="./references#CD007857-bbs2-0037" title="WangL , LiG , LiaoC , WangF . The effects of oral vs venous iron supplement in treatment of iron deficiency of maintained patients with anemia [abstract no: PUB324]. Journal of the American Society of Nephrology2003;14(Nov):842A. [CENTRAL: CN‐00747318] ">Wang 2003 HD</a>; <a href="./references#CD007857-bbs2-0039" title="WinneyRJ , SwainsonCP , ParkerA , BoneJM , RobsonJS . Iron therapy in hemodialysis patients: Oral or parenteral? [abstract]. Kidney International1977;12(1):88. [CENTRAL: CN‐00747346] ">Winney 1977 HD</a>). Thirty‐two studies were designed to increase Hb levels and four studies were designed to maintain Hb stability in iron replete patients and decrease ESA dose (<a href="./references#CD007857-bbs2-0009" title="FishbaneS , FreiGL , MaesakaJ . Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. American Journal of Kidney Diseases1995;26(1):41‐6. [MEDLINE: 7611266] ">Fishbane 1995 HD</a>; <a href="./references#CD007857-bbs2-0013" title="KotakiM , UdayK , HenriquezM , BlumS , DaveM . Intravenous iron therapy in hemodialysis [abstract no: A1021]. Journal of the American Society of Nephrology1996;7(9):1452. [CENTRAL: CN‐01657494] KotakiM , UdayK , HenriquezM , BlumS , DaveM . Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin. Clinical Nephrology1997;48(1):63‐4. [MEDLINE: 9247787] ">Kotaki 1997 HD</a>; <a href="./references#CD007857-bbs2-0022" title="MichaelB , TroutJR , HoelG , VolinnW , JorgensenN , DahlNV , et al. Effectiveness of continuous low‐dose intravenous ferric gluconate therapy for maintaining Hgb and decreasing epoetin requirements in hemodialysis patients [abstract no: F‐PO849]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):289A. [CENTRAL: CN‐00689934] ">Michael 2007 HD</a>; <a href="./references#CD007857-bbs2-0038" title="WaradyBA , KauszA , LernerG , BrewerED , ChadhaV , BrugnaraC , et al. Iron therapy in the pediatric hemodialysis population. Pediatric Nephrology2004;19(6):655‐61. [MEDLINE: 15064942] WaradyBA , KauszAT , LernerG , BrewerED , ChadhaV , BrugnaraC , et al. A comparison of intravenous and oral iron therapy in children receiving hemodialysis [abstract no: F‐PO789]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):221A. [CENTRAL: CN‐01657600] ">Warady 2002 HD</a>). One study was designed to examine changes in GFR during (<a href="./references#CD007857-bbs2-0002" title="AgarwalR , KusekJW , PappasMK . A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney International2015;88(4):905‐14. [DOI: 10.1038/ki.2015.163; MEDLINE: 26083656] ">Agarwal 2015 CKD</a>) while one study was designed to determine the time to the start of additional anaemia management other than iron (<a href="./references#CD007857-bbs2-0008" title="GaillardCA , BockAH , CarreraF , EckardtK , VanWyckDB , BansalSS , et al. Hepcidin response to intravenous (IV) or oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis CKD (ND‐CKD) [abstract no: TH‐OR040]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. GaillardCA , BockAH , CarreraF , EckardtKU , VanWyckDB , BansalSS , et al. Hepcidin response to iron therapy in patients with non‐dialysis dependent CKD: an analysis of the FIND‐CKD trial. PLoS ONE [Electronic Resource]2016;11(6):e0157063. [MEDLINE: 27276035] MacdougallI , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. A model to predict haematopoietic non‐response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD): an analysis from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193‐4. [EMBASE: 72326413] MacdougallIC , BockA , CarreraF , CushwayT , MoriC , RogerS . Rationale and design of a new RCT of iron therapy in anemic non‐dialysis CKD patients: FIND‐CKD trial [abstract no: SA‐PO2402]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):660A. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. The FIND‐CKD study‐‐a randomized controlled trial of intravenous iron versus oral iron in non‐dialysis chronic kidney disease patients: background and rationale. Nephrology Dialysis Transplantation2014;29(4):843‐50. [MEDLINE: 24170814] MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. FIND‐CKD: a 56‐week randomized trial of intravenous ferric carboxymaltose versus oral iron in anemic patients with chronic kidney disease and iron deficiency [abstract no: SA‐PO1079]. Journal of the American Society of Nephrology2013;24(Abstracts):3B. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. Intravenous ferric carboxymaltose vs oral iron in anaemic patients with non‐dialysis dependent chronic kidney disease and iron deficiency: results of the randomised FIND‐CKD study [abstract no: SO049]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. MacdougallIC , BockAH , CarreraF , EckardtK , GaillardC , VanWyckD , et al. Efficacy of oral iron for treating iron deficiency in anaemic patients with non‐dialysis dependent CKD (ND‐CKD) [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii581. [EMBASE: 617290898] MacdougallIC , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. Iron administration to non‐dialysis CKD patients for one year does not cause worsening of renal function: results from the FIND‐CKD trial [abstract no: FR‐PO809]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):555A. MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Erythropoietic response to oral iron in patients with nondialysis‐dependent chronic kidney disease in the FIND‐CKD trial. Clinical Nephrology2017;88(12):301‐10. [MEDLINE: 29092739] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. FIND‐CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrology Dialysis Transplantation2014;29(11):2075‐84. [MEDLINE: 24891437] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Renal function in patients with non‐dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND‐CKD trial. BMC Nephrology2017;18(1):24. [MEDLINE: 28095881] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Hepcidin response to iron therapy in patients with non‐dialysis CKD: an analysis of the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8‐9. [EMBASE: 72206297] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Low rate of early response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD) [abstract no: TH‐PO906]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. RogerS , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. The safety of intravenous (IV) ferric carboxymaltose (FCM) in patients with non‐dialysis dependent CKD (ND‐CKD): 1‐year results from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i15‐6. [EMBASE: 72325953] RogerSD , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. IV ferric carboxymaltose (FCM) is a convenient and well‐tolerated first‐line therapy for the treatment of anaemia in patients with iron deficiency and non‐dialysis dependent chronic kidney disease (ND‐CKD): results of the randomised FIND‐CKD study [abstract no: SO048]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. RogerSD , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Intravenous (IV) ferric carboxymaltose (FCM) versus oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis dependant CKD (ND‐CKD): a safety analysis [abstract no: TH‐PO652]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):238A. ">FIND‐CKD 2014 CKD</a>). </p> <p>The duration of follow‐up ranged from 35 days to 26 months.</p> <p>Studies compared different oral and IV iron preparations. The oral iron agents investigated were ferrous sulphate (25 studies), ferrous fumarate (7), ferrous succinate (2), iron gluconate (1), liposomal iron (1), heme iron polypeptide (1) and unnamed agents in two studies. The IV iron agents investigated were iron sucrose (15 studies), iron dextran (7), ferumoxytol (4), sodium ferric gluconate complex (5), ferric carboxymaltose (2), iron isomaltoside (1), ferric citrate (1), and ferric hydroxide polymaltose (3). The IV iron agent was not reported in <a href="./references#CD007857-bbs2-0013" title="KotakiM , UdayK , HenriquezM , BlumS , DaveM . Intravenous iron therapy in hemodialysis [abstract no: A1021]. Journal of the American Society of Nephrology1996;7(9):1452. [CENTRAL: CN‐01657494] KotakiM , UdayK , HenriquezM , BlumS , DaveM . Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin. Clinical Nephrology1997;48(1):63‐4. [MEDLINE: 9247787] ">Kotaki 1997 HD</a>. The calculated total dose of elemental iron ranged from 2520 mg to 63,000 mg in the oral iron groups and from 500 to 10,920 mg in the IV iron groups. Three studies (<a href="./references#CD007857-bbs2-0007" title="ErtenY , OzdemirFN , GuzG , SezerS , HaberalA , KayaS , et al. Comparison of the effect of intravenous and oral iron therapies on hemodialysis patients [abstract no: M384]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):248A. [CENTRAL: CN‐01657553] ErtenY , OzdemirFN , GuzG , SezerS , HaberalA , KayaS , et al. Comparison of the effect of intravenous and oral iron therapies on hemodialysis patients [abstract]. 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6‐9; Rimini, Italy. 1998:337. [CENTRAL: CN‐00445251] ">Erten 1998 HD</a>; <a href="./references#CD007857-bbs2-0008" title="GaillardCA , BockAH , CarreraF , EckardtK , VanWyckDB , BansalSS , et al. Hepcidin response to intravenous (IV) or oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis CKD (ND‐CKD) [abstract no: TH‐OR040]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. GaillardCA , BockAH , CarreraF , EckardtKU , VanWyckDB , BansalSS , et al. Hepcidin response to iron therapy in patients with non‐dialysis dependent CKD: an analysis of the FIND‐CKD trial. PLoS ONE [Electronic Resource]2016;11(6):e0157063. [MEDLINE: 27276035] MacdougallI , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. A model to predict haematopoietic non‐response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD): an analysis from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193‐4. [EMBASE: 72326413] MacdougallIC , BockA , CarreraF , CushwayT , MoriC , RogerS . Rationale and design of a new RCT of iron therapy in anemic non‐dialysis CKD patients: FIND‐CKD trial [abstract no: SA‐PO2402]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):660A. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. The FIND‐CKD study‐‐a randomized controlled trial of intravenous iron versus oral iron in non‐dialysis chronic kidney disease patients: background and rationale. Nephrology Dialysis Transplantation2014;29(4):843‐50. [MEDLINE: 24170814] MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. FIND‐CKD: a 56‐week randomized trial of intravenous ferric carboxymaltose versus oral iron in anemic patients with chronic kidney disease and iron deficiency [abstract no: SA‐PO1079]. Journal of the American Society of Nephrology2013;24(Abstracts):3B. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. Intravenous ferric carboxymaltose vs oral iron in anaemic patients with non‐dialysis dependent chronic kidney disease and iron deficiency: results of the randomised FIND‐CKD study [abstract no: SO049]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. MacdougallIC , BockAH , CarreraF , EckardtK , GaillardC , VanWyckD , et al. Efficacy of oral iron for treating iron deficiency in anaemic patients with non‐dialysis dependent CKD (ND‐CKD) [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii581. [EMBASE: 617290898] MacdougallIC , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. Iron administration to non‐dialysis CKD patients for one year does not cause worsening of renal function: results from the FIND‐CKD trial [abstract no: FR‐PO809]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):555A. MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Erythropoietic response to oral iron in patients with nondialysis‐dependent chronic kidney disease in the FIND‐CKD trial. Clinical Nephrology2017;88(12):301‐10. [MEDLINE: 29092739] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. FIND‐CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrology Dialysis Transplantation2014;29(11):2075‐84. [MEDLINE: 24891437] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Renal function in patients with non‐dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND‐CKD trial. BMC Nephrology2017;18(1):24. [MEDLINE: 28095881] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Hepcidin response to iron therapy in patients with non‐dialysis CKD: an analysis of the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8‐9. [EMBASE: 72206297] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Low rate of early response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD) [abstract no: TH‐PO906]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. RogerS , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. The safety of intravenous (IV) ferric carboxymaltose (FCM) in patients with non‐dialysis dependent CKD (ND‐CKD): 1‐year results from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i15‐6. [EMBASE: 72325953] RogerSD , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. IV ferric carboxymaltose (FCM) is a convenient and well‐tolerated first‐line therapy for the treatment of anaemia in patients with iron deficiency and non‐dialysis dependent chronic kidney disease (ND‐CKD): results of the randomised FIND‐CKD study [abstract no: SO048]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. RogerSD , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Intravenous (IV) ferric carboxymaltose (FCM) versus oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis dependant CKD (ND‐CKD): a safety analysis [abstract no: TH‐PO652]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):238A. ">FIND‐CKD 2014 CKD</a>; <a href="./references#CD007857-bbs2-0012" title="KalraPA , BhandariS , SaxenaS , AgarwalD , WirtzG , KletzmayrJ , et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non‐dialysis‐dependent chronic kidney disease patients with anaemia. Nephrology Dialysis Transplantation2016;31(4):646‐55. [MEDLINE: 26250435] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside 1000 (monofer) compared to oral iron sulphate in European patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii200. [EMBASE: 72206812] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside1000 (monofer) compared to oral iron sulphate in patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract no: SA‐PO1106]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B7. ">Kalra 2016 CKD</a>) included two IV iron treatment groups. For these studies, data from patients who received the higher total dose of IV iron were included in the meta‐analyses. </p> <p>In twenty‐two studies all participants were treated with an ESA. ESA therapy was started at study commencement in six studies (<a href="./references#CD007857-bbs2-0003" title="AggarwalHK , KumarH , SinghS , NandN . Iron therapy in patients of CRF receiving recombinant human EPO which route of iron? [abstract]. Indian Journal of Nephrology2002;12(4):205. [CENTRAL: CN‐00460253] AggarwalHK , NandN , SinghS , SinghM , Hemant , KaushikG . Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. Journal of the Association of Physicians of India2003;51:170‐4. [MEDLINE: 12725261] AggarwalSH , HemantK , SinghS , NandN , SharmaBD . Comparison of oral versus intravenous iron therapy in patients of chronic renal failure receiving recombined human erythropoietin (R‐HUEPO) [abstract no: 56]. Journal of the Association of Physicians of India2001;50(Oct). [CENTRAL: CN‐00663209] ">Aggarwal 2003 CKD</a>; <a href="./references#CD007857-bbs2-0006" title="CharytanC , QunibiW , BailieGR , Venofer Clinical Studies Group. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron2005;100(3):c55‐62. [MEDLINE: 15824508] CharytanC , QunibiW , SinghH , SchwenkM , AronoffG , BesarabA . Safety of Venofer®, [iron sucrose injection] administered by rapid IV push (IVP) in predialysis CKD patients [abstract no: SU‐PO260]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):521a. [CENTRAL: CN‐00444759] ">Charytan 2005 CKD</a>; <a href="./references#CD007857-bbs2-0011" title="HussainR , ChishtiSH , NaqviS . Experience of iron saccharate supplementation in haemodialysis patients treated with erythropoietin. Nephrology1998;4(1‐2):105‐8. [EMBASE: 1998205059] HussainR , ChishtiSH , NaqviSA . Experience of iron sucrose supplementation in haemodialysis patients treated with erythropoietin [abstract]. 3rd International Congress of Nephrology, Urology &amp; Transplantation Society of SAARC Countries; 1999 Feb 18‐21; Colombo, Sri Lanka. 1999:152. [CENTRAL: CN‐00460975] ">Hussain 1998 HD</a>; <a href="./references#CD007857-bbs2-0018" title="LyeWC . Ferric gluconate polymaltose complex (Ferrum) is safe and effective for intravenous use in hemodialysis (HD) patients [abstract no: A1489]. Journal of the American Society of Nephrology2000;11(Sept):284A. ">Lye 2000 HD</a>; <a href="./references#CD007857-bbs2-0019" title="MacdougallIC , TuckerB , ThompsonJ , BakerIR , RaineAE . A randomised controlled study of iron supplementation in patients treated with erythropoietin [abstract]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):428. [CENTRAL: CN‐00484929] MacdougallIC , TuckerB , ThompsonJ , TomsonCR , BakerLR , RaineAE . A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney International1996;50(5):1694‐9. [MEDLINE: 8914038] MacdougallIC , TuckerB , ThompsonJ , TomsonCR , BakerLR , RaineAE . Randomised controlled study of iron supplementation in patients treated with erythropoietin [abstract]. Nephrology Dialysis Transplantation1993;8(12):1424. [CENTRAL: CN‐00260914] MacdougallIC , TuckerB , ThompsonJ , TomsonCRV , BakerLR , RaineAE . Randomised controlled study of iron supplementation in patients treated with erythropoietin [abstract]. Nephrology Dialysis Transplantation1993;8(9):960. [CENTRAL: CN‐01657602] ">Macdougall 1996 HD,PD,CKD</a>; <a href="./references#CD007857-bbs2-0032" title="StovesJ , InglisH , NewsteadCG . A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrology Dialysis Transplantation2001;16(5):967‐74. [MEDLINE: 11328902] ">Stoves 2001 CKD</a>) and before study commencement in 15 studies (<a href="./references#CD007857-bbs2-0005" title="BroumandB , GhodsA , TaheriFM , HanjaniMR . Intravenous versus oral iron supplementation in the management of anemia in end stage renal disease [abstract]. 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6‐9; Rimini, Italy. 1998:330. [CENTRAL: CN‐00483339] ">Broumand 1998 HD</a>; <a href="./references#CD007857-bbs2-0007" title="ErtenY , OzdemirFN , GuzG , SezerS , HaberalA , KayaS , et al. Comparison of the effect of intravenous and oral iron therapies on hemodialysis patients [abstract no: M384]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):248A. [CENTRAL: CN‐01657553] ErtenY , OzdemirFN , GuzG , SezerS , HaberalA , KayaS , et al. Comparison of the effect of intravenous and oral iron therapies on hemodialysis patients [abstract]. 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6‐9; Rimini, Italy. 1998:337. [CENTRAL: CN‐00445251] ">Erten 1998 HD</a>; <a href="./references#CD007857-bbs2-0009" title="FishbaneS , FreiGL , MaesakaJ . Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. American Journal of Kidney Diseases1995;26(1):41‐6. [MEDLINE: 7611266] ">Fishbane 1995 HD</a>; <a href="./references#CD007857-bbs2-0013" title="KotakiM , UdayK , HenriquezM , BlumS , DaveM . Intravenous iron therapy in hemodialysis [abstract no: A1021]. Journal of the American Society of Nephrology1996;7(9):1452. [CENTRAL: CN‐01657494] KotakiM , UdayK , HenriquezM , BlumS , DaveM . Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin. Clinical Nephrology1997;48(1):63‐4. [MEDLINE: 9247787] ">Kotaki 1997 HD</a>; <a href="./references#CD007857-bbs2-0014" title="LeeheyDJ , KaskasMO , BastaniB , Ferrlecit CKD Study Group. Sodium ferric gluconate complex (SFGC) in the treatment of chronic kidney disease (CKD) patients on stable erythropoietic therapy [abstract no: F‐PO966]. Journal of the American Society of Nephrology2005;16:547A. [CENTRAL: CN‐00747316] ">Leehey 2005 CKD</a>; <a href="./references#CD007857-bbs2-0015" title="LiH , WangSX . Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Blood Purification2008;26(2):151‐6. [MEDLINE: 18212498] LiH , WangSX . Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study. Chung‐Hua i Hsueh Tsa Chih [Chinese Medical Journal]2009;89(7):457‐62. [MEDLINE: 19567093] ">Li 2008 HD</a>; <a href="./references#CD007857-bbs2-0016" title="LiH , WangSX . Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study. Chung‐Hua i Hsueh Tsa Chih [Chinese Medical Journal]2009;89(7):457‐62. [MEDLINE: 19567093] LiH , WangSX . Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Peritoneal Dialysis International2008;28(2):149‐54. [MEDLINE: 18332450] ">Li 2008 PD</a>; <a href="./references#CD007857-bbs2-0020" title="MacdougallIC , UK Multicentre IV Iron Study Group. UK multicentre randomized controlled study of IV vs oral iron supplementation in dialysis patients receiving epoetin [abstract no: A1472]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):291A. [CENTRAL: CN‐00747320] ">Macdougall 1999 HD,PD</a>; <a href="./references#CD007857-bbs2-0022" title="MichaelB , TroutJR , HoelG , VolinnW , JorgensenN , DahlNV , et al. Effectiveness of continuous low‐dose intravenous ferric gluconate therapy for maintaining Hgb and decreasing epoetin requirements in hemodialysis patients [abstract no: F‐PO849]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):289A. [CENTRAL: CN‐00689934] ">Michael 2007 HD</a>; <a href="./references#CD007857-bbs2-0023" title="MudgeDW , TanK , MilesR , JohnsonDW , CampbellSB , HawleyCM , et al. Intravenous versus oral iron for post‐transplant anaemia: a randomised controlled trial [abstract no: 149]. Transplantation2010;90(Suppl 1):679. [EMBASE: 71532404] MudgeDW , TanKS , MilesR , JohnsonDW , BadveSV , CampbellSB , et al. A randomized controlled trial of intravenous or oral iron for posttransplant anemia in kidney transplantation. Transplantation2012;93(8):822‐6. [MEDLINE: 22290270] MudgeDW , TanKS , MilesR , JohnsonDW , CampbellSB , HawleyCM , et al. Intravenous versus oral iron supplementation for correction of post‐transplant anaemia in renal transplant patients. BMC Nephrology2009;10:14. [MEDLINE: 19500381] ">Mudge 2009 TX</a>; <a href="./references#CD007857-bbs2-0027" title="GermainM , BrennerL , DioguardiJ , GilbertsonD , BesarabA . Comparison of safety and efficacy of ferumoxytol in CKD subtypes: kidney transplant recipients, hemodialysis patients and non‐hemodialysis patients [abstract no: SA‐PO2530]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00747289] LuM , CohenMH , RievesD , PazdurR . FDA report. Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. American Journal of Hematology2010;85(5):315‐9. [MEDLINE: 20201089] ProvenzanoR , SchillerB , RaoM , CoyneD , BrennerL , PereiraBJ . Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clinical Journal of the American Society of Nephrology: CJASN2009;4(2):386‐93. [MEDLINE: 19176796] SpinowitzB , KrauzA , DioguardiJ , KovesdyC . Evaluation of ferumoxytol safety and efficacy in all stages of chronic kidney disease (CKD) [abstract no: 249]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00688845] ">Provenzano 2009 HD</a>; <a href="./references#CD007857-bbs2-0029" title="RagabM , MahmoudK , RagabA . Maintenance intravenous iron sucrose therapy in children under regular hemodialysis. Journal of Medical Sciences2007;7(7):1112‐6. [EMBASE: 2007615596] ">Ragab 2007 HD</a>; <a href="./references#CD007857-bbs2-0034" title="SvaraF , SulkovaS , KvasnickaJ , PolakovicV . Iron supplementation during erythropoietin therapy in patients on hemodialysis [Doplnovani zeleza pri lecbe erytropoetinem u hemodialyzovanych pacientu]. Vnitrni Lekarstvi1996;42(12):849‐52. [MEDLINE: 9072885] ">Svara 1996 HD</a>; <a href="./references#CD007857-bbs2-0035" title="TsuchidaA , PaudyalB , PaudyalP , IshiiY , HiromuraK , NojimaY , et al. Effectiveness of oral iron to manage anemia in long‐term hemodialysis patients with the use of ultrapure dialysate. Experimental &amp; Therapeutic Medicine2010;1(5):777‐81. [EMBASE: 2010419867] ">Tsuchida 2010 HD</a>; <a href="./references#CD007857-bbs2-0038" title="WaradyBA , KauszA , LernerG , BrewerED , ChadhaV , BrugnaraC , et al. Iron therapy in the pediatric hemodialysis population. Pediatric Nephrology2004;19(6):655‐61. [MEDLINE: 15064942] WaradyBA , KauszAT , LernerG , BrewerED , ChadhaV , BrugnaraC , et al. A comparison of intravenous and oral iron therapy in children receiving hemodialysis [abstract no: F‐PO789]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):221A. [CENTRAL: CN‐01657600] ">Warady 2002 HD</a>). It was unclear when ESA treatment was commenced in <a href="./references#CD007857-bbs2-0037" title="WangL , LiG , LiaoC , WangF . The effects of oral vs venous iron supplement in treatment of iron deficiency of maintained patients with anemia [abstract no: PUB324]. Journal of the American Society of Nephrology2003;14(Nov):842A. [CENTRAL: CN‐00747318] ">Wang 2003 HD</a>. Seven studies reported that no included patients received ESA treatment (<a href="./references#CD007857-bbs2-0001" title="AgarwalR . Sodium ferric gluconate complex in sucrose (SFGC) injection improves energy level in chronic kidney disease (CKD) patients independent of increase in hemoglobin levels [abstract no: F‐PO337]. Journal of the American Society of Nephrology2004;15(Oct):140A. [CENTRAL: CN‐01657325] AgarwalR , RizkalaAR , BastaniB , KaskasMO , LeeheyDJ , BesarabA . A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. American Journal of Nephrology2006;26(5):445‐54. [MEDLINE: 17035697] ">Agarwal 2006 CKD</a>; <a href="./references#CD007857-bbs2-0004" title="AhsanN , HolmanMJ , O'BrienB , LanghoffEG , YangHC . Intravenous infusion of total is superior to oral iron in the treatment of post‐kidney transplant functional anemia [abstract no: A3131]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):672A. [CENTRAL: CN‐00676050] ">Ahsan 1997 TX</a>; <a href="./references#CD007857-bbs2-0010" title="FudinR , JaichenkoJ , ShostakA , BennettM , GotloibL . Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron1998;79(3):299‐305. [MEDLINE: 9678430] ">Fudin 1998 HD</a>; <a href="./references#CD007857-bbs2-0012" title="KalraPA , BhandariS , SaxenaS , AgarwalD , WirtzG , KletzmayrJ , et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non‐dialysis‐dependent chronic kidney disease patients with anaemia. Nephrology Dialysis Transplantation2016;31(4):646‐55. [MEDLINE: 26250435] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside 1000 (monofer) compared to oral iron sulphate in European patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii200. [EMBASE: 72206812] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside1000 (monofer) compared to oral iron sulphate in patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract no: SA‐PO1106]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B7. ">Kalra 2016 CKD</a>; <a href="./references#CD007857-bbs2-0021" title="McMahonL , KentAB , RogerS , KerrP , HealyH , IrishA , et al. IV iron sucrose versus oral iron for the anaemia of chronic kidney disease (CKD) ‐ a randomized controlled trial [abstract no: O82]. Nephrology2008;13(Suppl 3):A120. [CENTRAL: CN‐00747281] McMahonLP , KentAB , KerrPG , HealyH , IrishAB , CooperB , et al. Maintenance of elevated versus physiological iron indices in non‐anaemic patients with chronic kidney disease: a randomized controlled trial. Nephrology Dialysis Transplantation2010;25(3):920‐6. [MEDLINE: 19906658] McMahonLP , KentAB , RogerSD , KerrPG , HealyH , IrishAB , et al. IV iron sucrose versus oral iron for the anemia of chronic kidney disease (CKD) ‐ a randomized controlled trial [abstract no: SU‐PO1028]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):813A. [CENTRAL: CN‐00690668] ">McMahon 2009 CKD</a>; <a href="./references#CD007857-bbs2-0033" title="StricklandID , Chaput de SaintongeDM , BoultonFE , FrancisB , RoubikovaJ , WatersJI . The therapeutic equivalence of oral and intravenous iron in renal dialysis patients. Clinical Nephrology1977;7(2):55‐7. [MEDLINE: 321170] ">Strickland 1977 HD</a>; <a href="./references#CD007857-bbs2-0039" title="WinneyRJ , SwainsonCP , ParkerA , BoneJM , RobsonJS . Iron therapy in hemodialysis patients: Oral or parenteral? [abstract]. Kidney International1977;12(1):88. [CENTRAL: CN‐00747346] ">Winney 1977 HD</a>), but nine studies indicated that varying proportions of patients received an ESA (<a href="./references#CD007857-bbs2-0002" title="AgarwalR , KusekJW , PappasMK . A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney International2015;88(4):905‐14. [DOI: 10.1038/ki.2015.163; MEDLINE: 26083656] ">Agarwal 2015 CKD</a>; <a href="./references#CD007857-bbs2-0008" title="GaillardCA , BockAH , CarreraF , EckardtK , VanWyckDB , BansalSS , et al. Hepcidin response to intravenous (IV) or oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis CKD (ND‐CKD) [abstract no: TH‐OR040]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. GaillardCA , BockAH , CarreraF , EckardtKU , VanWyckDB , BansalSS , et al. Hepcidin response to iron therapy in patients with non‐dialysis dependent CKD: an analysis of the FIND‐CKD trial. PLoS ONE [Electronic Resource]2016;11(6):e0157063. [MEDLINE: 27276035] MacdougallI , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. A model to predict haematopoietic non‐response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD): an analysis from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193‐4. [EMBASE: 72326413] MacdougallIC , BockA , CarreraF , CushwayT , MoriC , RogerS . Rationale and design of a new RCT of iron therapy in anemic non‐dialysis CKD patients: FIND‐CKD trial [abstract no: SA‐PO2402]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):660A. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. The FIND‐CKD study‐‐a randomized controlled trial of intravenous iron versus oral iron in non‐dialysis chronic kidney disease patients: background and rationale. Nephrology Dialysis Transplantation2014;29(4):843‐50. [MEDLINE: 24170814] MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. FIND‐CKD: a 56‐week randomized trial of intravenous ferric carboxymaltose versus oral iron in anemic patients with chronic kidney disease and iron deficiency [abstract no: SA‐PO1079]. Journal of the American Society of Nephrology2013;24(Abstracts):3B. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. Intravenous ferric carboxymaltose vs oral iron in anaemic patients with non‐dialysis dependent chronic kidney disease and iron deficiency: results of the randomised FIND‐CKD study [abstract no: SO049]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. MacdougallIC , BockAH , CarreraF , EckardtK , GaillardC , VanWyckD , et al. Efficacy of oral iron for treating iron deficiency in anaemic patients with non‐dialysis dependent CKD (ND‐CKD) [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii581. [EMBASE: 617290898] MacdougallIC , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. Iron administration to non‐dialysis CKD patients for one year does not cause worsening of renal function: results from the FIND‐CKD trial [abstract no: FR‐PO809]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):555A. MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Erythropoietic response to oral iron in patients with nondialysis‐dependent chronic kidney disease in the FIND‐CKD trial. Clinical Nephrology2017;88(12):301‐10. [MEDLINE: 29092739] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. FIND‐CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrology Dialysis Transplantation2014;29(11):2075‐84. [MEDLINE: 24891437] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Renal function in patients with non‐dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND‐CKD trial. BMC Nephrology2017;18(1):24. [MEDLINE: 28095881] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Hepcidin response to iron therapy in patients with non‐dialysis CKD: an analysis of the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8‐9. [EMBASE: 72206297] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Low rate of early response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD) [abstract no: TH‐PO906]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. RogerS , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. The safety of intravenous (IV) ferric carboxymaltose (FCM) in patients with non‐dialysis dependent CKD (ND‐CKD): 1‐year results from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i15‐6. [EMBASE: 72325953] RogerSD , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. IV ferric carboxymaltose (FCM) is a convenient and well‐tolerated first‐line therapy for the treatment of anaemia in patients with iron deficiency and non‐dialysis dependent chronic kidney disease (ND‐CKD): results of the randomised FIND‐CKD study [abstract no: SO048]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. RogerSD , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Intravenous (IV) ferric carboxymaltose (FCM) versus oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis dependant CKD (ND‐CKD): a safety analysis [abstract no: TH‐PO652]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):238A. ">FIND‐CKD 2014 CKD</a>; <a href="./references#CD007857-bbs2-0024" title="NagarajuSP , CohnA , AkbariA , DavisJL , ZimmermanDL . Heme iron polypeptide for the treatment of iron deficiency anemia in non‐dialysis chronic kidney disease patients: a randomized controlled trial. BMC Nephrology2013;14:64. [MEDLINE: 23514036] ">Nagaraju 2013 CKD</a>; <a href="./references#CD007857-bbs2-0017" title="BesarabA , CoyneD , BoltonWK , SharmaA , FotiA , BrennerL . Ferumoxytol as an intravenous iron replacement therapy: safety results from two phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO0805]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):762A. [CENTRAL: CN‐00747286] BoltonWK , BesarabA , GermainM , KovesdyCP , HutchinsonJ , KrauszA . Ferumoxytol as an IV iron replacement therapy: efficacy results from two Phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO798]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):761A. [CENTRAL: CN‐00747287] BoltonWK , FishbaneS , LiJ , MilichL , BrennerR . Increases in hemoglobin and the effect of ESA use in CKD patients treated with IV ferumoxytol [abstract]. American Journal of Kidney Diseases2009;53(4):A30. [EMBASE: 70141518] FishbaneS , BoltonWK , WinkelmayerWC , StraussW , LiZ , PereiraBJ . Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Clinical Nephrology2012;78(3):181‐8. [MEDLINE: 22874106] GermainM , BrennerL , DioguardiJ , GilbertsonD , BesarabA . Comparison of safety and efficacy of ferumoxytol in CKD subtypes: kidney transplant recipients, hemodialysis patients and non‐hemodialysis patients [abstract no: SA‐PO2530]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00747289] LuM , CohenMH , RievesD , PazdurR . FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. American Journal of Hematology2010;85(5):315‐9. [MEDLINE: 20201089] SpinowitzB , BesarabA , BoltonWK , PereiraBJ , ProvenzanoR , RaoM , et al. Ferumoxytol as intravenous iron replacement therapy in chronic kidney disease (CKD) patients not on dialysis ‐ evaluation of safety and efficacy in two phase III studies [abstract no: F‐PO026]. Journal of the American Society of Nephrology2006;17(Abstracts):342A. [CENTRAL: CN‐00644267] SpinowitzB , KauszA , MillerP , BrennerL , SinghA . Achievement of target hemoglobin with ferumoxytol versus oral iron in anemic CKD patients [abstract no: SU‐PO1031]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):814A. [CENTRAL: CN‐00688845] SpinowitzB , KrauzA , DioguardiJ , KovesdyC . Evaluation of ferumoxytol safety and efficacy in all stages of chronic kidney disease (CKD) [abstract no: 249]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00747323] ">Lu 2010 CKD</a>; <a href="./references#CD007857-bbs2-0026" title="PisaniA , RiccioE , SabbatiniM , AndreucciM , DelRioA , ViscianoB . Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrology Dialysis Transplantation2014;30(4):645‐52. [MEDLINE: 25395392] ViscianoB , NazzaroP , RiccioE , DelRioA , MozzilloGR , PisaniA . Liposomial iron for the treatment of iron deficiency anemia in non dialysis chronic kidney disease patients: a randomized controlled trial [abstract]. Nephrology Dialysis Transplantation2014;29(5 Suppl 3):iii141‐2. [EMBASE: 71491842] ViscianoB , NazzaroP , TarantinoG , TaddeiA , DelRioA , MozzilloGR , et al. Liposomial iron: a new proposal for the treatment of anaemia in chronic kidney disease [Il ferro liposomiale: una nuova proposta per il trattamento dell’anemia nei pazienti affetti da insufficenza renale cronica]. Giornale Italiano di Nefrologia2013;30(5). [MEDLINE: 24402627] ">Pisani 2014 CKD</a>; <a href="./references#CD007857-bbs2-0028" title="BenjaminJ . A randomized controlled trial comparing IV ferric carboxymaltose (FCM) to oral iron in anemic nondialysis dependent CKD patients (with or without erythropoiesis stimulating agent use) [abstract no: M574]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐01658222] BenjaminJ , QunibiW . Comparison of intravenous (IV) ferric carboxymaltose (FCM) to oral iron in anemic non‐dialysis dependent (NDD)‐CKD patients with or without ESA therapy [abstract no: SA‐PO2422]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):666A. QunibiW , MartinezC , SmithM , BenjaminJ , DinhQ . A randomized controlled trial comparing IV ferric carboxymaltose (FCM) to oral iron in anemic patients with non‐dialysis‐dependent CKD [abstract no: SU‐PO1030]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):814A. [CENTRAL: CN‐00689191] QunibiWY , MartinezC , SmithM , BenjaminJ , MangioneA , RogerSD . A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non‐dialysis‐dependent chronic kidney disease patients. Nephrology Dialysis Transplantation2011;26(5):1599‐607. [MEDLINE: 20929915] ">Qunibi 2011 CKD</a>; <a href="./references#CD007857-bbs2-0031" title="BesarabA , CoyneD , BoltonWK , SharmaA , FotiA , BrennerL . Ferumoxytol as an intravenous iron replacement therapy: safety results from two phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO0805]. Journal of the American Society of Nephrology2007;18(Abstracts issue):762A. [CENTRAL: CN‐00747286] BoltonWK , BesarabA , GermainM , KovesdyCP , HutchinsonJ , KrauszA . Ferumoxytol as an IV iron replacement therapy: efficacy results from two Phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO798]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):761A. [CENTRAL: CN‐00747287] BoltonWK , FishbaneS , LiJ , MilichL , BrennerR . Increases in hemoglobin and the effect of ESA use in CKD patients treated with IV ferumoxytol [abstract]. American Journal of Kidney Diseases2009;53(4):A30. [EMBASE: 70141518] BrennerL , MillerP , RodriguezS , ParikhN , CoyneDW . Treatment of iron‐deficiency anemia with IV ferumoxytol in CKD patients: efficacy compared with oral iron across different age groups [abstract]. Blood2007;110(11). [CENTRAL: CN‐00646734] FishbaneS , BoltonWK , WinkelmayerWC , StraussW , LiZ , PereiraBJ . Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Clinical Nephrology2012;78(3):181‐8. [MEDLINE: 22874106] GermainM , BrennerL , DioguardiJ , GilbertsonD , BesarabA . Comparison of safety and efficacy of ferumoxytol in CKD subtypes: kidney transplant recipients, hemodialysis patients and non‐hemodialysis patients [abstract no: SA‐PO2530]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00747289] HorlWH . Comparing the efficacy of intravenous iron and oral iron in nondialysis patients with chronic kidney disease. Nature Clinical Practice Nephrology2008;4(10):530‐1. [EMBASE: 2008457134] LuM , CohenMH , RievesD , PazdurR . FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. American Journal of Hematology2010;85(5):315‐9. [MEDLINE: 20201089] SpinowitzB , BernardoM , NobleS , BaptistaJ , PereiraB , BrennerL . Safety and efficacy of ferumoxytol as an intravenous iron replacement therapy: results from a phase III study of chronic kidney disease (CKD) patients not on dialysis [abstract no: 30]. American Journal of Kidney Diseases2007;49(4):A32. [CENTRAL: CN‐00644268] SpinowitzB , BesarabA , BoltonWK , PereiraBJ , ProvenzanoR , RaoM , et al. Ferumoxytol as intravenous iron replacement therapy in chronic kidney disease (CKD) patients not on dialysis ‐ evaluation of safety and efficacy in two phase III studies [abstract no: F‐PO026]. Journal of the American Society of Nephrology2006;17(Abstracts):342A. [CENTRAL: CN‐00644267] SpinowitzB , KauszA , MillerP , BrennerL , SinghA . Achievement of target hemoglobin with ferumoxytol versus oral iron in anemic CKD patients [abstract no: SU‐PO1031]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):814A. [CENTRAL: CN‐00688845] SpinowitzB , KrauzA , DioguardiJ , KovesdyC . Evaluation of ferumoxytol safety and efficacy in all stages of chronic kidney disease (CKD) [abstract no: 249]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00747323] SpinowitzBS , KauszAT , BaptistaJ , NobleSD , SothinathanR , BernardoMV , et al. Ferumoxytol for treating iron deficiency anemia in CKD. Journal of the American Society of Nephrology2008;19(8):1599‐605. [MEDLINE: 18525001] ">Spinowitz 2008 CKD</a>; <a href="./references#CD007857-bbs2-0030" title="SouzaRM , DefferrariR , KarohlC , BarrosE , ThomeF . Iron status evaluation and iron supplementation therapy in hemodialysis (HD) chronic renal failure (CRF) patients: a randomized clinical trial [abstract]. Nephrology1997;3(Suppl 1):S307. [CENTRAL: CN‐00461775] ">Souza 1997 HD</a>; <a href="./references#CD007857-bbs2-0036" title="VanWyckDB , RoppoloM , MartinezCO , MazeyRM , McMurrayS , United States Iron Sucrose (Venofer) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis‐dependent CKD. Kidney International2005;68(6):2846‐56. [MEDLINE: 16316362] VanWyckDB , RoppoloM , MartinezCO , McMurraySD , MazeyR . A randomized controlled trial comparing IV iron sucrose to oral iron in anemic patients with non‐dialysis‐dependent CKD [abstract no: F‐FC051]. Journal of the American Society of Nephrology2005;16:49A. [CENTRAL: CN‐01657327] ">Van Wyck 2005 CKD</a>). </p> <p>The outcomes reported in 38 studies are presented in <a href="#CD007857-fig-0001">Figure 1</a>. One study was terminated and did not provide any outcomes (<a href="./references#CD007857-bbs2-0025" title="StraussMD . A randomized, open‐label, active‐controlled study of the safety, efficacy, and pharmacokinetics of ferumoxytol compared with oral iron for the treatment of iron deficiency anemia in pediatric subjects with chronic kidney disease. www.clinicaltrials.gov/ct2/show/NCT01155375 (first received 1 July 2010). ">NCT01155375 HD,PD,CKD</a>). Final and/or change in Hb, serum ferritin and TSAT levels were reported in 31, 33 and 27 studies respectively. Four studies reported final HCT levels but not Hb levels (<a href="./references#CD007857-bbs2-0004" title="AhsanN , HolmanMJ , O'BrienB , LanghoffEG , YangHC . Intravenous infusion of total is superior to oral iron in the treatment of post‐kidney transplant functional anemia [abstract no: A3131]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):672A. [CENTRAL: CN‐00676050] ">Ahsan 1997 TX</a>; <a href="./references#CD007857-bbs2-0009" title="FishbaneS , FreiGL , MaesakaJ . Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. American Journal of Kidney Diseases1995;26(1):41‐6. [MEDLINE: 7611266] ">Fishbane 1995 HD</a>; <a href="./references#CD007857-bbs2-0013" title="KotakiM , UdayK , HenriquezM , BlumS , DaveM . Intravenous iron therapy in hemodialysis [abstract no: A1021]. Journal of the American Society of Nephrology1996;7(9):1452. [CENTRAL: CN‐01657494] KotakiM , UdayK , HenriquezM , BlumS , DaveM . Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin. Clinical Nephrology1997;48(1):63‐4. [MEDLINE: 9247787] ">Kotaki 1997 HD</a>; <a href="./references#CD007857-bbs2-0034" title="SvaraF , SulkovaS , KvasnickaJ , PolakovicV . Iron supplementation during erythropoietin therapy in patients on hemodialysis [Doplnovani zeleza pri lecbe erytropoetinem u hemodialyzovanych pacientu]. Vnitrni Lekarstvi1996;42(12):849‐52. [MEDLINE: 9072885] ">Svara 1996 HD</a>). Only 11 studies reported death (all causes) (<a href="./references#CD007857-bbs2-0002" title="AgarwalR , KusekJW , PappasMK . A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney International2015;88(4):905‐14. [DOI: 10.1038/ki.2015.163; MEDLINE: 26083656] ">Agarwal 2015 CKD</a>; <a href="./references#CD007857-bbs2-0008" title="GaillardCA , BockAH , CarreraF , EckardtK , VanWyckDB , BansalSS , et al. Hepcidin response to intravenous (IV) or oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis CKD (ND‐CKD) [abstract no: TH‐OR040]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. GaillardCA , BockAH , CarreraF , EckardtKU , VanWyckDB , BansalSS , et al. Hepcidin response to iron therapy in patients with non‐dialysis dependent CKD: an analysis of the FIND‐CKD trial. PLoS ONE [Electronic Resource]2016;11(6):e0157063. [MEDLINE: 27276035] MacdougallI , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. A model to predict haematopoietic non‐response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD): an analysis from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193‐4. [EMBASE: 72326413] MacdougallIC , BockA , CarreraF , CushwayT , MoriC , RogerS . Rationale and design of a new RCT of iron therapy in anemic non‐dialysis CKD patients: FIND‐CKD trial [abstract no: SA‐PO2402]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):660A. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. The FIND‐CKD study‐‐a randomized controlled trial of intravenous iron versus oral iron in non‐dialysis chronic kidney disease patients: background and rationale. Nephrology Dialysis Transplantation2014;29(4):843‐50. [MEDLINE: 24170814] MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. FIND‐CKD: a 56‐week randomized trial of intravenous ferric carboxymaltose versus oral iron in anemic patients with chronic kidney disease and iron deficiency [abstract no: SA‐PO1079]. Journal of the American Society of Nephrology2013;24(Abstracts):3B. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. Intravenous ferric carboxymaltose vs oral iron in anaemic patients with non‐dialysis dependent chronic kidney disease and iron deficiency: results of the randomised FIND‐CKD study [abstract no: SO049]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. MacdougallIC , BockAH , CarreraF , EckardtK , GaillardC , VanWyckD , et al. Efficacy of oral iron for treating iron deficiency in anaemic patients with non‐dialysis dependent CKD (ND‐CKD) [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii581. [EMBASE: 617290898] MacdougallIC , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. Iron administration to non‐dialysis CKD patients for one year does not cause worsening of renal function: results from the FIND‐CKD trial [abstract no: FR‐PO809]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):555A. MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Erythropoietic response to oral iron in patients with nondialysis‐dependent chronic kidney disease in the FIND‐CKD trial. Clinical Nephrology2017;88(12):301‐10. [MEDLINE: 29092739] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. FIND‐CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrology Dialysis Transplantation2014;29(11):2075‐84. [MEDLINE: 24891437] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Renal function in patients with non‐dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND‐CKD trial. BMC Nephrology2017;18(1):24. [MEDLINE: 28095881] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Hepcidin response to iron therapy in patients with non‐dialysis CKD: an analysis of the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8‐9. [EMBASE: 72206297] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Low rate of early response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD) [abstract no: TH‐PO906]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. RogerS , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. The safety of intravenous (IV) ferric carboxymaltose (FCM) in patients with non‐dialysis dependent CKD (ND‐CKD): 1‐year results from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i15‐6. [EMBASE: 72325953] RogerSD , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. IV ferric carboxymaltose (FCM) is a convenient and well‐tolerated first‐line therapy for the treatment of anaemia in patients with iron deficiency and non‐dialysis dependent chronic kidney disease (ND‐CKD): results of the randomised FIND‐CKD study [abstract no: SO048]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. RogerSD , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Intravenous (IV) ferric carboxymaltose (FCM) versus oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis dependant CKD (ND‐CKD): a safety analysis [abstract no: TH‐PO652]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):238A. ">FIND‐CKD 2014 CKD</a>; <a href="./references#CD007857-bbs2-0009" title="FishbaneS , FreiGL , MaesakaJ . Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. American Journal of Kidney Diseases1995;26(1):41‐6. [MEDLINE: 7611266] ">Fishbane 1995 HD</a>; <a href="./references#CD007857-bbs2-0010" title="FudinR , JaichenkoJ , ShostakA , BennettM , GotloibL . Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron1998;79(3):299‐305. [MEDLINE: 9678430] ">Fudin 1998 HD</a>; <a href="./references#CD007857-bbs2-0012" title="KalraPA , BhandariS , SaxenaS , AgarwalD , WirtzG , KletzmayrJ , et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non‐dialysis‐dependent chronic kidney disease patients with anaemia. Nephrology Dialysis Transplantation2016;31(4):646‐55. [MEDLINE: 26250435] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside 1000 (monofer) compared to oral iron sulphate in European patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii200. [EMBASE: 72206812] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside1000 (monofer) compared to oral iron sulphate in patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract no: SA‐PO1106]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B7. ">Kalra 2016 CKD</a>; <a href="./references#CD007857-bbs2-0021" title="McMahonL , KentAB , RogerS , KerrP , HealyH , IrishA , et al. IV iron sucrose versus oral iron for the anaemia of chronic kidney disease (CKD) ‐ a randomized controlled trial [abstract no: O82]. Nephrology2008;13(Suppl 3):A120. [CENTRAL: CN‐00747281] McMahonLP , KentAB , KerrPG , HealyH , IrishAB , CooperB , et al. Maintenance of elevated versus physiological iron indices in non‐anaemic patients with chronic kidney disease: a randomized controlled trial. Nephrology Dialysis Transplantation2010;25(3):920‐6. [MEDLINE: 19906658] McMahonLP , KentAB , RogerSD , KerrPG , HealyH , IrishAB , et al. IV iron sucrose versus oral iron for the anemia of chronic kidney disease (CKD) ‐ a randomized controlled trial [abstract no: SU‐PO1028]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):813A. [CENTRAL: CN‐00690668] ">McMahon 2009 CKD</a>; <a href="./references#CD007857-bbs2-0017" title="BesarabA , CoyneD , BoltonWK , SharmaA , FotiA , BrennerL . Ferumoxytol as an intravenous iron replacement therapy: safety results from two phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO0805]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):762A. [CENTRAL: CN‐00747286] BoltonWK , BesarabA , GermainM , KovesdyCP , HutchinsonJ , KrauszA . Ferumoxytol as an IV iron replacement therapy: efficacy results from two Phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO798]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):761A. [CENTRAL: CN‐00747287] BoltonWK , FishbaneS , LiJ , MilichL , BrennerR . Increases in hemoglobin and the effect of ESA use in CKD patients treated with IV ferumoxytol [abstract]. American Journal of Kidney Diseases2009;53(4):A30. [EMBASE: 70141518] FishbaneS , BoltonWK , WinkelmayerWC , StraussW , LiZ , PereiraBJ . Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Clinical Nephrology2012;78(3):181‐8. [MEDLINE: 22874106] GermainM , BrennerL , DioguardiJ , GilbertsonD , BesarabA . Comparison of safety and efficacy of ferumoxytol in CKD subtypes: kidney transplant recipients, hemodialysis patients and non‐hemodialysis patients [abstract no: SA‐PO2530]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00747289] LuM , CohenMH , RievesD , PazdurR . FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. American Journal of Hematology2010;85(5):315‐9. [MEDLINE: 20201089] SpinowitzB , BesarabA , BoltonWK , PereiraBJ , ProvenzanoR , RaoM , et al. Ferumoxytol as intravenous iron replacement therapy in chronic kidney disease (CKD) patients not on dialysis ‐ evaluation of safety and efficacy in two phase III studies [abstract no: F‐PO026]. Journal of the American Society of Nephrology2006;17(Abstracts):342A. [CENTRAL: CN‐00644267] SpinowitzB , KauszA , MillerP , BrennerL , SinghA . Achievement of target hemoglobin with ferumoxytol versus oral iron in anemic CKD patients [abstract no: SU‐PO1031]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):814A. [CENTRAL: CN‐00688845] SpinowitzB , KrauzA , DioguardiJ , KovesdyC . Evaluation of ferumoxytol safety and efficacy in all stages of chronic kidney disease (CKD) [abstract no: 249]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00747323] ">Lu 2010 CKD</a>; <a href="./references#CD007857-bbs2-0027" title="GermainM , BrennerL , DioguardiJ , GilbertsonD , BesarabA . Comparison of safety and efficacy of ferumoxytol in CKD subtypes: kidney transplant recipients, hemodialysis patients and non‐hemodialysis patients [abstract no: SA‐PO2530]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00747289] LuM , CohenMH , RievesD , PazdurR . FDA report. Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. American Journal of Hematology2010;85(5):315‐9. [MEDLINE: 20201089] ProvenzanoR , SchillerB , RaoM , CoyneD , BrennerL , PereiraBJ . Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clinical Journal of the American Society of Nephrology: CJASN2009;4(2):386‐93. [MEDLINE: 19176796] SpinowitzB , KrauzA , DioguardiJ , KovesdyC . Evaluation of ferumoxytol safety and efficacy in all stages of chronic kidney disease (CKD) [abstract no: 249]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00688845] ">Provenzano 2009 HD</a>; <a href="./references#CD007857-bbs2-0028" title="BenjaminJ . A randomized controlled trial comparing IV ferric carboxymaltose (FCM) to oral iron in anemic nondialysis dependent CKD patients (with or without erythropoiesis stimulating agent use) [abstract no: M574]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐01658222] BenjaminJ , QunibiW . Comparison of intravenous (IV) ferric carboxymaltose (FCM) to oral iron in anemic non‐dialysis dependent (NDD)‐CKD patients with or without ESA therapy [abstract no: SA‐PO2422]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):666A. QunibiW , MartinezC , SmithM , BenjaminJ , DinhQ . A randomized controlled trial comparing IV ferric carboxymaltose (FCM) to oral iron in anemic patients with non‐dialysis‐dependent CKD [abstract no: SU‐PO1030]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):814A. [CENTRAL: CN‐00689191] QunibiWY , MartinezC , SmithM , BenjaminJ , MangioneA , RogerSD . A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non‐dialysis‐dependent chronic kidney disease patients. Nephrology Dialysis Transplantation2011;26(5):1599‐607. [MEDLINE: 20929915] ">Qunibi 2011 CKD</a>; <a href="./references#CD007857-bbs2-0032" title="StovesJ , InglisH , NewsteadCG . A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrology Dialysis Transplantation2001;16(5):967‐74. [MEDLINE: 11328902] ">Stoves 2001 CKD</a>; <a href="./references#CD007857-bbs2-0035" title="TsuchidaA , PaudyalB , PaudyalP , IshiiY , HiromuraK , NojimaY , et al. Effectiveness of oral iron to manage anemia in long‐term hemodialysis patients with the use of ultrapure dialysate. Experimental &amp; Therapeutic Medicine2010;1(5):777‐81. [EMBASE: 2010419867] ">Tsuchida 2010 HD</a>) while three studies reported on cardiovascular events including death (<a href="./references#CD007857-bbs2-0002" title="AgarwalR , KusekJW , PappasMK . A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney International2015;88(4):905‐14. [DOI: 10.1038/ki.2015.163; MEDLINE: 26083656] ">Agarwal 2015 CKD</a>; <a href="./references#CD007857-bbs2-0010" title="FudinR , JaichenkoJ , ShostakA , BennettM , GotloibL . Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron1998;79(3):299‐305. [MEDLINE: 9678430] ">Fudin 1998 HD</a>; <a href="./references#CD007857-bbs2-0032" title="StovesJ , InglisH , NewsteadCG . A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrology Dialysis Transplantation2001;16(5):967‐74. [MEDLINE: 11328902] ">Stoves 2001 CKD</a>). Five studies reported on quality of life assessment (<a href="./references#CD007857-bbs2-0001" title="AgarwalR . Sodium ferric gluconate complex in sucrose (SFGC) injection improves energy level in chronic kidney disease (CKD) patients independent of increase in hemoglobin levels [abstract no: F‐PO337]. Journal of the American Society of Nephrology2004;15(Oct):140A. [CENTRAL: CN‐01657325] AgarwalR , RizkalaAR , BastaniB , KaskasMO , LeeheyDJ , BesarabA . A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. American Journal of Nephrology2006;26(5):445‐54. [MEDLINE: 17035697] ">Agarwal 2006 CKD</a>; <a href="./references#CD007857-bbs2-0002" title="AgarwalR , KusekJW , PappasMK . A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney International2015;88(4):905‐14. [DOI: 10.1038/ki.2015.163; MEDLINE: 26083656] ">Agarwal 2015 CKD</a>; <a href="./references#CD007857-bbs2-0008" title="GaillardCA , BockAH , CarreraF , EckardtK , VanWyckDB , BansalSS , et al. Hepcidin response to intravenous (IV) or oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis CKD (ND‐CKD) [abstract no: TH‐OR040]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. GaillardCA , BockAH , CarreraF , EckardtKU , VanWyckDB , BansalSS , et al. Hepcidin response to iron therapy in patients with non‐dialysis dependent CKD: an analysis of the FIND‐CKD trial. PLoS ONE [Electronic Resource]2016;11(6):e0157063. [MEDLINE: 27276035] MacdougallI , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. A model to predict haematopoietic non‐response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD): an analysis from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193‐4. [EMBASE: 72326413] MacdougallIC , BockA , CarreraF , CushwayT , MoriC , RogerS . Rationale and design of a new RCT of iron therapy in anemic non‐dialysis CKD patients: FIND‐CKD trial [abstract no: SA‐PO2402]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):660A. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. The FIND‐CKD study‐‐a randomized controlled trial of intravenous iron versus oral iron in non‐dialysis chronic kidney disease patients: background and rationale. Nephrology Dialysis Transplantation2014;29(4):843‐50. [MEDLINE: 24170814] MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. FIND‐CKD: a 56‐week randomized trial of intravenous ferric carboxymaltose versus oral iron in anemic patients with chronic kidney disease and iron deficiency [abstract no: SA‐PO1079]. Journal of the American Society of Nephrology2013;24(Abstracts):3B. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. Intravenous ferric carboxymaltose vs oral iron in anaemic patients with non‐dialysis dependent chronic kidney disease and iron deficiency: results of the randomised FIND‐CKD study [abstract no: SO049]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. MacdougallIC , BockAH , CarreraF , EckardtK , GaillardC , VanWyckD , et al. Efficacy of oral iron for treating iron deficiency in anaemic patients with non‐dialysis dependent CKD (ND‐CKD) [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii581. [EMBASE: 617290898] MacdougallIC , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. Iron administration to non‐dialysis CKD patients for one year does not cause worsening of renal function: results from the FIND‐CKD trial [abstract no: FR‐PO809]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):555A. MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Erythropoietic response to oral iron in patients with nondialysis‐dependent chronic kidney disease in the FIND‐CKD trial. Clinical Nephrology2017;88(12):301‐10. [MEDLINE: 29092739] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. FIND‐CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrology Dialysis Transplantation2014;29(11):2075‐84. [MEDLINE: 24891437] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Renal function in patients with non‐dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND‐CKD trial. BMC Nephrology2017;18(1):24. [MEDLINE: 28095881] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Hepcidin response to iron therapy in patients with non‐dialysis CKD: an analysis of the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8‐9. [EMBASE: 72206297] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Low rate of early response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD) [abstract no: TH‐PO906]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. RogerS , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. The safety of intravenous (IV) ferric carboxymaltose (FCM) in patients with non‐dialysis dependent CKD (ND‐CKD): 1‐year results from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i15‐6. [EMBASE: 72325953] RogerSD , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. IV ferric carboxymaltose (FCM) is a convenient and well‐tolerated first‐line therapy for the treatment of anaemia in patients with iron deficiency and non‐dialysis dependent chronic kidney disease (ND‐CKD): results of the randomised FIND‐CKD study [abstract no: SO048]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. RogerSD , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Intravenous (IV) ferric carboxymaltose (FCM) versus oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis dependant CKD (ND‐CKD): a safety analysis [abstract no: TH‐PO652]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):238A. ">FIND‐CKD 2014 CKD</a>; <a href="./references#CD007857-bbs2-0012" title="KalraPA , BhandariS , SaxenaS , AgarwalD , WirtzG , KletzmayrJ , et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non‐dialysis‐dependent chronic kidney disease patients with anaemia. Nephrology Dialysis Transplantation2016;31(4):646‐55. [MEDLINE: 26250435] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside 1000 (monofer) compared to oral iron sulphate in European patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii200. [EMBASE: 72206812] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside1000 (monofer) compared to oral iron sulphate in patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract no: SA‐PO1106]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B7. ">Kalra 2016 CKD</a>; <a href="./references#CD007857-bbs2-0036" title="VanWyckDB , RoppoloM , MartinezCO , MazeyRM , McMurrayS , United States Iron Sucrose (Venofer) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis‐dependent CKD. Kidney International2005;68(6):2846‐56. [MEDLINE: 16316362] VanWyckDB , RoppoloM , MartinezCO , McMurraySD , MazeyR . A randomized controlled trial comparing IV iron sucrose to oral iron in anemic patients with non‐dialysis‐dependent CKD [abstract no: F‐FC051]. Journal of the American Society of Nephrology2005;16:49A. [CENTRAL: CN‐01657327] ">Van Wyck 2005 CKD</a>). Eighteen studies reported on adverse events (<a href="./references#CD007857-bbs2-0001" title="AgarwalR . Sodium ferric gluconate complex in sucrose (SFGC) injection improves energy level in chronic kidney disease (CKD) patients independent of increase in hemoglobin levels [abstract no: F‐PO337]. Journal of the American Society of Nephrology2004;15(Oct):140A. [CENTRAL: CN‐01657325] AgarwalR , RizkalaAR , BastaniB , KaskasMO , LeeheyDJ , BesarabA . A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. American Journal of Nephrology2006;26(5):445‐54. [MEDLINE: 17035697] ">Agarwal 2006 CKD</a>; <a href="./references#CD007857-bbs2-0002" title="AgarwalR , KusekJW , PappasMK . A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney International2015;88(4):905‐14. [DOI: 10.1038/ki.2015.163; MEDLINE: 26083656] ">Agarwal 2015 CKD</a>; <a href="./references#CD007857-bbs2-0006" title="CharytanC , QunibiW , BailieGR , Venofer Clinical Studies Group. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron2005;100(3):c55‐62. [MEDLINE: 15824508] CharytanC , QunibiW , SinghH , SchwenkM , AronoffG , BesarabA . Safety of Venofer®, [iron sucrose injection] administered by rapid IV push (IVP) in predialysis CKD patients [abstract no: SU‐PO260]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):521a. [CENTRAL: CN‐00444759] ">Charytan 2005 CKD</a>; <a href="./references#CD007857-bbs2-0008" title="GaillardCA , BockAH , CarreraF , EckardtK , VanWyckDB , BansalSS , et al. Hepcidin response to intravenous (IV) or oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis CKD (ND‐CKD) [abstract no: TH‐OR040]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. GaillardCA , BockAH , CarreraF , EckardtKU , VanWyckDB , BansalSS , et al. Hepcidin response to iron therapy in patients with non‐dialysis dependent CKD: an analysis of the FIND‐CKD trial. PLoS ONE [Electronic Resource]2016;11(6):e0157063. [MEDLINE: 27276035] MacdougallI , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. A model to predict haematopoietic non‐response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD): an analysis from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193‐4. [EMBASE: 72326413] MacdougallIC , BockA , CarreraF , CushwayT , MoriC , RogerS . Rationale and design of a new RCT of iron therapy in anemic non‐dialysis CKD patients: FIND‐CKD trial [abstract no: SA‐PO2402]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):660A. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. The FIND‐CKD study‐‐a randomized controlled trial of intravenous iron versus oral iron in non‐dialysis chronic kidney disease patients: background and rationale. Nephrology Dialysis Transplantation2014;29(4):843‐50. [MEDLINE: 24170814] MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. FIND‐CKD: a 56‐week randomized trial of intravenous ferric carboxymaltose versus oral iron in anemic patients with chronic kidney disease and iron deficiency [abstract no: SA‐PO1079]. Journal of the American Society of Nephrology2013;24(Abstracts):3B. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. Intravenous ferric carboxymaltose vs oral iron in anaemic patients with non‐dialysis dependent chronic kidney disease and iron deficiency: results of the randomised FIND‐CKD study [abstract no: SO049]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. MacdougallIC , BockAH , CarreraF , EckardtK , GaillardC , VanWyckD , et al. Efficacy of oral iron for treating iron deficiency in anaemic patients with non‐dialysis dependent CKD (ND‐CKD) [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii581. [EMBASE: 617290898] MacdougallIC , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. Iron administration to non‐dialysis CKD patients for one year does not cause worsening of renal function: results from the FIND‐CKD trial [abstract no: FR‐PO809]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):555A. MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Erythropoietic response to oral iron in patients with nondialysis‐dependent chronic kidney disease in the FIND‐CKD trial. Clinical Nephrology2017;88(12):301‐10. [MEDLINE: 29092739] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. FIND‐CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrology Dialysis Transplantation2014;29(11):2075‐84. [MEDLINE: 24891437] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Renal function in patients with non‐dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND‐CKD trial. BMC Nephrology2017;18(1):24. [MEDLINE: 28095881] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Hepcidin response to iron therapy in patients with non‐dialysis CKD: an analysis of the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8‐9. [EMBASE: 72206297] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Low rate of early response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD) [abstract no: TH‐PO906]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. RogerS , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. The safety of intravenous (IV) ferric carboxymaltose (FCM) in patients with non‐dialysis dependent CKD (ND‐CKD): 1‐year results from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i15‐6. [EMBASE: 72325953] RogerSD , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. IV ferric carboxymaltose (FCM) is a convenient and well‐tolerated first‐line therapy for the treatment of anaemia in patients with iron deficiency and non‐dialysis dependent chronic kidney disease (ND‐CKD): results of the randomised FIND‐CKD study [abstract no: SO048]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. RogerSD , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Intravenous (IV) ferric carboxymaltose (FCM) versus oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis dependant CKD (ND‐CKD): a safety analysis [abstract no: TH‐PO652]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):238A. ">FIND‐CKD 2014 CKD</a>; <a href="./references#CD007857-bbs2-0009" title="FishbaneS , FreiGL , MaesakaJ . Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. American Journal of Kidney Diseases1995;26(1):41‐6. [MEDLINE: 7611266] ">Fishbane 1995 HD</a>; <a href="./references#CD007857-bbs2-0011" title="HussainR , ChishtiSH , NaqviS . Experience of iron saccharate supplementation in haemodialysis patients treated with erythropoietin. Nephrology1998;4(1‐2):105‐8. [EMBASE: 1998205059] HussainR , ChishtiSH , NaqviSA . Experience of iron sucrose supplementation in haemodialysis patients treated with erythropoietin [abstract]. 3rd International Congress of Nephrology, Urology &amp; Transplantation Society of SAARC Countries; 1999 Feb 18‐21; Colombo, Sri Lanka. 1999:152. [CENTRAL: CN‐00460975] ">Hussain 1998 HD</a>; <a href="./references#CD007857-bbs2-0012" title="KalraPA , BhandariS , SaxenaS , AgarwalD , WirtzG , KletzmayrJ , et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non‐dialysis‐dependent chronic kidney disease patients with anaemia. Nephrology Dialysis Transplantation2016;31(4):646‐55. [MEDLINE: 26250435] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside 1000 (monofer) compared to oral iron sulphate in European patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii200. [EMBASE: 72206812] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside1000 (monofer) compared to oral iron sulphate in patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract no: SA‐PO1106]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B7. ">Kalra 2016 CKD</a>; <a href="./references#CD007857-bbs2-0015" title="LiH , WangSX . Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Blood Purification2008;26(2):151‐6. [MEDLINE: 18212498] LiH , WangSX . Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study. Chung‐Hua i Hsueh Tsa Chih [Chinese Medical Journal]2009;89(7):457‐62. [MEDLINE: 19567093] ">Li 2008 HD</a>; <a href="./references#CD007857-bbs2-0016" title="LiH , WangSX . Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study. Chung‐Hua i Hsueh Tsa Chih [Chinese Medical Journal]2009;89(7):457‐62. [MEDLINE: 19567093] LiH , WangSX . Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Peritoneal Dialysis International2008;28(2):149‐54. [MEDLINE: 18332450] ">Li 2008 PD</a>; <a href="./references#CD007857-bbs2-0024" title="NagarajuSP , CohnA , AkbariA , DavisJL , ZimmermanDL . Heme iron polypeptide for the treatment of iron deficiency anemia in non‐dialysis chronic kidney disease patients: a randomized controlled trial. BMC Nephrology2013;14:64. [MEDLINE: 23514036] ">Nagaraju 2013 CKD</a>; <a href="./references#CD007857-bbs2-0017" title="BesarabA , CoyneD , BoltonWK , SharmaA , FotiA , BrennerL . Ferumoxytol as an intravenous iron replacement therapy: safety results from two phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO0805]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):762A. [CENTRAL: CN‐00747286] BoltonWK , BesarabA , GermainM , KovesdyCP , HutchinsonJ , KrauszA . Ferumoxytol as an IV iron replacement therapy: efficacy results from two Phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO798]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):761A. [CENTRAL: CN‐00747287] BoltonWK , FishbaneS , LiJ , MilichL , BrennerR . Increases in hemoglobin and the effect of ESA use in CKD patients treated with IV ferumoxytol [abstract]. American Journal of Kidney Diseases2009;53(4):A30. [EMBASE: 70141518] FishbaneS , BoltonWK , WinkelmayerWC , StraussW , LiZ , PereiraBJ . Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Clinical Nephrology2012;78(3):181‐8. [MEDLINE: 22874106] GermainM , BrennerL , DioguardiJ , GilbertsonD , BesarabA . Comparison of safety and efficacy of ferumoxytol in CKD subtypes: kidney transplant recipients, hemodialysis patients and non‐hemodialysis patients [abstract no: SA‐PO2530]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00747289] LuM , CohenMH , RievesD , PazdurR . FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. American Journal of Hematology2010;85(5):315‐9. [MEDLINE: 20201089] SpinowitzB , BesarabA , BoltonWK , PereiraBJ , ProvenzanoR , RaoM , et al. Ferumoxytol as intravenous iron replacement therapy in chronic kidney disease (CKD) patients not on dialysis ‐ evaluation of safety and efficacy in two phase III studies [abstract no: F‐PO026]. Journal of the American Society of Nephrology2006;17(Abstracts):342A. [CENTRAL: CN‐00644267] SpinowitzB , KauszA , MillerP , BrennerL , SinghA . Achievement of target hemoglobin with ferumoxytol versus oral iron in anemic CKD patients [abstract no: SU‐PO1031]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):814A. [CENTRAL: CN‐00688845] SpinowitzB , KrauzA , DioguardiJ , KovesdyC . Evaluation of ferumoxytol safety and efficacy in all stages of chronic kidney disease (CKD) [abstract no: 249]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00747323] ">Lu 2010 CKD</a>; <a href="./references#CD007857-bbs2-0026" title="PisaniA , RiccioE , SabbatiniM , AndreucciM , DelRioA , ViscianoB . Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrology Dialysis Transplantation2014;30(4):645‐52. [MEDLINE: 25395392] ViscianoB , NazzaroP , RiccioE , DelRioA , MozzilloGR , PisaniA . Liposomial iron for the treatment of iron deficiency anemia in non dialysis chronic kidney disease patients: a randomized controlled trial [abstract]. Nephrology Dialysis Transplantation2014;29(5 Suppl 3):iii141‐2. [EMBASE: 71491842] ViscianoB , NazzaroP , TarantinoG , TaddeiA , DelRioA , MozzilloGR , et al. Liposomial iron: a new proposal for the treatment of anaemia in chronic kidney disease [Il ferro liposomiale: una nuova proposta per il trattamento dell’anemia nei pazienti affetti da insufficenza renale cronica]. Giornale Italiano di Nefrologia2013;30(5). [MEDLINE: 24402627] ">Pisani 2014 CKD</a>; <a href="./references#CD007857-bbs2-0027" title="GermainM , BrennerL , DioguardiJ , GilbertsonD , BesarabA . Comparison of safety and efficacy of ferumoxytol in CKD subtypes: kidney transplant recipients, hemodialysis patients and non‐hemodialysis patients [abstract no: SA‐PO2530]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00747289] LuM , CohenMH , RievesD , PazdurR . FDA report. Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. American Journal of Hematology2010;85(5):315‐9. [MEDLINE: 20201089] ProvenzanoR , SchillerB , RaoM , CoyneD , BrennerL , PereiraBJ . Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clinical Journal of the American Society of Nephrology: CJASN2009;4(2):386‐93. [MEDLINE: 19176796] SpinowitzB , KrauzA , DioguardiJ , KovesdyC . Evaluation of ferumoxytol safety and efficacy in all stages of chronic kidney disease (CKD) [abstract no: 249]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00688845] ">Provenzano 2009 HD</a>; <a href="./references#CD007857-bbs2-0028" title="BenjaminJ . A randomized controlled trial comparing IV ferric carboxymaltose (FCM) to oral iron in anemic nondialysis dependent CKD patients (with or without erythropoiesis stimulating agent use) [abstract no: M574]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐01658222] BenjaminJ , QunibiW . Comparison of intravenous (IV) ferric carboxymaltose (FCM) to oral iron in anemic non‐dialysis dependent (NDD)‐CKD patients with or without ESA therapy [abstract no: SA‐PO2422]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):666A. QunibiW , MartinezC , SmithM , BenjaminJ , DinhQ . A randomized controlled trial comparing IV ferric carboxymaltose (FCM) to oral iron in anemic patients with non‐dialysis‐dependent CKD [abstract no: SU‐PO1030]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):814A. [CENTRAL: CN‐00689191] QunibiWY , MartinezC , SmithM , BenjaminJ , MangioneA , RogerSD . A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non‐dialysis‐dependent chronic kidney disease patients. Nephrology Dialysis Transplantation2011;26(5):1599‐607. [MEDLINE: 20929915] ">Qunibi 2011 CKD</a>; <a href="./references#CD007857-bbs2-0031" title="BesarabA , CoyneD , BoltonWK , SharmaA , FotiA , BrennerL . Ferumoxytol as an intravenous iron replacement therapy: safety results from two phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO0805]. Journal of the American Society of Nephrology2007;18(Abstracts issue):762A. [CENTRAL: CN‐00747286] BoltonWK , BesarabA , GermainM , KovesdyCP , HutchinsonJ , KrauszA . Ferumoxytol as an IV iron replacement therapy: efficacy results from two Phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO798]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):761A. [CENTRAL: CN‐00747287] BoltonWK , FishbaneS , LiJ , MilichL , BrennerR . Increases in hemoglobin and the effect of ESA use in CKD patients treated with IV ferumoxytol [abstract]. American Journal of Kidney Diseases2009;53(4):A30. [EMBASE: 70141518] BrennerL , MillerP , RodriguezS , ParikhN , CoyneDW . Treatment of iron‐deficiency anemia with IV ferumoxytol in CKD patients: efficacy compared with oral iron across different age groups [abstract]. Blood2007;110(11). [CENTRAL: CN‐00646734] FishbaneS , BoltonWK , WinkelmayerWC , StraussW , LiZ , PereiraBJ . Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Clinical Nephrology2012;78(3):181‐8. [MEDLINE: 22874106] GermainM , BrennerL , DioguardiJ , GilbertsonD , BesarabA . Comparison of safety and efficacy of ferumoxytol in CKD subtypes: kidney transplant recipients, hemodialysis patients and non‐hemodialysis patients [abstract no: SA‐PO2530]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00747289] HorlWH . Comparing the efficacy of intravenous iron and oral iron in nondialysis patients with chronic kidney disease. Nature Clinical Practice Nephrology2008;4(10):530‐1. [EMBASE: 2008457134] LuM , CohenMH , RievesD , PazdurR . FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. American Journal of Hematology2010;85(5):315‐9. [MEDLINE: 20201089] SpinowitzB , BernardoM , NobleS , BaptistaJ , PereiraB , BrennerL . Safety and efficacy of ferumoxytol as an intravenous iron replacement therapy: results from a phase III study of chronic kidney disease (CKD) patients not on dialysis [abstract no: 30]. American Journal of Kidney Diseases2007;49(4):A32. [CENTRAL: CN‐00644268] SpinowitzB , BesarabA , BoltonWK , PereiraBJ , ProvenzanoR , RaoM , et al. Ferumoxytol as intravenous iron replacement therapy in chronic kidney disease (CKD) patients not on dialysis ‐ evaluation of safety and efficacy in two phase III studies [abstract no: F‐PO026]. Journal of the American Society of Nephrology2006;17(Abstracts):342A. [CENTRAL: CN‐00644267] SpinowitzB , KauszA , MillerP , BrennerL , SinghA . Achievement of target hemoglobin with ferumoxytol versus oral iron in anemic CKD patients [abstract no: SU‐PO1031]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):814A. [CENTRAL: CN‐00688845] SpinowitzB , KrauzA , DioguardiJ , KovesdyC . Evaluation of ferumoxytol safety and efficacy in all stages of chronic kidney disease (CKD) [abstract no: 249]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00747323] SpinowitzBS , KauszAT , BaptistaJ , NobleSD , SothinathanR , BernardoMV , et al. Ferumoxytol for treating iron deficiency anemia in CKD. Journal of the American Society of Nephrology2008;19(8):1599‐605. [MEDLINE: 18525001] ">Spinowitz 2008 CKD</a>; <a href="./references#CD007857-bbs2-0033" title="StricklandID , Chaput de SaintongeDM , BoultonFE , FrancisB , RoubikovaJ , WatersJI . The therapeutic equivalence of oral and intravenous iron in renal dialysis patients. Clinical Nephrology1977;7(2):55‐7. [MEDLINE: 321170] ">Strickland 1977 HD</a>; <a href="./references#CD007857-bbs2-0035" title="TsuchidaA , PaudyalB , PaudyalP , IshiiY , HiromuraK , NojimaY , et al. Effectiveness of oral iron to manage anemia in long‐term hemodialysis patients with the use of ultrapure dialysate. Experimental &amp; Therapeutic Medicine2010;1(5):777‐81. [EMBASE: 2010419867] ">Tsuchida 2010 HD</a>; <a href="./references#CD007857-bbs2-0036" title="VanWyckDB , RoppoloM , MartinezCO , MazeyRM , McMurrayS , United States Iron Sucrose (Venofer) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis‐dependent CKD. Kidney International2005;68(6):2846‐56. [MEDLINE: 16316362] VanWyckDB , RoppoloM , MartinezCO , McMurraySD , MazeyR . A randomized controlled trial comparing IV iron sucrose to oral iron in anemic patients with non‐dialysis‐dependent CKD [abstract no: F‐FC051]. Journal of the American Society of Nephrology2005;16:49A. [CENTRAL: CN‐01657327] ">Van Wyck 2005 CKD</a>). </p> </section> <section id="CD007857-sec-0074"> <h4 class="title">Excluded studies</h4> <p>From the 2012 review, twenty‐three reports were excluded based on titles and abstracts; one study was not an RCT and the remainder involved ineligible interventions. Five more studies (eight reports) were excluded after full text review because participants were not randomised or compared intramuscular with oral iron. </p> <p>Three studies (four reports) identified in the search for the 2019 update were excluded. One study (<a href="./references#CD007857-bbs2-0042" title="CharytanC , BernardoMV , KochTA , ButcherA , MorrisD , BregmanDB . Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active‐controlled, multi‐center study. Nephrology Dialysis Transplantation2013;28(4):953‐64. [MEDLINE: 23222534] ">Charytan 2013</a>) involved an ineligible comparator (standard medical care which could be oral or IV iron), one study (<a href="./references#CD007857-bbs2-0043" title="BarracloughKA , BrownF , HawleyCM , LearyD , NobleE , CampbellSB , et al. A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial. Nephrology Dialysis Transplantation2012;27(11):4146‐53. [MEDLINE: 22962411] BarracloughKA , NobleE , LearyD , BrownB , HawleyCM , CampbellSB , et al. Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial). BMC Nephrology2009;10:20. [MEDLINE: 19635169] ">HEMATOCRIT 2012</a>) compared two oral iron preparations and one study (<a href="./references#CD007857-bbs2-0040" title="AdhikaryL , AcharyaS . Efficacy of IV iron compared to oral iron for increment of haemoglobin level in anemic chronic kidney disease patients on erythropoietin therapy. Jnma, Journal of the Nepal Medical Association2011;51(183):133‐6. [MEDLINE: 22922860] ">Adhikary 2011</a>) included non‐randomised patients. </p> </section> </section> <section id="CD007857-sec-0075"> <h3 class="title">Risk of bias in included studies</h3> <p>The assessment of risk of bias is shown in <a href="#CD007857-fig-0002">Figure 2</a> and <a href="#CD007857-fig-0003">Figure 3</a>. <a href="#CD007857-fig-0002">Figure 2</a> shows relative proportional rankings of studies for each risk of bias indicator. <a href="#CD007857-fig-0003">Figure 3</a> shows the risk of bias items for individual studies. </p> <div class="figure" id="CD007857-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: Review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD007857-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: Review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD007857-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: Review authors' judgements about each risk of bias item for each included study" data-id="CD007857-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: Review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD007857-sec-0076"> <h4 class="title">Allocation</h4> <p>Random sequence generation was at low risk of bias in 20 studies (<a href="./references#CD007857-bbs2-0001" title="AgarwalR . Sodium ferric gluconate complex in sucrose (SFGC) injection improves energy level in chronic kidney disease (CKD) patients independent of increase in hemoglobin levels [abstract no: F‐PO337]. Journal of the American Society of Nephrology2004;15(Oct):140A. [CENTRAL: CN‐01657325] AgarwalR , RizkalaAR , BastaniB , KaskasMO , LeeheyDJ , BesarabA . A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. American Journal of Nephrology2006;26(5):445‐54. [MEDLINE: 17035697] ">Agarwal 2006 CKD</a>; <a href="./references#CD007857-bbs2-0002" title="AgarwalR , KusekJW , PappasMK . A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney International2015;88(4):905‐14. [DOI: 10.1038/ki.2015.163; MEDLINE: 26083656] ">Agarwal 2015 CKD</a>; <a href="./references#CD007857-bbs2-0008" title="GaillardCA , BockAH , CarreraF , EckardtK , VanWyckDB , BansalSS , et al. Hepcidin response to intravenous (IV) or oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis CKD (ND‐CKD) [abstract no: TH‐OR040]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. GaillardCA , BockAH , CarreraF , EckardtKU , VanWyckDB , BansalSS , et al. Hepcidin response to iron therapy in patients with non‐dialysis dependent CKD: an analysis of the FIND‐CKD trial. PLoS ONE [Electronic Resource]2016;11(6):e0157063. [MEDLINE: 27276035] MacdougallI , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. A model to predict haematopoietic non‐response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD): an analysis from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193‐4. [EMBASE: 72326413] MacdougallIC , BockA , CarreraF , CushwayT , MoriC , RogerS . Rationale and design of a new RCT of iron therapy in anemic non‐dialysis CKD patients: FIND‐CKD trial [abstract no: SA‐PO2402]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):660A. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. The FIND‐CKD study‐‐a randomized controlled trial of intravenous iron versus oral iron in non‐dialysis chronic kidney disease patients: background and rationale. Nephrology Dialysis Transplantation2014;29(4):843‐50. [MEDLINE: 24170814] MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. FIND‐CKD: a 56‐week randomized trial of intravenous ferric carboxymaltose versus oral iron in anemic patients with chronic kidney disease and iron deficiency [abstract no: SA‐PO1079]. Journal of the American Society of Nephrology2013;24(Abstracts):3B. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. Intravenous ferric carboxymaltose vs oral iron in anaemic patients with non‐dialysis dependent chronic kidney disease and iron deficiency: results of the randomised FIND‐CKD study [abstract no: SO049]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. MacdougallIC , BockAH , CarreraF , EckardtK , GaillardC , VanWyckD , et al. Efficacy of oral iron for treating iron deficiency in anaemic patients with non‐dialysis dependent CKD (ND‐CKD) [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii581. [EMBASE: 617290898] MacdougallIC , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. Iron administration to non‐dialysis CKD patients for one year does not cause worsening of renal function: results from the FIND‐CKD trial [abstract no: FR‐PO809]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):555A. MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Erythropoietic response to oral iron in patients with nondialysis‐dependent chronic kidney disease in the FIND‐CKD trial. Clinical Nephrology2017;88(12):301‐10. [MEDLINE: 29092739] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. FIND‐CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrology Dialysis Transplantation2014;29(11):2075‐84. [MEDLINE: 24891437] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Renal function in patients with non‐dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND‐CKD trial. BMC Nephrology2017;18(1):24. [MEDLINE: 28095881] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Hepcidin response to iron therapy in patients with non‐dialysis CKD: an analysis of the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8‐9. [EMBASE: 72206297] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Low rate of early response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD) [abstract no: TH‐PO906]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. RogerS , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. The safety of intravenous (IV) ferric carboxymaltose (FCM) in patients with non‐dialysis dependent CKD (ND‐CKD): 1‐year results from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i15‐6. [EMBASE: 72325953] RogerSD , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. IV ferric carboxymaltose (FCM) is a convenient and well‐tolerated first‐line therapy for the treatment of anaemia in patients with iron deficiency and non‐dialysis dependent chronic kidney disease (ND‐CKD): results of the randomised FIND‐CKD study [abstract no: SO048]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. RogerSD , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Intravenous (IV) ferric carboxymaltose (FCM) versus oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis dependant CKD (ND‐CKD): a safety analysis [abstract no: TH‐PO652]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):238A. ">FIND‐CKD 2014 CKD</a>; <a href="./references#CD007857-bbs2-0010" title="FudinR , JaichenkoJ , ShostakA , BennettM , GotloibL . Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron1998;79(3):299‐305. [MEDLINE: 9678430] ">Fudin 1998 HD</a>; <a href="./references#CD007857-bbs2-0012" title="KalraPA , BhandariS , SaxenaS , AgarwalD , WirtzG , KletzmayrJ , et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non‐dialysis‐dependent chronic kidney disease patients with anaemia. Nephrology Dialysis Transplantation2016;31(4):646‐55. [MEDLINE: 26250435] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside 1000 (monofer) compared to oral iron sulphate in European patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii200. [EMBASE: 72206812] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside1000 (monofer) compared to oral iron sulphate in patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract no: SA‐PO1106]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B7. ">Kalra 2016 CKD</a>; <a href="./references#CD007857-bbs2-0014" title="LeeheyDJ , KaskasMO , BastaniB , Ferrlecit CKD Study Group. Sodium ferric gluconate complex (SFGC) in the treatment of chronic kidney disease (CKD) patients on stable erythropoietic therapy [abstract no: F‐PO966]. Journal of the American Society of Nephrology2005;16:547A. [CENTRAL: CN‐00747316] ">Leehey 2005 CKD</a>; <a href="./references#CD007857-bbs2-0015" title="LiH , WangSX . Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Blood Purification2008;26(2):151‐6. [MEDLINE: 18212498] LiH , WangSX . Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study. Chung‐Hua i Hsueh Tsa Chih [Chinese Medical Journal]2009;89(7):457‐62. [MEDLINE: 19567093] ">Li 2008 HD</a>; <a href="./references#CD007857-bbs2-0016" title="LiH , WangSX . Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study. Chung‐Hua i Hsueh Tsa Chih [Chinese Medical Journal]2009;89(7):457‐62. [MEDLINE: 19567093] LiH , WangSX . Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Peritoneal Dialysis International2008;28(2):149‐54. [MEDLINE: 18332450] ">Li 2008 PD</a>; <a href="./references#CD007857-bbs2-0019" title="MacdougallIC , TuckerB , ThompsonJ , BakerIR , RaineAE . A randomised controlled study of iron supplementation in patients treated with erythropoietin [abstract]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):428. [CENTRAL: CN‐00484929] MacdougallIC , TuckerB , ThompsonJ , TomsonCR , BakerLR , RaineAE . A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney International1996;50(5):1694‐9. [MEDLINE: 8914038] MacdougallIC , TuckerB , ThompsonJ , TomsonCR , BakerLR , RaineAE . Randomised controlled study of iron supplementation in patients treated with erythropoietin [abstract]. Nephrology Dialysis Transplantation1993;8(12):1424. [CENTRAL: CN‐00260914] MacdougallIC , TuckerB , ThompsonJ , TomsonCRV , BakerLR , RaineAE . Randomised controlled study of iron supplementation in patients treated with erythropoietin [abstract]. Nephrology Dialysis Transplantation1993;8(9):960. [CENTRAL: CN‐01657602] ">Macdougall 1996 HD,PD,CKD</a>; <a href="./references#CD007857-bbs2-0021" title="McMahonL , KentAB , RogerS , KerrP , HealyH , IrishA , et al. IV iron sucrose versus oral iron for the anaemia of chronic kidney disease (CKD) ‐ a randomized controlled trial [abstract no: O82]. Nephrology2008;13(Suppl 3):A120. [CENTRAL: CN‐00747281] McMahonLP , KentAB , KerrPG , HealyH , IrishAB , CooperB , et al. Maintenance of elevated versus physiological iron indices in non‐anaemic patients with chronic kidney disease: a randomized controlled trial. Nephrology Dialysis Transplantation2010;25(3):920‐6. [MEDLINE: 19906658] McMahonLP , KentAB , RogerSD , KerrPG , HealyH , IrishAB , et al. IV iron sucrose versus oral iron for the anemia of chronic kidney disease (CKD) ‐ a randomized controlled trial [abstract no: SU‐PO1028]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):813A. [CENTRAL: CN‐00690668] ">McMahon 2009 CKD</a>; <a href="./references#CD007857-bbs2-0023" title="MudgeDW , TanK , MilesR , JohnsonDW , CampbellSB , HawleyCM , et al. Intravenous versus oral iron for post‐transplant anaemia: a randomised controlled trial [abstract no: 149]. Transplantation2010;90(Suppl 1):679. [EMBASE: 71532404] MudgeDW , TanKS , MilesR , JohnsonDW , BadveSV , CampbellSB , et al. A randomized controlled trial of intravenous or oral iron for posttransplant anemia in kidney transplantation. Transplantation2012;93(8):822‐6. [MEDLINE: 22290270] MudgeDW , TanKS , MilesR , JohnsonDW , CampbellSB , HawleyCM , et al. Intravenous versus oral iron supplementation for correction of post‐transplant anaemia in renal transplant patients. BMC Nephrology2009;10:14. [MEDLINE: 19500381] ">Mudge 2009 TX</a>; <a href="./references#CD007857-bbs2-0024" title="NagarajuSP , CohnA , AkbariA , DavisJL , ZimmermanDL . Heme iron polypeptide for the treatment of iron deficiency anemia in non‐dialysis chronic kidney disease patients: a randomized controlled trial. BMC Nephrology2013;14:64. [MEDLINE: 23514036] ">Nagaraju 2013 CKD</a>; <a href="./references#CD007857-bbs2-0017" title="BesarabA , CoyneD , BoltonWK , SharmaA , FotiA , BrennerL . Ferumoxytol as an intravenous iron replacement therapy: safety results from two phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO0805]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):762A. [CENTRAL: CN‐00747286] BoltonWK , BesarabA , GermainM , KovesdyCP , HutchinsonJ , KrauszA . Ferumoxytol as an IV iron replacement therapy: efficacy results from two Phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO798]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):761A. [CENTRAL: CN‐00747287] BoltonWK , FishbaneS , LiJ , MilichL , BrennerR . Increases in hemoglobin and the effect of ESA use in CKD patients treated with IV ferumoxytol [abstract]. American Journal of Kidney Diseases2009;53(4):A30. [EMBASE: 70141518] FishbaneS , BoltonWK , WinkelmayerWC , StraussW , LiZ , PereiraBJ . Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Clinical Nephrology2012;78(3):181‐8. [MEDLINE: 22874106] GermainM , BrennerL , DioguardiJ , GilbertsonD , BesarabA . Comparison of safety and efficacy of ferumoxytol in CKD subtypes: kidney transplant recipients, hemodialysis patients and non‐hemodialysis patients [abstract no: SA‐PO2530]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00747289] LuM , CohenMH , RievesD , PazdurR . FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. American Journal of Hematology2010;85(5):315‐9. [MEDLINE: 20201089] SpinowitzB , BesarabA , BoltonWK , PereiraBJ , ProvenzanoR , RaoM , et al. Ferumoxytol as intravenous iron replacement therapy in chronic kidney disease (CKD) patients not on dialysis ‐ evaluation of safety and efficacy in two phase III studies [abstract no: F‐PO026]. Journal of the American Society of Nephrology2006;17(Abstracts):342A. [CENTRAL: CN‐00644267] SpinowitzB , KauszA , MillerP , BrennerL , SinghA . Achievement of target hemoglobin with ferumoxytol versus oral iron in anemic CKD patients [abstract no: SU‐PO1031]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):814A. [CENTRAL: CN‐00688845] SpinowitzB , KrauzA , DioguardiJ , KovesdyC . Evaluation of ferumoxytol safety and efficacy in all stages of chronic kidney disease (CKD) [abstract no: 249]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00747323] ">Lu 2010 CKD</a>; <a href="./references#CD007857-bbs2-0026" title="PisaniA , RiccioE , SabbatiniM , AndreucciM , DelRioA , ViscianoB . Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrology Dialysis Transplantation2014;30(4):645‐52. [MEDLINE: 25395392] ViscianoB , NazzaroP , RiccioE , DelRioA , MozzilloGR , PisaniA . Liposomial iron for the treatment of iron deficiency anemia in non dialysis chronic kidney disease patients: a randomized controlled trial [abstract]. Nephrology Dialysis Transplantation2014;29(5 Suppl 3):iii141‐2. [EMBASE: 71491842] ViscianoB , NazzaroP , TarantinoG , TaddeiA , DelRioA , MozzilloGR , et al. Liposomial iron: a new proposal for the treatment of anaemia in chronic kidney disease [Il ferro liposomiale: una nuova proposta per il trattamento dell’anemia nei pazienti affetti da insufficenza renale cronica]. Giornale Italiano di Nefrologia2013;30(5). [MEDLINE: 24402627] ">Pisani 2014 CKD</a>; <a href="./references#CD007857-bbs2-0028" title="BenjaminJ . A randomized controlled trial comparing IV ferric carboxymaltose (FCM) to oral iron in anemic nondialysis dependent CKD patients (with or without erythropoiesis stimulating agent use) [abstract no: M574]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐01658222] BenjaminJ , QunibiW . Comparison of intravenous (IV) ferric carboxymaltose (FCM) to oral iron in anemic non‐dialysis dependent (NDD)‐CKD patients with or without ESA therapy [abstract no: SA‐PO2422]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):666A. QunibiW , MartinezC , SmithM , BenjaminJ , DinhQ . A randomized controlled trial comparing IV ferric carboxymaltose (FCM) to oral iron in anemic patients with non‐dialysis‐dependent CKD [abstract no: SU‐PO1030]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):814A. [CENTRAL: CN‐00689191] QunibiWY , MartinezC , SmithM , BenjaminJ , MangioneA , RogerSD . A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non‐dialysis‐dependent chronic kidney disease patients. Nephrology Dialysis Transplantation2011;26(5):1599‐607. [MEDLINE: 20929915] ">Qunibi 2011 CKD</a>; <a href="./references#CD007857-bbs2-0031" title="BesarabA , CoyneD , BoltonWK , SharmaA , FotiA , BrennerL . Ferumoxytol as an intravenous iron replacement therapy: safety results from two phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO0805]. Journal of the American Society of Nephrology2007;18(Abstracts issue):762A. [CENTRAL: CN‐00747286] BoltonWK , BesarabA , GermainM , KovesdyCP , HutchinsonJ , KrauszA . Ferumoxytol as an IV iron replacement therapy: efficacy results from two Phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO798]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):761A. [CENTRAL: CN‐00747287] BoltonWK , FishbaneS , LiJ , MilichL , BrennerR . Increases in hemoglobin and the effect of ESA use in CKD patients treated with IV ferumoxytol [abstract]. American Journal of Kidney Diseases2009;53(4):A30. [EMBASE: 70141518] BrennerL , MillerP , RodriguezS , ParikhN , CoyneDW . Treatment of iron‐deficiency anemia with IV ferumoxytol in CKD patients: efficacy compared with oral iron across different age groups [abstract]. Blood2007;110(11). [CENTRAL: CN‐00646734] FishbaneS , BoltonWK , WinkelmayerWC , StraussW , LiZ , PereiraBJ . Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Clinical Nephrology2012;78(3):181‐8. [MEDLINE: 22874106] GermainM , BrennerL , DioguardiJ , GilbertsonD , BesarabA . Comparison of safety and efficacy of ferumoxytol in CKD subtypes: kidney transplant recipients, hemodialysis patients and non‐hemodialysis patients [abstract no: SA‐PO2530]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00747289] HorlWH . Comparing the efficacy of intravenous iron and oral iron in nondialysis patients with chronic kidney disease. Nature Clinical Practice Nephrology2008;4(10):530‐1. [EMBASE: 2008457134] LuM , CohenMH , RievesD , PazdurR . FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. American Journal of Hematology2010;85(5):315‐9. [MEDLINE: 20201089] SpinowitzB , BernardoM , NobleS , BaptistaJ , PereiraB , BrennerL . Safety and efficacy of ferumoxytol as an intravenous iron replacement therapy: results from a phase III study of chronic kidney disease (CKD) patients not on dialysis [abstract no: 30]. American Journal of Kidney Diseases2007;49(4):A32. [CENTRAL: CN‐00644268] SpinowitzB , BesarabA , BoltonWK , PereiraBJ , ProvenzanoR , RaoM , et al. Ferumoxytol as intravenous iron replacement therapy in chronic kidney disease (CKD) patients not on dialysis ‐ evaluation of safety and efficacy in two phase III studies [abstract no: F‐PO026]. Journal of the American Society of Nephrology2006;17(Abstracts):342A. [CENTRAL: CN‐00644267] SpinowitzB , KauszA , MillerP , BrennerL , SinghA . Achievement of target hemoglobin with ferumoxytol versus oral iron in anemic CKD patients [abstract no: SU‐PO1031]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):814A. [CENTRAL: CN‐00688845] SpinowitzB , KrauzA , DioguardiJ , KovesdyC . Evaluation of ferumoxytol safety and efficacy in all stages of chronic kidney disease (CKD) [abstract no: 249]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00747323] SpinowitzBS , KauszAT , BaptistaJ , NobleSD , SothinathanR , BernardoMV , et al. Ferumoxytol for treating iron deficiency anemia in CKD. Journal of the American Society of Nephrology2008;19(8):1599‐605. [MEDLINE: 18525001] ">Spinowitz 2008 CKD</a>; <a href="./references#CD007857-bbs2-0032" title="StovesJ , InglisH , NewsteadCG . A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrology Dialysis Transplantation2001;16(5):967‐74. [MEDLINE: 11328902] ">Stoves 2001 CKD</a>; <a href="./references#CD007857-bbs2-0033" title="StricklandID , Chaput de SaintongeDM , BoultonFE , FrancisB , RoubikovaJ , WatersJI . The therapeutic equivalence of oral and intravenous iron in renal dialysis patients. Clinical Nephrology1977;7(2):55‐7. [MEDLINE: 321170] ">Strickland 1977 HD</a>; <a href="./references#CD007857-bbs2-0036" title="VanWyckDB , RoppoloM , MartinezCO , MazeyRM , McMurrayS , United States Iron Sucrose (Venofer) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis‐dependent CKD. Kidney International2005;68(6):2846‐56. [MEDLINE: 16316362] VanWyckDB , RoppoloM , MartinezCO , McMurraySD , MazeyR . A randomized controlled trial comparing IV iron sucrose to oral iron in anemic patients with non‐dialysis‐dependent CKD [abstract no: F‐FC051]. Journal of the American Society of Nephrology2005;16:49A. [CENTRAL: CN‐01657327] ">Van Wyck 2005 CKD</a>; <a href="./references#CD007857-bbs2-0038" title="WaradyBA , KauszA , LernerG , BrewerED , ChadhaV , BrugnaraC , et al. Iron therapy in the pediatric hemodialysis population. Pediatric Nephrology2004;19(6):655‐61. [MEDLINE: 15064942] WaradyBA , KauszAT , LernerG , BrewerED , ChadhaV , BrugnaraC , et al. A comparison of intravenous and oral iron therapy in children receiving hemodialysis [abstract no: F‐PO789]. Journal of the American Society of Nephrology2002;13(Program &amp; Abstracts):221A. [CENTRAL: CN‐01657600] ">Warady 2002 HD</a>). Random sequence generation was not reported in 18 studies. </p> <p>Allocation concealment was at low risk of bias in 14 studies (<a href="./references#CD007857-bbs2-0001" title="AgarwalR . Sodium ferric gluconate complex in sucrose (SFGC) injection improves energy level in chronic kidney disease (CKD) patients independent of increase in hemoglobin levels [abstract no: F‐PO337]. Journal of the American Society of Nephrology2004;15(Oct):140A. [CENTRAL: CN‐01657325] AgarwalR , RizkalaAR , BastaniB , KaskasMO , LeeheyDJ , BesarabA . A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. American Journal of Nephrology2006;26(5):445‐54. [MEDLINE: 17035697] ">Agarwal 2006 CKD</a>; <a href="./references#CD007857-bbs2-0002" title="AgarwalR , KusekJW , PappasMK . A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney International2015;88(4):905‐14. [DOI: 10.1038/ki.2015.163; MEDLINE: 26083656] ">Agarwal 2015 CKD</a>; <a href="./references#CD007857-bbs2-0008" title="GaillardCA , BockAH , CarreraF , EckardtK , VanWyckDB , BansalSS , et al. Hepcidin response to intravenous (IV) or oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis CKD (ND‐CKD) [abstract no: TH‐OR040]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. GaillardCA , BockAH , CarreraF , EckardtKU , VanWyckDB , BansalSS , et al. Hepcidin response to iron therapy in patients with non‐dialysis dependent CKD: an analysis of the FIND‐CKD trial. PLoS ONE [Electronic Resource]2016;11(6):e0157063. [MEDLINE: 27276035] MacdougallI , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. A model to predict haematopoietic non‐response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD): an analysis from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193‐4. [EMBASE: 72326413] MacdougallIC , BockA , CarreraF , CushwayT , MoriC , RogerS . Rationale and design of a new RCT of iron therapy in anemic non‐dialysis CKD patients: FIND‐CKD trial [abstract no: SA‐PO2402]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):660A. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. The FIND‐CKD study‐‐a randomized controlled trial of intravenous iron versus oral iron in non‐dialysis chronic kidney disease patients: background and rationale. Nephrology Dialysis Transplantation2014;29(4):843‐50. [MEDLINE: 24170814] MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. FIND‐CKD: a 56‐week randomized trial of intravenous ferric carboxymaltose versus oral iron in anemic patients with chronic kidney disease and iron deficiency [abstract no: SA‐PO1079]. Journal of the American Society of Nephrology2013;24(Abstracts):3B. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. Intravenous ferric carboxymaltose vs oral iron in anaemic patients with non‐dialysis dependent chronic kidney disease and iron deficiency: results of the randomised FIND‐CKD study [abstract no: SO049]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. MacdougallIC , BockAH , CarreraF , EckardtK , GaillardC , VanWyckD , et al. Efficacy of oral iron for treating iron deficiency in anaemic patients with non‐dialysis dependent CKD (ND‐CKD) [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii581. [EMBASE: 617290898] MacdougallIC , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. Iron administration to non‐dialysis CKD patients for one year does not cause worsening of renal function: results from the FIND‐CKD trial [abstract no: FR‐PO809]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):555A. MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Erythropoietic response to oral iron in patients with nondialysis‐dependent chronic kidney disease in the FIND‐CKD trial. Clinical Nephrology2017;88(12):301‐10. [MEDLINE: 29092739] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. FIND‐CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrology Dialysis Transplantation2014;29(11):2075‐84. [MEDLINE: 24891437] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Renal function in patients with non‐dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND‐CKD trial. BMC Nephrology2017;18(1):24. [MEDLINE: 28095881] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Hepcidin response to iron therapy in patients with non‐dialysis CKD: an analysis of the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8‐9. [EMBASE: 72206297] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Low rate of early response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD) [abstract no: TH‐PO906]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. RogerS , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. The safety of intravenous (IV) ferric carboxymaltose (FCM) in patients with non‐dialysis dependent CKD (ND‐CKD): 1‐year results from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i15‐6. [EMBASE: 72325953] RogerSD , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. IV ferric carboxymaltose (FCM) is a convenient and well‐tolerated first‐line therapy for the treatment of anaemia in patients with iron deficiency and non‐dialysis dependent chronic kidney disease (ND‐CKD): results of the randomised FIND‐CKD study [abstract no: SO048]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. RogerSD , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Intravenous (IV) ferric carboxymaltose (FCM) versus oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis dependant CKD (ND‐CKD): a safety analysis [abstract no: TH‐PO652]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):238A. ">FIND‐CKD 2014 CKD</a>; <a href="./references#CD007857-bbs2-0012" title="KalraPA , BhandariS , SaxenaS , AgarwalD , WirtzG , KletzmayrJ , et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non‐dialysis‐dependent chronic kidney disease patients with anaemia. Nephrology Dialysis Transplantation2016;31(4):646‐55. [MEDLINE: 26250435] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside 1000 (monofer) compared to oral iron sulphate in European patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii200. [EMBASE: 72206812] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside1000 (monofer) compared to oral iron sulphate in patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract no: SA‐PO1106]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B7. ">Kalra 2016 CKD</a>; <a href="./references#CD007857-bbs2-0014" title="LeeheyDJ , KaskasMO , BastaniB , Ferrlecit CKD Study Group. Sodium ferric gluconate complex (SFGC) in the treatment of chronic kidney disease (CKD) patients on stable erythropoietic therapy [abstract no: F‐PO966]. Journal of the American Society of Nephrology2005;16:547A. [CENTRAL: CN‐00747316] ">Leehey 2005 CKD</a>; <a href="./references#CD007857-bbs2-0019" title="MacdougallIC , TuckerB , ThompsonJ , BakerIR , RaineAE . A randomised controlled study of iron supplementation in patients treated with erythropoietin [abstract]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):428. [CENTRAL: CN‐00484929] MacdougallIC , TuckerB , ThompsonJ , TomsonCR , BakerLR , RaineAE . A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney International1996;50(5):1694‐9. [MEDLINE: 8914038] MacdougallIC , TuckerB , ThompsonJ , TomsonCR , BakerLR , RaineAE . Randomised controlled study of iron supplementation in patients treated with erythropoietin [abstract]. Nephrology Dialysis Transplantation1993;8(12):1424. [CENTRAL: CN‐00260914] MacdougallIC , TuckerB , ThompsonJ , TomsonCRV , BakerLR , RaineAE . Randomised controlled study of iron supplementation in patients treated with erythropoietin [abstract]. Nephrology Dialysis Transplantation1993;8(9):960. [CENTRAL: CN‐01657602] ">Macdougall 1996 HD,PD,CKD</a>; <a href="./references#CD007857-bbs2-0023" title="MudgeDW , TanK , MilesR , JohnsonDW , CampbellSB , HawleyCM , et al. Intravenous versus oral iron for post‐transplant anaemia: a randomised controlled trial [abstract no: 149]. Transplantation2010;90(Suppl 1):679. [EMBASE: 71532404] MudgeDW , TanKS , MilesR , JohnsonDW , BadveSV , CampbellSB , et al. A randomized controlled trial of intravenous or oral iron for posttransplant anemia in kidney transplantation. Transplantation2012;93(8):822‐6. [MEDLINE: 22290270] MudgeDW , TanKS , MilesR , JohnsonDW , CampbellSB , HawleyCM , et al. Intravenous versus oral iron supplementation for correction of post‐transplant anaemia in renal transplant patients. BMC Nephrology2009;10:14. [MEDLINE: 19500381] ">Mudge 2009 TX</a>; <a href="./references#CD007857-bbs2-0024" title="NagarajuSP , CohnA , AkbariA , DavisJL , ZimmermanDL . Heme iron polypeptide for the treatment of iron deficiency anemia in non‐dialysis chronic kidney disease patients: a randomized controlled trial. BMC Nephrology2013;14:64. [MEDLINE: 23514036] ">Nagaraju 2013 CKD</a>; <a href="./references#CD007857-bbs2-0017" title="BesarabA , CoyneD , BoltonWK , SharmaA , FotiA , BrennerL . Ferumoxytol as an intravenous iron replacement therapy: safety results from two phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO0805]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):762A. [CENTRAL: CN‐00747286] BoltonWK , BesarabA , GermainM , KovesdyCP , HutchinsonJ , KrauszA . Ferumoxytol as an IV iron replacement therapy: efficacy results from two Phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO798]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):761A. [CENTRAL: CN‐00747287] BoltonWK , FishbaneS , LiJ , MilichL , BrennerR . Increases in hemoglobin and the effect of ESA use in CKD patients treated with IV ferumoxytol [abstract]. American Journal of Kidney Diseases2009;53(4):A30. [EMBASE: 70141518] FishbaneS , BoltonWK , WinkelmayerWC , StraussW , LiZ , PereiraBJ . Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Clinical Nephrology2012;78(3):181‐8. [MEDLINE: 22874106] GermainM , BrennerL , DioguardiJ , GilbertsonD , BesarabA . Comparison of safety and efficacy of ferumoxytol in CKD subtypes: kidney transplant recipients, hemodialysis patients and non‐hemodialysis patients [abstract no: SA‐PO2530]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00747289] LuM , CohenMH , RievesD , PazdurR . FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. American Journal of Hematology2010;85(5):315‐9. [MEDLINE: 20201089] SpinowitzB , BesarabA , BoltonWK , PereiraBJ , ProvenzanoR , RaoM , et al. Ferumoxytol as intravenous iron replacement therapy in chronic kidney disease (CKD) patients not on dialysis ‐ evaluation of safety and efficacy in two phase III studies [abstract no: F‐PO026]. Journal of the American Society of Nephrology2006;17(Abstracts):342A. [CENTRAL: CN‐00644267] SpinowitzB , KauszA , MillerP , BrennerL , SinghA . Achievement of target hemoglobin with ferumoxytol versus oral iron in anemic CKD patients [abstract no: SU‐PO1031]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):814A. [CENTRAL: CN‐00688845] SpinowitzB , KrauzA , DioguardiJ , KovesdyC . Evaluation of ferumoxytol safety and efficacy in all stages of chronic kidney disease (CKD) [abstract no: 249]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00747323] ">Lu 2010 CKD</a>; <a href="./references#CD007857-bbs2-0026" title="PisaniA , RiccioE , SabbatiniM , AndreucciM , DelRioA , ViscianoB . Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrology Dialysis Transplantation2014;30(4):645‐52. [MEDLINE: 25395392] ViscianoB , NazzaroP , RiccioE , DelRioA , MozzilloGR , PisaniA . Liposomial iron for the treatment of iron deficiency anemia in non dialysis chronic kidney disease patients: a randomized controlled trial [abstract]. Nephrology Dialysis Transplantation2014;29(5 Suppl 3):iii141‐2. [EMBASE: 71491842] ViscianoB , NazzaroP , TarantinoG , TaddeiA , DelRioA , MozzilloGR , et al. Liposomial iron: a new proposal for the treatment of anaemia in chronic kidney disease [Il ferro liposomiale: una nuova proposta per il trattamento dell’anemia nei pazienti affetti da insufficenza renale cronica]. Giornale Italiano di Nefrologia2013;30(5). [MEDLINE: 24402627] ">Pisani 2014 CKD</a>; <a href="./references#CD007857-bbs2-0027" title="GermainM , BrennerL , DioguardiJ , GilbertsonD , BesarabA . Comparison of safety and efficacy of ferumoxytol in CKD subtypes: kidney transplant recipients, hemodialysis patients and non‐hemodialysis patients [abstract no: SA‐PO2530]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00747289] LuM , CohenMH , RievesD , PazdurR . FDA report. Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. American Journal of Hematology2010;85(5):315‐9. [MEDLINE: 20201089] ProvenzanoR , SchillerB , RaoM , CoyneD , BrennerL , PereiraBJ . Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clinical Journal of the American Society of Nephrology: CJASN2009;4(2):386‐93. [MEDLINE: 19176796] SpinowitzB , KrauzA , DioguardiJ , KovesdyC . Evaluation of ferumoxytol safety and efficacy in all stages of chronic kidney disease (CKD) [abstract no: 249]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00688845] ">Provenzano 2009 HD</a>; <a href="./references#CD007857-bbs2-0028" title="BenjaminJ . A randomized controlled trial comparing IV ferric carboxymaltose (FCM) to oral iron in anemic nondialysis dependent CKD patients (with or without erythropoiesis stimulating agent use) [abstract no: M574]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐01658222] BenjaminJ , QunibiW . Comparison of intravenous (IV) ferric carboxymaltose (FCM) to oral iron in anemic non‐dialysis dependent (NDD)‐CKD patients with or without ESA therapy [abstract no: SA‐PO2422]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):666A. QunibiW , MartinezC , SmithM , BenjaminJ , DinhQ . A randomized controlled trial comparing IV ferric carboxymaltose (FCM) to oral iron in anemic patients with non‐dialysis‐dependent CKD [abstract no: SU‐PO1030]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):814A. [CENTRAL: CN‐00689191] QunibiWY , MartinezC , SmithM , BenjaminJ , MangioneA , RogerSD . A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non‐dialysis‐dependent chronic kidney disease patients. Nephrology Dialysis Transplantation2011;26(5):1599‐607. [MEDLINE: 20929915] ">Qunibi 2011 CKD</a>; <a href="./references#CD007857-bbs2-0031" title="BesarabA , CoyneD , BoltonWK , SharmaA , FotiA , BrennerL . Ferumoxytol as an intravenous iron replacement therapy: safety results from two phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO0805]. Journal of the American Society of Nephrology2007;18(Abstracts issue):762A. [CENTRAL: CN‐00747286] BoltonWK , BesarabA , GermainM , KovesdyCP , HutchinsonJ , KrauszA . Ferumoxytol as an IV iron replacement therapy: efficacy results from two Phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO798]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):761A. [CENTRAL: CN‐00747287] BoltonWK , FishbaneS , LiJ , MilichL , BrennerR . Increases in hemoglobin and the effect of ESA use in CKD patients treated with IV ferumoxytol [abstract]. American Journal of Kidney Diseases2009;53(4):A30. [EMBASE: 70141518] BrennerL , MillerP , RodriguezS , ParikhN , CoyneDW . Treatment of iron‐deficiency anemia with IV ferumoxytol in CKD patients: efficacy compared with oral iron across different age groups [abstract]. Blood2007;110(11). [CENTRAL: CN‐00646734] FishbaneS , BoltonWK , WinkelmayerWC , StraussW , LiZ , PereiraBJ . Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Clinical Nephrology2012;78(3):181‐8. [MEDLINE: 22874106] GermainM , BrennerL , DioguardiJ , GilbertsonD , BesarabA . Comparison of safety and efficacy of ferumoxytol in CKD subtypes: kidney transplant recipients, hemodialysis patients and non‐hemodialysis patients [abstract no: SA‐PO2530]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00747289] HorlWH . Comparing the efficacy of intravenous iron and oral iron in nondialysis patients with chronic kidney disease. Nature Clinical Practice Nephrology2008;4(10):530‐1. [EMBASE: 2008457134] LuM , CohenMH , RievesD , PazdurR . FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. American Journal of Hematology2010;85(5):315‐9. [MEDLINE: 20201089] SpinowitzB , BernardoM , NobleS , BaptistaJ , PereiraB , BrennerL . Safety and efficacy of ferumoxytol as an intravenous iron replacement therapy: results from a phase III study of chronic kidney disease (CKD) patients not on dialysis [abstract no: 30]. American Journal of Kidney Diseases2007;49(4):A32. [CENTRAL: CN‐00644268] SpinowitzB , BesarabA , BoltonWK , PereiraBJ , ProvenzanoR , RaoM , et al. Ferumoxytol as intravenous iron replacement therapy in chronic kidney disease (CKD) patients not on dialysis ‐ evaluation of safety and efficacy in two phase III studies [abstract no: F‐PO026]. Journal of the American Society of Nephrology2006;17(Abstracts):342A. [CENTRAL: CN‐00644267] SpinowitzB , KauszA , MillerP , BrennerL , SinghA . Achievement of target hemoglobin with ferumoxytol versus oral iron in anemic CKD patients [abstract no: SU‐PO1031]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):814A. [CENTRAL: CN‐00688845] SpinowitzB , KrauzA , DioguardiJ , KovesdyC . Evaluation of ferumoxytol safety and efficacy in all stages of chronic kidney disease (CKD) [abstract no: 249]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00747323] SpinowitzBS , KauszAT , BaptistaJ , NobleSD , SothinathanR , BernardoMV , et al. Ferumoxytol for treating iron deficiency anemia in CKD. Journal of the American Society of Nephrology2008;19(8):1599‐605. [MEDLINE: 18525001] ">Spinowitz 2008 CKD</a>; <a href="./references#CD007857-bbs2-0036" title="VanWyckDB , RoppoloM , MartinezCO , MazeyRM , McMurrayS , United States Iron Sucrose (Venofer) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis‐dependent CKD. Kidney International2005;68(6):2846‐56. [MEDLINE: 16316362] VanWyckDB , RoppoloM , MartinezCO , McMurraySD , MazeyR . A randomized controlled trial comparing IV iron sucrose to oral iron in anemic patients with non‐dialysis‐dependent CKD [abstract no: F‐FC051]. Journal of the American Society of Nephrology2005;16:49A. [CENTRAL: CN‐01657327] ">Van Wyck 2005 CKD</a>); at high risk of bias in two studies (<a href="./references#CD007857-bbs2-0010" title="FudinR , JaichenkoJ , ShostakA , BennettM , GotloibL . Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron1998;79(3):299‐305. [MEDLINE: 9678430] ">Fudin 1998 HD</a>; <a href="./references#CD007857-bbs2-0018" title="LyeWC . Ferric gluconate polymaltose complex (Ferrum) is safe and effective for intravenous use in hemodialysis (HD) patients [abstract no: A1489]. Journal of the American Society of Nephrology2000;11(Sept):284A. ">Lye 2000 HD</a>), and for the remaining 23 studies allocation concealment was unclear. </p> </section> <section id="CD007857-sec-0077"> <h4 class="title">Blinding</h4> <p>No studies blinded either participants or personnel so were considered to be at high risk of bias. As all studies used laboratory data as primary outcomes, all studies were judged as having a low risk of bias for outcome assessment. </p> </section> <section id="CD007857-sec-0078"> <h4 class="title">Incomplete outcome data</h4> <p>Outcomes data reporting was considered to be complete with a low risk of bias in 22 studies. Five studies (<a href="./references#CD007857-bbs2-0006" title="CharytanC , QunibiW , BailieGR , Venofer Clinical Studies Group. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron2005;100(3):c55‐62. [MEDLINE: 15824508] CharytanC , QunibiW , SinghH , SchwenkM , AronoffG , BesarabA . Safety of Venofer®, [iron sucrose injection] administered by rapid IV push (IVP) in predialysis CKD patients [abstract no: SU‐PO260]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):521a. [CENTRAL: CN‐00444759] ">Charytan 2005 CKD</a>; <a href="./references#CD007857-bbs2-0009" title="FishbaneS , FreiGL , MaesakaJ . Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. American Journal of Kidney Diseases1995;26(1):41‐6. [MEDLINE: 7611266] ">Fishbane 1995 HD</a>; <a href="./references#CD007857-bbs2-0010" title="FudinR , JaichenkoJ , ShostakA , BennettM , GotloibL . Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron1998;79(3):299‐305. [MEDLINE: 9678430] ">Fudin 1998 HD</a>; <a href="./references#CD007857-bbs2-0032" title="StovesJ , InglisH , NewsteadCG . A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrology Dialysis Transplantation2001;16(5):967‐74. [MEDLINE: 11328902] ">Stoves 2001 CKD</a>; <a href="./references#CD007857-bbs2-0033" title="StricklandID , Chaput de SaintongeDM , BoultonFE , FrancisB , RoubikovaJ , WatersJI . The therapeutic equivalence of oral and intravenous iron in renal dialysis patients. Clinical Nephrology1977;7(2):55‐7. [MEDLINE: 321170] ">Strickland 1977 HD</a>) reported that from 7% to 36% of patients were excluded from the analyses, so were considered to be at high risk of bias. The risk of bias was unclear in 12 studies because there was insufficient information provided to determine if data from all patients who entered the study were included in the analysis. </p> </section> <section id="CD007857-sec-0079"> <h4 class="title">Selective reporting</h4> <p>We identified 20 studies that were considered to have reported all outcomes based on the detailed protocols described in the trial methods. Eight studies (<a href="./references#CD007857-bbs2-0002" title="AgarwalR , KusekJW , PappasMK . A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney International2015;88(4):905‐14. [DOI: 10.1038/ki.2015.163; MEDLINE: 26083656] ">Agarwal 2015 CKD</a>; <a href="./references#CD007857-bbs2-0003" title="AggarwalHK , KumarH , SinghS , NandN . Iron therapy in patients of CRF receiving recombinant human EPO which route of iron? [abstract]. Indian Journal of Nephrology2002;12(4):205. [CENTRAL: CN‐00460253] AggarwalHK , NandN , SinghS , SinghM , Hemant , KaushikG . Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. Journal of the Association of Physicians of India2003;51:170‐4. [MEDLINE: 12725261] AggarwalSH , HemantK , SinghS , NandN , SharmaBD . Comparison of oral versus intravenous iron therapy in patients of chronic renal failure receiving recombined human erythropoietin (R‐HUEPO) [abstract no: 56]. Journal of the Association of Physicians of India2001;50(Oct). [CENTRAL: CN‐00663209] ">Aggarwal 2003 CKD</a>; <a href="./references#CD007857-bbs2-0005" title="BroumandB , GhodsA , TaheriFM , HanjaniMR . Intravenous versus oral iron supplementation in the management of anemia in end stage renal disease [abstract]. 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6‐9; Rimini, Italy. 1998:330. [CENTRAL: CN‐00483339] ">Broumand 1998 HD</a>; <a href="./references#CD007857-bbs2-0006" title="CharytanC , QunibiW , BailieGR , Venofer Clinical Studies Group. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron2005;100(3):c55‐62. [MEDLINE: 15824508] CharytanC , QunibiW , SinghH , SchwenkM , AronoffG , BesarabA . Safety of Venofer®, [iron sucrose injection] administered by rapid IV push (IVP) in predialysis CKD patients [abstract no: SU‐PO260]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):521a. [CENTRAL: CN‐00444759] ">Charytan 2005 CKD</a>; <a href="./references#CD007857-bbs2-0014" title="LeeheyDJ , KaskasMO , BastaniB , Ferrlecit CKD Study Group. Sodium ferric gluconate complex (SFGC) in the treatment of chronic kidney disease (CKD) patients on stable erythropoietic therapy [abstract no: F‐PO966]. Journal of the American Society of Nephrology2005;16:547A. [CENTRAL: CN‐00747316] ">Leehey 2005 CKD</a>; <a href="./references#CD007857-bbs2-0029" title="RagabM , MahmoudK , RagabA . Maintenance intravenous iron sucrose therapy in children under regular hemodialysis. Journal of Medical Sciences2007;7(7):1112‐6. [EMBASE: 2007615596] ">Ragab 2007 HD</a>; <a href="./references#CD007857-bbs2-0032" title="StovesJ , InglisH , NewsteadCG . A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrology Dialysis Transplantation2001;16(5):967‐74. [MEDLINE: 11328902] ">Stoves 2001 CKD</a>; <a href="./references#CD007857-bbs2-0033" title="StricklandID , Chaput de SaintongeDM , BoultonFE , FrancisB , RoubikovaJ , WatersJI . The therapeutic equivalence of oral and intravenous iron in renal dialysis patients. Clinical Nephrology1977;7(2):55‐7. [MEDLINE: 321170] ">Strickland 1977 HD</a>) reported outcomes incompletely so that either outcomes could not be included in meta‐analyses or included only with imputed standard deviations or as incidence rates. It was unclear if outcomes were selectively reported in 11 studies. </p> </section> <section id="CD007857-sec-0080"> <h4 class="title">Other potential sources of bias</h4> <p>Sixteen studies reported receiving monetary support from pharmaceutical companies; three studies reported funding from non‐pharmaceutical company sources and the remainder did not report on how their study was funded. In funnel plots, patient centred outcomes showed funnel plot symmetry (example provided in <a href="#CD007857-fig-0004">Figure 4</a>), suggesting a low likelihood of publication and other biases. However, for biochemical outcomes, there was some funnel plot asymmetry (example provided in <a href="#CD007857-fig-0005">Figure 5</a>) which suggests that the meta‐analyses of these outcomes may be affected by some bias. </p> <div class="figure" id="CD007857-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Patient‐centred outcomes.Outcome: 1.1 Death (all causes)Eggers test P = 0.25" data-id="CD007857-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Patient‐centred outcomes.Outcome: 1.1 Death (all causes)</p> <p>Eggers test P = 0.25</p> </div> </div> </div> <div class="figure" id="CD007857-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 Laboratory/pharmaceutical outcomes, outcome: 2.4 Transferrin saturation: Final or change [%].Eggers test P = 0.00" data-id="CD007857-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Laboratory/pharmaceutical outcomes, outcome: 2.4 Transferrin saturation: Final or change [%]. </p> <p>Eggers test P = 0.00</p> </div> </div> </div> </section> </section> <section id="CD007857-sec-0081"> <h3 class="title" id="CD007857-sec-0081">Effects of interventions</h3> <p>See: <a href="./full#CD007857-tbl-0001"><b>Summary of findings for the main comparison</b> Patient‐centred outcomes for oral versus IV iron in adults and children with chronic kidney disease</a>; <a href="./full#CD007857-tbl-0002"><b>Summary of findings 2</b> Laboratory and pharmaceutical outcomes for adults and children with chronic kidney disease</a> </p> <section id="CD007857-sec-0082"> <h4 class="title">Effects of IV iron compared with oral iron on patient‐centred outcomes</h4> <p> <ul id="CD007857-list-0016"> <li> <p>Death (all causes) was only reported in 11 studies. There was insufficient evidence to determine whether IV iron compared with oral iron may makes any difference to death (low certainty evidence) (<a href="./references#CD007857-fig-0006" title="">Analysis 1.1</a> (11 studies, 1952 participants): RR 1.12, 95% CI 0.64 to 1.94; I<sup>2</sup> = 0%). The absolute risk was 33 per 1000 with IV iron compared with 30 per 1000 with oral iron. </p> </li> <li> <p>Cardiovascular death was reported in only three studies. It is uncertain whether IV iron compared with oral iron reduces cardiovascular death because the certainty of this evidence was very low (<a href="./references#CD007857-fig-0007" title="">Analysis 1.2</a> (3 studies, 206 participants): RR 1.71, 95% CI 0.41 to 7.18; I<sup>2</sup> = 0%). </p> </li> <li> <p>Quality of life was only reported in five studies (<a href="./references#CD007857-bbs2-0001" title="AgarwalR . Sodium ferric gluconate complex in sucrose (SFGC) injection improves energy level in chronic kidney disease (CKD) patients independent of increase in hemoglobin levels [abstract no: F‐PO337]. Journal of the American Society of Nephrology2004;15(Oct):140A. [CENTRAL: CN‐01657325] AgarwalR , RizkalaAR , BastaniB , KaskasMO , LeeheyDJ , BesarabA . A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. American Journal of Nephrology2006;26(5):445‐54. [MEDLINE: 17035697] ">Agarwal 2006 CKD</a>; <a href="./references#CD007857-bbs2-0002" title="AgarwalR , KusekJW , PappasMK . A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney International2015;88(4):905‐14. [DOI: 10.1038/ki.2015.163; MEDLINE: 26083656] ">Agarwal 2015 CKD</a>; <a href="./references#CD007857-bbs2-0008" title="GaillardCA , BockAH , CarreraF , EckardtK , VanWyckDB , BansalSS , et al. Hepcidin response to intravenous (IV) or oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis CKD (ND‐CKD) [abstract no: TH‐OR040]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. GaillardCA , BockAH , CarreraF , EckardtKU , VanWyckDB , BansalSS , et al. Hepcidin response to iron therapy in patients with non‐dialysis dependent CKD: an analysis of the FIND‐CKD trial. PLoS ONE [Electronic Resource]2016;11(6):e0157063. [MEDLINE: 27276035] MacdougallI , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. A model to predict haematopoietic non‐response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD): an analysis from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193‐4. [EMBASE: 72326413] MacdougallIC , BockA , CarreraF , CushwayT , MoriC , RogerS . Rationale and design of a new RCT of iron therapy in anemic non‐dialysis CKD patients: FIND‐CKD trial [abstract no: SA‐PO2402]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):660A. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. The FIND‐CKD study‐‐a randomized controlled trial of intravenous iron versus oral iron in non‐dialysis chronic kidney disease patients: background and rationale. Nephrology Dialysis Transplantation2014;29(4):843‐50. [MEDLINE: 24170814] MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. FIND‐CKD: a 56‐week randomized trial of intravenous ferric carboxymaltose versus oral iron in anemic patients with chronic kidney disease and iron deficiency [abstract no: SA‐PO1079]. Journal of the American Society of Nephrology2013;24(Abstracts):3B. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. Intravenous ferric carboxymaltose vs oral iron in anaemic patients with non‐dialysis dependent chronic kidney disease and iron deficiency: results of the randomised FIND‐CKD study [abstract no: SO049]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. MacdougallIC , BockAH , CarreraF , EckardtK , GaillardC , VanWyckD , et al. Efficacy of oral iron for treating iron deficiency in anaemic patients with non‐dialysis dependent CKD (ND‐CKD) [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii581. [EMBASE: 617290898] MacdougallIC , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. Iron administration to non‐dialysis CKD patients for one year does not cause worsening of renal function: results from the FIND‐CKD trial [abstract no: FR‐PO809]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):555A. MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Erythropoietic response to oral iron in patients with nondialysis‐dependent chronic kidney disease in the FIND‐CKD trial. Clinical Nephrology2017;88(12):301‐10. [MEDLINE: 29092739] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. FIND‐CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrology Dialysis Transplantation2014;29(11):2075‐84. [MEDLINE: 24891437] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Renal function in patients with non‐dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND‐CKD trial. BMC Nephrology2017;18(1):24. [MEDLINE: 28095881] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Hepcidin response to iron therapy in patients with non‐dialysis CKD: an analysis of the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8‐9. [EMBASE: 72206297] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Low rate of early response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD) [abstract no: TH‐PO906]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. RogerS , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. The safety of intravenous (IV) ferric carboxymaltose (FCM) in patients with non‐dialysis dependent CKD (ND‐CKD): 1‐year results from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i15‐6. [EMBASE: 72325953] RogerSD , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. IV ferric carboxymaltose (FCM) is a convenient and well‐tolerated first‐line therapy for the treatment of anaemia in patients with iron deficiency and non‐dialysis dependent chronic kidney disease (ND‐CKD): results of the randomised FIND‐CKD study [abstract no: SO048]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. RogerSD , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Intravenous (IV) ferric carboxymaltose (FCM) versus oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis dependant CKD (ND‐CKD): a safety analysis [abstract no: TH‐PO652]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):238A. ">FIND‐CKD 2014 CKD</a>; <a href="./references#CD007857-bbs2-0012" title="KalraPA , BhandariS , SaxenaS , AgarwalD , WirtzG , KletzmayrJ , et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non‐dialysis‐dependent chronic kidney disease patients with anaemia. Nephrology Dialysis Transplantation2016;31(4):646‐55. [MEDLINE: 26250435] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside 1000 (monofer) compared to oral iron sulphate in European patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii200. [EMBASE: 72206812] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside1000 (monofer) compared to oral iron sulphate in patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract no: SA‐PO1106]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B7. ">Kalra 2016 CKD</a>; <a href="./references#CD007857-bbs2-0036" title="VanWyckDB , RoppoloM , MartinezCO , MazeyRM , McMurrayS , United States Iron Sucrose (Venofer) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis‐dependent CKD. Kidney International2005;68(6):2846‐56. [MEDLINE: 16316362] VanWyckDB , RoppoloM , MartinezCO , McMurraySD , MazeyR . A randomized controlled trial comparing IV iron sucrose to oral iron in anemic patients with non‐dialysis‐dependent CKD [abstract no: F‐FC051]. Journal of the American Society of Nephrology2005;16:49A. [CENTRAL: CN‐01657327] ">Van Wyck 2005 CKD</a>). <a href="./references#CD007857-bbs2-0001" title="AgarwalR . Sodium ferric gluconate complex in sucrose (SFGC) injection improves energy level in chronic kidney disease (CKD) patients independent of increase in hemoglobin levels [abstract no: F‐PO337]. Journal of the American Society of Nephrology2004;15(Oct):140A. [CENTRAL: CN‐01657325] AgarwalR , RizkalaAR , BastaniB , KaskasMO , LeeheyDJ , BesarabA . A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. American Journal of Nephrology2006;26(5):445‐54. [MEDLINE: 17035697] ">Agarwal 2006 CKD</a> reported that the SF12 physical composite score improved by 4.8% in patients treated with IV iron, but there was no change in patients treated with oral iron. Kidney disease quality of life score (KDQOL) items ‐ improvement in the ability to do moderate activities and undertake work; and satisfaction with sex life ‐ were reported to be improved among patients treated with IV iron. Scores for a number of factors, including feelings of imposing a burden on family, were lower in patients who received IV iron. In contrast, <a href="./references#CD007857-bbs2-0036" title="VanWyckDB , RoppoloM , MartinezCO , MazeyRM , McMurrayS , United States Iron Sucrose (Venofer) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis‐dependent CKD. Kidney International2005;68(6):2846‐56. [MEDLINE: 16316362] VanWyckDB , RoppoloM , MartinezCO , McMurraySD , MazeyR . A randomized controlled trial comparing IV iron sucrose to oral iron in anemic patients with non‐dialysis‐dependent CKD [abstract no: F‐FC051]. Journal of the American Society of Nephrology2005;16:49A. [CENTRAL: CN‐01657327] ">Van Wyck 2005 CKD</a> found no differences between treatment groups when health concept categories in the SF36 instrument were applied. <a href="./references#CD007857-bbs2-0002" title="AgarwalR , KusekJW , PappasMK . A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney International2015;88(4):905‐14. [DOI: 10.1038/ki.2015.163; MEDLINE: 26083656] ">Agarwal 2015 CKD</a> reported no difference between groups or over time using the KDQOL. <a href="./references#CD007857-bbs2-0008" title="GaillardCA , BockAH , CarreraF , EckardtK , VanWyckDB , BansalSS , et al. Hepcidin response to intravenous (IV) or oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis CKD (ND‐CKD) [abstract no: TH‐OR040]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. GaillardCA , BockAH , CarreraF , EckardtKU , VanWyckDB , BansalSS , et al. Hepcidin response to iron therapy in patients with non‐dialysis dependent CKD: an analysis of the FIND‐CKD trial. PLoS ONE [Electronic Resource]2016;11(6):e0157063. [MEDLINE: 27276035] MacdougallI , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. A model to predict haematopoietic non‐response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD): an analysis from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193‐4. [EMBASE: 72326413] MacdougallIC , BockA , CarreraF , CushwayT , MoriC , RogerS . Rationale and design of a new RCT of iron therapy in anemic non‐dialysis CKD patients: FIND‐CKD trial [abstract no: SA‐PO2402]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):660A. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. The FIND‐CKD study‐‐a randomized controlled trial of intravenous iron versus oral iron in non‐dialysis chronic kidney disease patients: background and rationale. Nephrology Dialysis Transplantation2014;29(4):843‐50. [MEDLINE: 24170814] MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. FIND‐CKD: a 56‐week randomized trial of intravenous ferric carboxymaltose versus oral iron in anemic patients with chronic kidney disease and iron deficiency [abstract no: SA‐PO1079]. Journal of the American Society of Nephrology2013;24(Abstracts):3B. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. Intravenous ferric carboxymaltose vs oral iron in anaemic patients with non‐dialysis dependent chronic kidney disease and iron deficiency: results of the randomised FIND‐CKD study [abstract no: SO049]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. MacdougallIC , BockAH , CarreraF , EckardtK , GaillardC , VanWyckD , et al. Efficacy of oral iron for treating iron deficiency in anaemic patients with non‐dialysis dependent CKD (ND‐CKD) [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii581. [EMBASE: 617290898] MacdougallIC , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. Iron administration to non‐dialysis CKD patients for one year does not cause worsening of renal function: results from the FIND‐CKD trial [abstract no: FR‐PO809]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):555A. MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Erythropoietic response to oral iron in patients with nondialysis‐dependent chronic kidney disease in the FIND‐CKD trial. Clinical Nephrology2017;88(12):301‐10. [MEDLINE: 29092739] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. FIND‐CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrology Dialysis Transplantation2014;29(11):2075‐84. [MEDLINE: 24891437] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Renal function in patients with non‐dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND‐CKD trial. BMC Nephrology2017;18(1):24. [MEDLINE: 28095881] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Hepcidin response to iron therapy in patients with non‐dialysis CKD: an analysis of the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8‐9. [EMBASE: 72206297] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Low rate of early response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD) [abstract no: TH‐PO906]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. RogerS , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. The safety of intravenous (IV) ferric carboxymaltose (FCM) in patients with non‐dialysis dependent CKD (ND‐CKD): 1‐year results from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i15‐6. [EMBASE: 72325953] RogerSD , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. IV ferric carboxymaltose (FCM) is a convenient and well‐tolerated first‐line therapy for the treatment of anaemia in patients with iron deficiency and non‐dialysis dependent chronic kidney disease (ND‐CKD): results of the randomised FIND‐CKD study [abstract no: SO048]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. RogerSD , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Intravenous (IV) ferric carboxymaltose (FCM) versus oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis dependant CKD (ND‐CKD): a safety analysis [abstract no: TH‐PO652]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):238A. ">FIND‐CKD 2014 CKD</a> reported no difference between groups using the SF‐36 tool. Using the Linear Analogue Scale Assessment score, <a href="./references#CD007857-bbs2-0012" title="KalraPA , BhandariS , SaxenaS , AgarwalD , WirtzG , KletzmayrJ , et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non‐dialysis‐dependent chronic kidney disease patients with anaemia. Nephrology Dialysis Transplantation2016;31(4):646‐55. [MEDLINE: 26250435] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside 1000 (monofer) compared to oral iron sulphate in European patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii200. [EMBASE: 72206812] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside1000 (monofer) compared to oral iron sulphate in patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract no: SA‐PO1106]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B7. ">Kalra 2016 CKD</a> identified an improvement in quality of life from baseline to eight weeks in both treatment groups with no difference between groups (<a href="./references#CD007857-fig-0008" title="">Analysis 1.3</a> (1 study, 312 participants): MD 1.45, 95% CI ‐5.89 to 8.79). </p> </li> <li> <p>IV iron compared with oral iron may make little or no difference to the number of participants needing to start dialysis (low certainty evidence) (<a href="./references#CD007857-fig-0009" title="">Analysis 1.4</a> (4 studies, 743 participants): RR 0.81, 95% CI 0.41 to 1.61; I<sup>2</sup> = 0%). The absolute risk for starting dialysis was 38 per 1000 with IV iron and 46 per 1000 with oral iron. </p> </li> <li> <p>IV iron compared with oral iron may make little or no difference to the need for transfusion (low certainty evidence) (<a href="./references#CD007857-fig-0010" title="">Analysis 1.5</a> (5 studies, 774 participants): RR 0.86, 95% CI 0.55 to 1.34; I<sup>2</sup> = 0%). The absolute risk for needing transfusion was 87 per 1000 with IV iron and 101 with oral iron. </p> </li> <li> <p>Although nine studies reported that patient adherence to oral iron was assessed, only three provided numerical data (<a href="./references#CD007857-bbs2-0006" title="CharytanC , QunibiW , BailieGR , Venofer Clinical Studies Group. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron2005;100(3):c55‐62. [MEDLINE: 15824508] CharytanC , QunibiW , SinghH , SchwenkM , AronoffG , BesarabA . Safety of Venofer®, [iron sucrose injection] administered by rapid IV push (IVP) in predialysis CKD patients [abstract no: SU‐PO260]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):521a. [CENTRAL: CN‐00444759] ">Charytan 2005 CKD</a>; <a href="./references#CD007857-bbs2-0036" title="VanWyckDB , RoppoloM , MartinezCO , MazeyRM , McMurrayS , United States Iron Sucrose (Venofer) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis‐dependent CKD. Kidney International2005;68(6):2846‐56. [MEDLINE: 16316362] VanWyckDB , RoppoloM , MartinezCO , McMurraySD , MazeyR . A randomized controlled trial comparing IV iron sucrose to oral iron in anemic patients with non‐dialysis‐dependent CKD [abstract no: F‐FC051]. Journal of the American Society of Nephrology2005;16:49A. [CENTRAL: CN‐01657327] ">Van Wyck 2005 CKD</a>; <a href="./references#CD007857-bbs2-0026" title="PisaniA , RiccioE , SabbatiniM , AndreucciM , DelRioA , ViscianoB . Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrology Dialysis Transplantation2014;30(4):645‐52. [MEDLINE: 25395392] ViscianoB , NazzaroP , RiccioE , DelRioA , MozzilloGR , PisaniA . Liposomial iron for the treatment of iron deficiency anemia in non dialysis chronic kidney disease patients: a randomized controlled trial [abstract]. Nephrology Dialysis Transplantation2014;29(5 Suppl 3):iii141‐2. [EMBASE: 71491842] ViscianoB , NazzaroP , TarantinoG , TaddeiA , DelRioA , MozzilloGR , et al. Liposomial iron: a new proposal for the treatment of anaemia in chronic kidney disease [Il ferro liposomiale: una nuova proposta per il trattamento dell’anemia nei pazienti affetti da insufficenza renale cronica]. Giornale Italiano di Nefrologia2013;30(5). [MEDLINE: 24402627] ">Pisani 2014 CKD</a>). Mean adherence rates for IV iron therapy were 95%, 97% and 96% respectively, and adherence to oral iron therapy was 85% and 88% and 95.8%. </p> </li> <li> <p>The certainty of the evidence was downgraded because of imprecision, heterogeneity between studies and publication bias. </p> </li> </ul> </p> <p>See <a href="./full#CD007857-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD007857-sec-0083"> <h4 class="title">Effect of IV iron compared with oral iron on laboratory outcomes</h4> <p> <ul id="CD007857-list-0017"> <li> <p>The numbers of patients reaching target Hb or increasing Hb by at least 1 g/dL were reported in 13 studies. Target Hb or an increase in Hb by 1 g/dL may be achieved by more participants receiving IV iron compared with oral iron (low certainty evidence) (<a href="./references#CD007857-fig-0012" title="">Analysis 2.1</a> (13 studies, 2206 participants): RR 1.71, 95% CI 1.43 to 2.04; I<sup>2</sup> = 60%) in all patients (<a href="./full#CD007857-tbl-0002">summary of findings Table 2</a>) and in the subgroups of dialysis participants and CKD participants (<a href="#CD007857-tbl-0003">Table 1</a>). There was low to moderate heterogeneity. The absolute benefit for reaching the target Hb was 542 per 1000 for IV iron and 317 per 1000 for oral iron. </p> </li> </ul> </p> <div class="table" id="CD007857-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Laboratory outcomes in dialysis and chronic kidney disease participants</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Hb (g/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39 to 1.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 to 1.77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28 to 0.55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Ferritin (µg/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>224.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165.8 to 283.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1027</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>233.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>163.4 to 303.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>213.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>123.7 to 302.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>TSAT (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3089</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.10 to 10.28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.89 to 17.22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.67 to 7.97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Achieving target Hb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.43 to 2.04</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.52 to 2.66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 to 1.97</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CKD ‐ chronic kidney disease; Hb ‐ haemoglobin; TSAT ‐ transferrin saturation</p> </div> </div> <p> <ul id="CD007857-list-0018"> <li> <p>End of study or change (g/dL) in Hb were reported in 31 studies. IV iron compared with oral iron may increase Hb (low certainty evidence) (<a href="./references#CD007857-fig-0013" title="">Analysis 2.2</a> (31 studies, 3373 participants): MD 0.72 g/dL, 95% CI 0.39 to 1.05); I<sup>2</sup> = 94%) in all participants and in subgroups of dialysis and CKD participants (<a href="#CD007857-tbl-0003">Table 1</a>). There was a high levels of heterogeneity, which persisted when a fixed‐effect model was used for analyses. Excluding a study of 26 months treatment and MD 4.92 g/dL (<a href="./references#CD007857-bbs2-0010" title="FudinR , JaichenkoJ , ShostakA , BennettM , GotloibL . Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron1998;79(3):299‐305. [MEDLINE: 9678430] ">Fudin 1998 HD</a>) did not significantly reduce heterogeneity. Further analyses of heterogeneity are addressed in later sections. </p> </li> </ul> <ul id="CD007857-list-0019"> <li> <p>End of study or change (μg/L) in serum ferritin levels were reported in 33 studies. IV iron compared with oral iron may increase ferritin levels (low certainty evidence) in all participants (<a href="./references#CD007857-fig-0014" title="">Analysis 2.3</a> (33 studies, 3389 participants): MD 224.84 µg/L, 95% CI 165.85 to 283.83, I<sup>2</sup> = 99%) and in subgroups of dialysis and CKD participants (<a href="#CD007857-tbl-0003">Table 1</a>). There was a high level of heterogeneity in these analyses. </p> </li> <li> <p>End of study or change (%) in TSAT levels were reported in 27 studies. IV iron compared with oral iron may increase TSAT levels (low certainty evidence) in all participants (<a href="./references#CD007857-fig-0015" title="">Analysis 2.4</a> (27 studies, 3089 participants): MD 7.69 %, 95% CI 5.10 to 10.28, I<sup>2</sup> = 97%) and in subgroups of dialysis and CKD participants (<a href="#CD007857-tbl-0003">Table 1</a>). There was a high level of heterogeneity in these analyses. </p> </li> <li> <p>Five studies reported results for HCT rather than Hb. It is uncertain whether IV iron improves HCT because the certainty of this evidence was very low (<a href="./references#CD007857-fig-0016" title="">Analysis 2.5</a>.1 (5 studies, 180 participants): MD 1.09%, 95% CI ‐2.19 to 4.37, I<sup>2</sup> = 96%). There was a high level of heterogeneity in this analysis. </p> </li> <li> <p>Eleven studies reported end of study or change in ESA dose. IV iron probably leads to a reduction in ESA dose compared with oral iron (low certainty evidence) (<a href="./references#CD007857-fig-0017" title="">Analysis 2.6</a> (11 studies, 522 participants): SMD ‐0.72, 95% CI ‐1.12 to ‐0.31) with a high level of heterogeneity (I<sup>2</sup> = 77%). </p> </li> <li> <p>IV iron compared with oral iron may make little or no difference to eGFR at the end of study (low certainty evidence) (<a href="./references#CD007857-fig-0018" title="">Analysis 2.7</a> (8 studies,1052 participants): MD 0.83 mL/min, 95% CI ‐0.79 to 2.44). There was low to moderate heterogeneity (I<sup>2</sup> = 38%). </p> </li> <li> <p>The certainty of the evidence was downgraded because of high risk of bias, inconsistency, imprecision and possible publication bias. </p> </li> </ul> </p> <p>See <a href="./full#CD007857-tbl-0002">summary of findings Table 2</a>. </p> </section> <section id="CD007857-sec-0084"> <h4 class="title">Adverse effects</h4> <p>18 studies provided some information on adverse effects of therapy.</p> <p> <ul id="CD007857-list-0020"> <li> <p>IV iron compared with oral iron may increase the numbers of participants, who experience allergic reactions or hypotension (low certainty evidence) (<a href="./references#CD007857-fig-0011" title="">Analysis 1.6</a>.1 (15 studies, 2607 participants): RR 3.56, 95% CI 1.88 to 6.74; I<sup>2</sup> = 0%). The absolute risk for allergic reactions/hypotension was 24 per 1000 with IV iron and 7 per 1000 with oral iron. </p> </li> <li> <p>Only four studies reported data on infection. The most commonly reported infections were respiratory and urinary tract infections. IV iron compared with oral iron may make little or no difference to the risk of infection (low certainty evidence) (<a href="./references#CD007857-fig-0011" title="">Analysis 1.6</a>.2 (4 studies, 954 participants): RR 1.32, 95% CI 0.90 to 1.95; I<sup>2</sup> = 2%). </p> </li> <li> <p>IV iron compared with oral iron may be associated with fewer participants with all gastrointestinal adverse effects (low certainty evidence) (<a href="./references#CD007857-fig-0011" title="">Analysis 1.6</a>.3 (14 studies, 1986 participants): RR 0.47, 95% CI 0.33 to 0.66; I<sup>2</sup> = 63%), fewer participants with constipation (<a href="./references#CD007857-fig-0011" title="">Analysis 1.6</a>.4 (10 studies, 1618 participants): RR 0.32, 95% CI 0.18 to 0.57; I<sup>2</sup> = 19%) and possibly with diarrhoea (<a href="./references#CD007857-fig-0011" title="">Analysis 1.6</a>.5 (10 studies, 1625 participants): RR 0.70, 95% CI 0.47 to 1.05; I<sup>2</sup> = 0%). The absolute risk of all gastrointestinal adverse effects was 150 per 1000 with IV iron and 319 per 1000 with oral iron. </p> </li> <li> <p>Only three studies reported data on iron overload. Each of these studies defined iron overload as ferritin levels &gt; 800 ng/mL. IV iron compared with oral iron may make little or no difference to the risk of iron overload (low certainty evidence) (<a href="./references#CD007857-fig-0011" title="">Analysis 1.6</a>.8 (3 studies, 158 participants): RR 6.58, 95% CI 0.81 to 53.51; I<sup>2</sup> = 0%). </p> </li> </ul> </p> <p>See <a href="./full#CD007857-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD007857-sec-0085"> <h4 class="title">Exploration of heterogeneity using subgroup analyses: effect of different doses of IV or oral iron on haemoglobin, ferritin and TSAT </h4> <p>Subgroup analysis using testing for interaction was applied to investigate the effects of different total doses of IV iron (≤ 1000 mg, 1000 to 2000 mg, &gt; 2000 mg), different doses/month of IV iron (≤ 400 mg/month, &gt; 400 to 700 mg/month, &gt; 700 mg/month), different total doses of oral iron (&lt; 12,000 mg, 12,000 to 30,000 mg, &gt; 30,000 mg), and different doses/month of oral iron (&lt; 4000 mg/month, 4000 to &lt;6000 mg/month, ≥ 6000 mg/month) on levels of Hb, ferritin and TSAT. These values were chosen based on tertiles of doses investigated in the included studies. Results for the outcomes of Hb, ferritin and TSAT are shown as SMD in <a href="#CD007857-tbl-0004">Table 2</a>; <a href="#CD007857-tbl-0005">Table 3</a> and <a href="#CD007857-tbl-0006">Table 4</a> respectively. </p> <div class="table" id="CD007857-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Subgroup analysis and meta‐regression to examine heterogeneity in haemoglobin meta‐analyses</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total studies (N)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SMD (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Dose IV iron/study month </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 400 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17 (‐0.18 to 0.52)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 400 to 700 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.29 to 1.24)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 700 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.41 to 1.06)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Dose IV iron (mg total dose)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 1000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.25 to 0.66)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 to 1999 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48 (0.11 to 0.84)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.04 to 1.73)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Oral dose iron/study month</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 4000 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.37 to 1.38)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 4000 and &lt; 6000 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.28 to 0.64)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 6000 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.16 to 0.59)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Dose oral iron (mg total dose)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 12,000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.38 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1200 to 30,000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.29 to 1.03)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 30,000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45 (‐0.05 to 0.94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Any ESA use </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No EPO</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57 (0.05 to 1.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPO</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.32 to 0.78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>ESA timing of use </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Start of study</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.08 to 0.72)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Before study</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57 (0.28 to 0.85)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CKD stage </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 to 5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.26 to 0.50)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (5D)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.37 to 1.24)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Study duration </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 2 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.35 to 0.75)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2 to ≤ 4 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.28 to 1.19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 4 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.002 to 0.91)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Intervention aim </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase Hb</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.51 to 1.50)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maintain Hb</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.09 (‐0.53 to 0.36)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Pharmaceutical company sponsorship</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.40 to 1.23)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sponsored</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38 (0.28 to 0.48)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Imputed SD</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not imputed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.42 (0.02 to 0.81)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imputed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.35 to 0.76)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CKD: chronic kidney disease; EPO ‐ erythropoietin; ESA: erythropoiesis‐stimulating agent; Hb: haemoglobin; SD: standard deviation </p> </div> </div> <div class="table" id="CD007857-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Subgroup analysis and meta‐regression to examine heterogeneity in ferritin meta‐analyses   </span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total studies (N)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Dose IV iron/study month</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 400 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.59 (0.73 to 2.44)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.02</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 400 to 700 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.62 (1.41 to 1.83)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt;700 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32 (0.85 to 1.78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Dose IV iron (mg total dose) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 1000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.67 (1.03 to 2.30)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 to 1999 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.83 to 1.42)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.27 (0.55 to 3.99)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Oral dose iron/study month</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;4000 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.44 (0.77 to 2.11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.04</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 4000 to &lt; 6000 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.43 (1.16 to 1.69)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 6000 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.16 (1.18 to 3.14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Dose oral iron (mg total dose) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 12,000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.44 (1.05 to 1.83)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12000 to 30,000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.69 (1.05 to 2.34)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 30,000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.79 (1.15 to 2.43)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Any ESA use </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No EPO</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.46 to 2.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPO</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.62 (1.28 to 1.96)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>ESA timing of use </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Start of study</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.75 (0.88 to 2.62)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Before study</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.64 (1.22 to 2.06)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CKD stage</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 to 5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.70 (1.29 to 2.11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (5D)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50 (1.07 to 1.92)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Study duration</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 2 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (0.86 to 1.49)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2 to ≤ 4 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.64 (1.45 to 3.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 4 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.54 (1.05 to 2.04)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Intervention aim</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase Hb</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>336 (84 to 588)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maintain Hb</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>282 (177 to 261)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Pharmaceutical company sponsorship </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.84 (1.31 to 2.37)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sponsored</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.36 (1.02 to 1.71)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Imputed SD</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not imputed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (0.51 to 1.86)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imputed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.63 (1.31 to 1.94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CKD: chronic kidney disease; EPO ‐ erythropoietin; ESA: erythropoiesis‐stimulating agent; Hb: haemoglobin; SD: standard deviation </p> </div> </div> <div class="table" id="CD007857-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Subgroup analysis and meta‐regression to examine heterogeneity in transferrin saturation meta‐analyses</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total studies (N)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SMD (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Dose IV iron/study month</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 400 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.39 to 1.00)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 400 to 700 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.14 to 0.78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 700 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.00 (0.55 to 3.45)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Dose IV iron (mg total dose)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 1000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.34 to 0.90)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 to 1999 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41 (0.07 to 0.74)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.5 (‐1.46 to 8.39)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Oral dose iron/study month</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 4000 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56 (0.25 to 0.86)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 4000 to &lt; 6000 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54 (0.20 to 0.87)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 6000 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.64 (0.69 to 2.59)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Dose oral iron (mg total dose)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 12,000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56 (0.41 to 0.72)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1200 to 30,000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56 (0.00 to 1.13)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 30,000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.59 (0.55 to 2.63)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Any ESA use</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No EPO</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.36 to 1.31)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPO</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.42 to 1.03)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>ESA timing of use </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Start of study</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29 (‐0.42 to 1.00)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Before study</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.51 to 1.20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CKD stage</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 to 5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.35, 0.74)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (5D)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.75 to 1.80)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Study duration</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 2 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56 (0.41, 0.72)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2 to ≤ 4 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34 (0.32 to 2.35)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 4 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 (0.16 to 1.18)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Intervention aim</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase Hb</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.59 (4.07 to 17.11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maintain Hb</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.28 (‐3.73 to 40.30)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Pharmaceutical company sponsorship</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.52 to 1.62)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sponsored</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 (0.34 to 0.71)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Imputed SD</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not imputed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 (‐0.24 to 0.77)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imputed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.47 to 0.97)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CKD: chronic kidney disease; EPO ‐ erythropoietin; ESA: erythropoiesis‐stimulating agent; Hb: haemoglobin; SD: standard deviation </p> </div> </div> <p>There were no significant differences in total dose administered of IV iron or of IV iron/month between subgroups for Hb or TSAT. There was a significant difference found in the SMD for ferritin in the doses of IV iron per month, though the relationship did not appear to be linear (P = 0.02); there was no difference in ferritin levels with increasing total IV iron dose. </p> <p>There were no significant differences in total oral iron dose or oral iron/month dose for Hb between subgroups for Hb or TSAT. There was a significant difference found in the SMD for ferritin in the dose of oral iron per month but not with total oral iron dose. </p> <p>In subgroup analyses no significant differences in results were detected on testing for interaction among studies in which SDs were imputed and other studies (<a href="#CD007857-tbl-0004">Table 2</a>; <a href="#CD007857-tbl-0005">Table 3</a>; <a href="#CD007857-tbl-0006">Table 4</a>). </p> </section> <section id="CD007857-sec-0086"> <h4 class="title">Exploration of heterogeneity using subgroup analyses: effects of erythrocyte‐stimulating agents (ESAs) on the response to iron therapy </h4> <p>Subgroup analysis was used to investigate the differential response of Hb, ferritin and TSAT levels in patients who did or did not receive an ESA during iron therapy, and in patients who began ESA therapy at study commencement compared with those already on ESA. No significant differences were found among subgroups (<a href="#CD007857-tbl-0004">Table 2</a>; <a href="#CD007857-tbl-0005">Table 3</a>; <a href="#CD007857-tbl-0006">Table 4</a>). </p> </section> <section id="CD007857-sec-0087"> <h4 class="title">Other subgroup analyses</h4> <p>Subgroup analyses of study duration (≤ 2 months, ≥ 2 to 4 months, ≥ 4 months) showed no significant difference on testing for interaction (<a href="#CD007857-tbl-0004">Table 2</a>; <a href="#CD007857-tbl-0005">Table 3</a>; <a href="#CD007857-tbl-0006">Table 4</a>) for final levels or changes in levels in Hb, ferritin or TSAT. There was significant heterogeneity. </p> <p>Pharmaceutical company sponsorship previously showed some association with a lower mean reported Hb. With additional data in this updated review, no significant association could be demonstrated (<a href="#CD007857-tbl-0004">Table 2</a>). There were no significant differences for ferritin or TSAT levels (<a href="#CD007857-tbl-0005">Table 3</a>; <a href="#CD007857-tbl-0006">Table 4</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007857-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007857-sec-0088"></div> <section id="CD007857-sec-0089"> <h3 class="title" id="CD007857-sec-0089">Summary of main results</h3> <p>This review included 39 studies which compared IV iron with oral iron therapy in patients with CKD. Eleven studies were added to the original review; one paediatric study was terminated and provided no outcome data. There was considerable variability among studies in the total dose and duration of IV and oral iron therapies prescribed. Durations of studies ranged from 35 days to 26 months with only 14 studies having durations greater than four months. The doses/month of iron ranged from 200 mg to 1000 mg for IV iron and 840 mg to 10,500 mg for oral iron. Use of ESAs also varied. Eight studies reported that ESAs were not administered. Of the studies that reported ESA use, some maintained ESA doses unchanged and others altered the dose to maintain Hb within a target range. </p> <p>Patient‐centred outcomes such as death (all causes) (11 studies), cardiovascular death (three studies), and quality of life (five studies) were rarely reported with studies concentrating on surrogate laboratory outcomes. While no differences overall in these outcomes were detected between treatment groups, the data available were limited and of low quality (GRADE) so we have low certainty evidence that IV iron compared with oral iron makes little or no difference to these outcomes. </p> <p>Compared with oral iron, IV iron increased levels of Hb (31 studies), serum ferritin (33 studies) and TSAT (27 studies). The final weighted mean increase with IV iron compared with oral iron was 0.72 g/dL in Hb, 225 µg/L in ferritin and 8% in TSAT. The proportion of patients who reached the targeted Hb or increased their Hb by 1 g/dL was 71% higher among those treated with IV iron compared with oral iron. Increases in these outcomes were seen in dialysis and non‐dialysis participants (<a href="#CD007857-tbl-0003">Table 1</a>). The required ESA dose was reduced in patients treated with IV iron compared with oral iron, but was reported in only 11 studies involving 522 participants. eGFR did not decline more rapidly with IV iron compared with oral iron. However, the quality of the evidence (GRADE) was considered low for all outcomes indicating that we have low certainty evidence to support the findings above. </p> <p>Adverse effects were reported in 18 studies. Gastrointestinal adverse effects were more common with oral iron while allergic reactions and/or hypotension were more common with IV iron. However, the quality of the evidence (GRADE) was considered low indicating that we have low certainty evidence to support these findings. </p> <p>There was considerable heterogeneity between studies so that subgroup analyses using meta‐regression was carried out to investigate possible reasons for this heterogeneity. Subgroup analyses investigated the effect of different monthly and total doses of oral or IV iron, different uses of ESA, CKD stage, and different durations of treatment on Hb, ferritin and transferrin levels. Other than an increase in ferritin levels with increasing IV and oral iron per month, no differences were found in these analyses. Comparing the results of these subgroup analyses with those in the initial version of this systematic review, no increase in Hb SMD with increased oral iron dose/month could now be demonstrated. There was no longer a significant increase in ferritin levels with total IV or oral iron dose. The additional data from newly identified studies showed that studies sponsored by pharmaceutical companies were no longer associated with a significantly lower increase in MD in Hb compared with studies that did not report sponsorship. Heterogeneity among studies therefore remains largely unexplained, but was likely to be related to the significant variation in the relative doses of IV and oral iron used in each study. </p> </section> <section id="CD007857-sec-0090"> <h3 class="title" id="CD007857-sec-0090">Overall completeness and applicability of evidence</h3> <p>Most included studies reported on laboratory assessments of response to IV and oral iron treatment in patients with CKD stages 3 to 5 including those receiving dialysis. Our meta‐analyses identified that there are probably small increases in laboratory parameters of Hb, ferritin and transferrin in both dialysis and non‐dialysis patients though the certainty of the evidence was low. However, key patient‐centred outcomes were reported in only a few studies so we were unable to make definitive conclusions about the influence of IV iron compared with oral iron therapy on death (all causes), cardiovascular death, morbidity, or on quality of life. This review confirmed that gastrointestinal disorders are found to be more common in patients taking oral iron while hypotension and allergic reactions are more common in patients receiving IV iron. Although ESA dose was probably lower in patients treated with IV iron, only 11 studies (522 participants) reported on ESA dosage at the end of the study and all studies providing these data were in dialysis patients. </p> <p>The observed Hb increase of 1.01 g/dL in dialysis patients, together with a significant reduction in ESA dose, provides some support for the practice of administering IV iron to these patients, particularly among those unable to tolerate oral iron. However, studies have identified that high Hb levels achieved with IV iron and ESA are associated with increased cardiovascular death and morbidity (<a href="./references#CD007857-bbs2-0078" title="PhrommintikulA , HaasSJ , ElsikM , KrumH . Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta‐analysis. Lancet2007;369(9559):381‐8. [MEDLINE: 17276778] ">Phrommintikul 2007</a>). </p> <p>The Hb increase in non‐dialysis patients was modest (0.41 g/dL), but this was not significantly different from the response in dialysis patients. None of the included studies assessed if the patient‐centred benefits of achieving higher Hb levels outweighed financial costs or disruption to patients not on dialysis as a result of additional or prolonged hospital visits. While three further large studies (<a href="./references#CD007857-bbs2-0002" title="AgarwalR , KusekJW , PappasMK . A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney International2015;88(4):905‐14. [DOI: 10.1038/ki.2015.163; MEDLINE: 26083656] ">Agarwal 2015 CKD</a>; <a href="./references#CD007857-bbs2-0008" title="GaillardCA , BockAH , CarreraF , EckardtK , VanWyckDB , BansalSS , et al. Hepcidin response to intravenous (IV) or oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis CKD (ND‐CKD) [abstract no: TH‐OR040]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):11A. GaillardCA , BockAH , CarreraF , EckardtKU , VanWyckDB , BansalSS , et al. Hepcidin response to iron therapy in patients with non‐dialysis dependent CKD: an analysis of the FIND‐CKD trial. PLoS ONE [Electronic Resource]2016;11(6):e0157063. [MEDLINE: 27276035] MacdougallI , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. A model to predict haematopoietic non‐response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD): an analysis from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i193‐4. [EMBASE: 72326413] MacdougallIC , BockA , CarreraF , CushwayT , MoriC , RogerS . Rationale and design of a new RCT of iron therapy in anemic non‐dialysis CKD patients: FIND‐CKD trial [abstract no: SA‐PO2402]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):660A. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. The FIND‐CKD study‐‐a randomized controlled trial of intravenous iron versus oral iron in non‐dialysis chronic kidney disease patients: background and rationale. Nephrology Dialysis Transplantation2014;29(4):843‐50. [MEDLINE: 24170814] MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. FIND‐CKD: a 56‐week randomized trial of intravenous ferric carboxymaltose versus oral iron in anemic patients with chronic kidney disease and iron deficiency [abstract no: SA‐PO1079]. Journal of the American Society of Nephrology2013;24(Abstracts):3B. MacdougallIC , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. Intravenous ferric carboxymaltose vs oral iron in anaemic patients with non‐dialysis dependent chronic kidney disease and iron deficiency: results of the randomised FIND‐CKD study [abstract no: SO049]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. MacdougallIC , BockAH , CarreraF , EckardtK , GaillardC , VanWyckD , et al. Efficacy of oral iron for treating iron deficiency in anaemic patients with non‐dialysis dependent CKD (ND‐CKD) [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii581. [EMBASE: 617290898] MacdougallIC , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. Iron administration to non‐dialysis CKD patients for one year does not cause worsening of renal function: results from the FIND‐CKD trial [abstract no: FR‐PO809]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):555A. MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Erythropoietic response to oral iron in patients with nondialysis‐dependent chronic kidney disease in the FIND‐CKD trial. Clinical Nephrology2017;88(12):301‐10. [MEDLINE: 29092739] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. FIND‐CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrology Dialysis Transplantation2014;29(11):2075‐84. [MEDLINE: 24891437] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardC , VanWyckD , et al. Renal function in patients with non‐dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND‐CKD trial. BMC Nephrology2017;18(1):24. [MEDLINE: 28095881] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Hepcidin response to iron therapy in patients with non‐dialysis CKD: an analysis of the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii8‐9. [EMBASE: 72206297] MacdougallIC , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Low rate of early response to oral iron in patients with non‐dialysis dependent CKD (ND‐CKD) [abstract no: TH‐PO906]. Journal of the American Society of Nephrology2016;27(Abstract Suppl):304A. RogerS , BockAH , CarreraF , EckardtK , GaillardCA , VanWyckDB , et al. The safety of intravenous (IV) ferric carboxymaltose (FCM) in patients with non‐dialysis dependent CKD (ND‐CKD): 1‐year results from the FIND‐CKD trial [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i15‐6. [EMBASE: 72325953] RogerSD , BockA , CarreraF , EckardtKU , GaillardC , VanWyckDB , et al. IV ferric carboxymaltose (FCM) is a convenient and well‐tolerated first‐line therapy for the treatment of anaemia in patients with iron deficiency and non‐dialysis dependent chronic kidney disease (ND‐CKD): results of the randomised FIND‐CKD study [abstract no: SO048]. Nephrology Dialysis Transplantation2014;27(Suppl 3):ii21. RogerSD , BockAH , CarreraF , EckardtKU , GaillardCA , VanWyckDB , et al. Intravenous (IV) ferric carboxymaltose (FCM) versus oral iron in the randomized FIND‐CKD trial of patients with non‐dialysis dependant CKD (ND‐CKD): a safety analysis [abstract no: TH‐PO652]. Journal of the American Society of Nephrology2015;26(Abstract Suppl):238A. ">FIND‐CKD 2014 CKD</a>; <a href="./references#CD007857-bbs2-0012" title="KalraPA , BhandariS , SaxenaS , AgarwalD , WirtzG , KletzmayrJ , et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non‐dialysis‐dependent chronic kidney disease patients with anaemia. Nephrology Dialysis Transplantation2016;31(4):646‐55. [MEDLINE: 26250435] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside 1000 (monofer) compared to oral iron sulphate in European patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii200. [EMBASE: 72206812] KalraPA , BhandariS , ThomsenLL . Iron isomaltoside1000 (monofer) compared to oral iron sulphate in patients with non‐dialysis dependent chronic kidney disease (NDD‐CKD) [abstract no: SA‐PO1106]. Journal of the American Society of Nephrology2014;25(Abstract Suppl):B7. ">Kalra 2016 CKD</a>) in CKD patients assessed quality of life, none identified improved quality of life with the higher Hb associated with IV iron therapy so that only one of five studies, which assessed quality of life, identified some improvement in quality of life in non‐dialysis patients receiving IV iron (<a href="./references#CD007857-bbs2-0001" title="AgarwalR . Sodium ferric gluconate complex in sucrose (SFGC) injection improves energy level in chronic kidney disease (CKD) patients independent of increase in hemoglobin levels [abstract no: F‐PO337]. Journal of the American Society of Nephrology2004;15(Oct):140A. [CENTRAL: CN‐01657325] AgarwalR , RizkalaAR , BastaniB , KaskasMO , LeeheyDJ , BesarabA . A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. American Journal of Nephrology2006;26(5):445‐54. [MEDLINE: 17035697] ">Agarwal 2006 CKD</a>). A systematic review of RCTs identified no significant benefit on quality of life of higher Hb levels achieved with ESAs and iron supplements in CKD patients (<a href="./references#CD007857-bbs2-0049" title="CollisterD , KomendaP , HiebertB , GunasekaraR , XuY , EngF , et al. The effect of erythropoietin‐stimulating agents on health‐related quality of life in anemia of chronic kidney disease: a systematic review and meta‐analysis. Annals of Internal Medicine2016;164(7):472‐8. [MEDLINE: 26881842] ">Collister 2016</a>).There were no data relating to non‐dialysis patients to determine if ESA requirements were reduced. We were therefore unable to derive a definitive conclusion on the relative benefits and harms of IV iron for non‐dialysis patients. </p> <p>The applicability of the conclusions in children, PD patients and kidney transplant patients may be limited since few studies were identified for each of these patient groups. However, the magnitude and direction of results in these studies did not differ from the overall results. </p> </section> <section id="CD007857-sec-0091"> <h3 class="title" id="CD007857-sec-0091">Quality of the evidence</h3> <p>Our review included 39 studies, which involved 3852 participants. Twenty‐one studies enrolled dialysis patients, two involved transplant patients, two enrolled dialysis and non‐dialysis patients and the remainder enrolled CKD patients. There was considerable variation among studies in dose and duration of IV and oral iron administration. </p> <p>Of the 39 included studies, 12 were available only as abstracts. Twenty studies reported adequate random sequence generation while only 14 studies demonstrated adequate allocation concealment. Studies that lack adequate allocation concealment are considered to be at increased risk of bias (<a href="./references#CD007857-bbs2-0076" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352(9128):609‐13. [MEDLINE: 9746022] ">Moyer 1998</a>; <a href="./references#CD007857-bbs2-0081" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. [MEDLINE: 7823387] ">Schultz 1995</a>). Blinding of participants and personnel was not reported in any study. No study reported blinding of outcome assessment, but because primary outcomes were laboratory measurements and unlikely to be influenced by lack of blinding, all studies were considered to be at low risk of bias for blinding of outcome assessment. Twenty‐two studies reported complete outcome data while 20 studies were at low risk of selective reporting. The authors of 15 included studies indicated receiving some form of sponsorship from pharmaceutical companies. </p> <p>Although administration of IV iron consistently resulted in an increase in Hb or HCT, ferritin and TSAT, there was considerable heterogeneity among studies in the results of these laboratory outcomes. This effect could not be explained after examining for interactions related to participants, interventions and risk of bias items as reported. </p> <p>The certainty of the evidence for patient centred outcomes was considered low or very low because of small patient numbers included in these analyses and high risk or unclear risk of bias for allocation concealment in many studies (<a href="./full#CD007857-tbl-0001">summary of findings Table for the main comparison</a>). Similarly the certainty of the evidence for laboratory and pharmaceutical outcomes was considered to be low or very low because of considerable heterogeneity in study results and the high or unclear risk for allocation concealment in many studies (<a href="./full#CD007857-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD007857-sec-0092"> <h3 class="title" id="CD007857-sec-0092">Potential biases in the review process</h3> <p>The literature search has been run several times (up to December 2018) since the publication of the original review in 2012 to reduce the likelihood that additional studies eligible for inclusion were missed. Although the Cochrane Kidney and Transplant Specialised Register also includes references of reports of studies identified by handsearching resources including conference proceedings, it is a possibility that relevant studies may have been missed. </p> <p>The relatively high proportion of included studies that were available only as abstracts (12/39; 31%) is a potential source of bias as abstracts may not contain complete results or provide detailed information on risk of bias attributes. To address reporting gaps in studies, we contacted authors to seek additional information. Responses from nine study authors were received but information received related principally to risk of bias attributes. In this update, we only identified the full publication of one study (<a href="./references#CD007857-bbs2-0028" title="BenjaminJ . A randomized controlled trial comparing IV ferric carboxymaltose (FCM) to oral iron in anemic nondialysis dependent CKD patients (with or without erythropoiesis stimulating agent use) [abstract no: M574]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐01658222] BenjaminJ , QunibiW . Comparison of intravenous (IV) ferric carboxymaltose (FCM) to oral iron in anemic non‐dialysis dependent (NDD)‐CKD patients with or without ESA therapy [abstract no: SA‐PO2422]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):666A. QunibiW , MartinezC , SmithM , BenjaminJ , DinhQ . A randomized controlled trial comparing IV ferric carboxymaltose (FCM) to oral iron in anemic patients with non‐dialysis‐dependent CKD [abstract no: SU‐PO1030]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):814A. [CENTRAL: CN‐00689191] QunibiWY , MartinezC , SmithM , BenjaminJ , MangioneA , RogerSD . A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non‐dialysis‐dependent chronic kidney disease patients. Nephrology Dialysis Transplantation2011;26(5):1599‐607. [MEDLINE: 20929915] ">Qunibi 2011 CKD</a>) previously included as an abstract. A large completed RCT (<a href="./references#CD007857-bbs2-0017" title="BesarabA , CoyneD , BoltonWK , SharmaA , FotiA , BrennerL . Ferumoxytol as an intravenous iron replacement therapy: safety results from two phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO0805]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):762A. [CENTRAL: CN‐00747286] BoltonWK , BesarabA , GermainM , KovesdyCP , HutchinsonJ , KrauszA . Ferumoxytol as an IV iron replacement therapy: efficacy results from two Phase III studies in subjects with chronic kidney disease (CKD) [abstract no: SU‐PO798]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):761A. [CENTRAL: CN‐00747287] BoltonWK , FishbaneS , LiJ , MilichL , BrennerR . Increases in hemoglobin and the effect of ESA use in CKD patients treated with IV ferumoxytol [abstract]. American Journal of Kidney Diseases2009;53(4):A30. [EMBASE: 70141518] FishbaneS , BoltonWK , WinkelmayerWC , StraussW , LiZ , PereiraBJ . Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Clinical Nephrology2012;78(3):181‐8. [MEDLINE: 22874106] GermainM , BrennerL , DioguardiJ , GilbertsonD , BesarabA . Comparison of safety and efficacy of ferumoxytol in CKD subtypes: kidney transplant recipients, hemodialysis patients and non‐hemodialysis patients [abstract no: SA‐PO2530]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00747289] LuM , CohenMH , RievesD , PazdurR . FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. American Journal of Hematology2010;85(5):315‐9. [MEDLINE: 20201089] SpinowitzB , BesarabA , BoltonWK , PereiraBJ , ProvenzanoR , RaoM , et al. Ferumoxytol as intravenous iron replacement therapy in chronic kidney disease (CKD) patients not on dialysis ‐ evaluation of safety and efficacy in two phase III studies [abstract no: F‐PO026]. Journal of the American Society of Nephrology2006;17(Abstracts):342A. [CENTRAL: CN‐00644267] SpinowitzB , KauszA , MillerP , BrennerL , SinghA . Achievement of target hemoglobin with ferumoxytol versus oral iron in anemic CKD patients [abstract no: SU‐PO1031]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):814A. [CENTRAL: CN‐00688845] SpinowitzB , KrauzA , DioguardiJ , KovesdyC . Evaluation of ferumoxytol safety and efficacy in all stages of chronic kidney disease (CKD) [abstract no: 249]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00747323] ">Lu 2010 CKD</a>) comparing IV ferumoxytol with oral iron enrolled 519 participants but has only been published in abstract form in combination with other similar studies. </p> <p>Some outcomes were reported in only a few studies which increased the risk of selection bias. In particular, the final or change in ESA dose was reported in only 11 studies (522 patients) so that the observed significant decrease in ESA dose with IV iron therapy compared with oral iron may not be generalisable to the dialysis population. Similarly, adverse effects were reported in only 18 (46%) of the included studies. </p> </section> <section id="CD007857-sec-0093"> <h3 class="title" id="CD007857-sec-0093">Agreements and disagreements with other studies or reviews</h3> <p>A systematic review published in 2008 that included 13 studies applied a comprehensive literature review strategy that included searching some conference proceedings (American Society of Nephrology, European Renal Association ‐ European Dialysis and Transplant Association) (<a href="./references#CD007857-bbs2-0079" title="Rozen‐ZviB , Gafter‐GvilliA , PaulM , LeiboviciL , ShpilbergO , GafterU . Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta‐analysis. American Journal of Kidney Diseases2008;52(5):897‐906. [MEDLINE: 18845368] ">Rozen‐Zvi 2008</a>). This systematic review was updated to October 2015 and included 24 RCTs (<a href="./references#CD007857-bbs2-0085" title="ShepshelovichD , Rozen‐ZviB , AvniT , GafterU , Gafter‐GviliA . Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta‐analysis. American Journal of Kidney Diseases2016;68(5):677‐90. [MEDLINE: 27321965] ">Shepshelovich 2016</a>). Our updated review includes 22 of the 24 studies included by <a href="./references#CD007857-bbs2-0085" title="ShepshelovichD , Rozen‐ZviB , AvniT , GafterU , Gafter‐GviliA . Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta‐analysis. American Journal of Kidney Diseases2016;68(5):677‐90. [MEDLINE: 27321965] ">Shepshelovich 2016</a>. We excluded one study included in the 2008 systematic review and one included in the 2015 review because they included both randomised and non‐randomised data (<a href="./references#CD007857-bbs2-0041" title="AllegraV , MengozziG , VasileA . Iron deficiency in maintenance hemodialysis patients: Assessment of diagnosis criteria and of three different iron treatments. Nephron1991;57(2):175‐82. [MEDLINE: 1902285] ">Allegra 1991</a>; <a href="./references#CD007857-bbs2-0040" title="AdhikaryL , AcharyaS . Efficacy of IV iron compared to oral iron for increment of haemoglobin level in anemic chronic kidney disease patients on erythropoietin therapy. Jnma, Journal of the Nepal Medical Association2011;51(183):133‐6. [MEDLINE: 22922860] ">Adhikary 2011</a>). <a href="./references#CD007857-bbs2-0085" title="ShepshelovichD , Rozen‐ZviB , AvniT , GafterU , Gafter‐GviliA . Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta‐analysis. American Journal of Kidney Diseases2016;68(5):677‐90. [MEDLINE: 27321965] ">Shepshelovich 2016</a> identified 13 studies involving CKD participants and 11 studies involving dialysis patients. Both reviews reported similar increases in mean Hb, ferritin, TSAT and the proportion of participants achieving an increase in Hb in patients treated with IV iron compared with oral iron. In their initial systematic review, <a href="./references#CD007857-bbs2-0079" title="Rozen‐ZviB , Gafter‐GvilliA , PaulM , LeiboviciL , ShpilbergO , GafterU . Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta‐analysis. American Journal of Kidney Diseases2008;52(5):897‐906. [MEDLINE: 18845368] ">Rozen‐Zvi 2008</a> demonstrated a significant correlation between Hb and IV iron dose/month in dialysis patients but not non‐dialysis patients. We were unable to demonstrate an overall correlation or a correlation in dialysis patients alone in our 2012 review or in this update. Both reviews reported considerable heterogeneity for the outcomes of Hb, ferritin and TSAT concentrations which could not be explained. A systematic review of 103 RCTs has evaluated the safety of IV iron compared with oral iron, no iron, placebo or intramuscular iron (<a href="./references#CD007857-bbs2-0045" title="AvniT , BieberA , GrossmanA , GreenH , LeiboviciL , Gafter‐GviliA . The safety of intravenous iron preparations: systematic review and meta‐analysis. Mayo Clinic Proceedings2015;90(1):12‐23. [MEDLINE: 25572192] ">Avni 2015</a>). The review found no increase in overall serious adverse effects with IV iron. As in this review, the authors found that serious infusion reactions were more common and gastrointestinal adverse reactions were less common with IV iron, while there was no increase in infections with IV iron. Another systematic review (<a href="./references#CD007857-bbs2-0087" title="SusantitaphongP , AlqahtaniF , JaberBL . Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta‐analysis. American Journal of Kidney Diseases2014;39(2):130‐41. [MEDLINE: 24513913] ">Susantitaphong 2014</a>) included 34 single‐arm and RCTs evaluating IV iron in HD patients with relative or functional iron deficiency as defined by ferritin levels &gt; 200 ± TSAT &lt; 30%; studies of patients with absolute iron deficiency were excluded. Therefore only one study (<a href="./references#CD007857-bbs2-0027" title="GermainM , BrennerL , DioguardiJ , GilbertsonD , BesarabA . Comparison of safety and efficacy of ferumoxytol in CKD subtypes: kidney transplant recipients, hemodialysis patients and non‐hemodialysis patients [abstract no: SA‐PO2530]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00747289] LuM , CohenMH , RievesD , PazdurR . FDA report. Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. American Journal of Hematology2010;85(5):315‐9. [MEDLINE: 20201089] ProvenzanoR , SchillerB , RaoM , CoyneD , BrennerL , PereiraBJ . Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clinical Journal of the American Society of Nephrology: CJASN2009;4(2):386‐93. [MEDLINE: 19176796] SpinowitzB , KrauzA , DioguardiJ , KovesdyC . Evaluation of ferumoxytol safety and efficacy in all stages of chronic kidney disease (CKD) [abstract no: 249]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00688845] ">Provenzano 2009 HD</a>) included in our review was also included in that review. The review also concluded that IV iron resulted in increases in Hb, ferritin and TSAT and reductions in ESA dose though the changes were less evident in RCTs compared with single arm studies. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007857-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/urn:x-wiley:14651858:media:CD007857:CD007857-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_t/tCD007857-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram of studies included in the systematic review" data-id="CD007857-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram of studies included in the systematic review</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/full#CD007857-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007857-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/urn:x-wiley:14651858:media:CD007857:CD007857-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_t/tCD007857-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: Review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD007857-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: Review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/full#CD007857-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007857-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/urn:x-wiley:14651858:media:CD007857:CD007857-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_t/tCD007857-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: Review authors' judgements about each risk of bias item for each included study" data-id="CD007857-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: Review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/full#CD007857-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007857-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/urn:x-wiley:14651858:media:CD007857:CD007857-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_t/tCD007857-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Patient‐centred outcomes.Outcome: 1.1 Death (all causes)Eggers test P = 0.25" data-id="CD007857-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Patient‐centred outcomes.Outcome: 1.1 Death (all causes)</p> <p>Eggers test P = 0.25</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/full#CD007857-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007857-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/urn:x-wiley:14651858:media:CD007857:CD007857-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_t/tCD007857-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 Laboratory/pharmaceutical outcomes, outcome: 2.4 Transferrin saturation: Final or change [%].Eggers test P = 0.00" data-id="CD007857-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Laboratory/pharmaceutical outcomes, outcome: 2.4 Transferrin saturation: Final or change [%]. </p> <p>Eggers test P = 0.00</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/full#CD007857-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007857-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/urn:x-wiley:14651858:media:CD007857:CD007857-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_t/tCD007857-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Patient centred outcomes, Outcome 1 Death (all causes)." data-id="CD007857-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Patient centred outcomes, Outcome 1 Death (all causes).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/references#CD007857-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007857-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/urn:x-wiley:14651858:media:CD007857:CD007857-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_t/tCD007857-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Patient centred outcomes, Outcome 2 Cardiovascular death." data-id="CD007857-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Patient centred outcomes, Outcome 2 Cardiovascular death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/references#CD007857-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007857-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/urn:x-wiley:14651858:media:CD007857:CD007857-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_t/tCD007857-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Patient centred outcomes, Outcome 3 Quality of life." data-id="CD007857-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Patient centred outcomes, Outcome 3 Quality of life.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/references#CD007857-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007857-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/urn:x-wiley:14651858:media:CD007857:CD007857-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_t/tCD007857-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Patient centred outcomes, Outcome 4 Number of non‐dialysis patients needing to commence dialysis." data-id="CD007857-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Patient centred outcomes, Outcome 4 Number of non‐dialysis patients needing to commence dialysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/references#CD007857-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007857-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/urn:x-wiley:14651858:media:CD007857:CD007857-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_t/tCD007857-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Patient centred outcomes, Outcome 5 Number requiring transfusion." data-id="CD007857-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Patient centred outcomes, Outcome 5 Number requiring transfusion.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/references#CD007857-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007857-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/urn:x-wiley:14651858:media:CD007857:CD007857-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_t/tCD007857-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Patient centred outcomes, Outcome 6 Type of adverse event." data-id="CD007857-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Patient centred outcomes, Outcome 6 Type of adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/references#CD007857-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007857-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/urn:x-wiley:14651858:media:CD007857:CD007857-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_t/tCD007857-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Laboratory/pharmaceutical outcomes, Outcome 1 Number achieving target haemoglobin or increase ≥ 1 g/dL." data-id="CD007857-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Laboratory/pharmaceutical outcomes, Outcome 1 Number achieving target haemoglobin or increase ≥ 1 g/dL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/references#CD007857-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007857-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/urn:x-wiley:14651858:media:CD007857:CD007857-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_t/tCD007857-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Laboratory/pharmaceutical outcomes, Outcome 2 Haemoglobin: final or change (all patients)." data-id="CD007857-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Laboratory/pharmaceutical outcomes, Outcome 2 Haemoglobin: final or change (all patients). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/references#CD007857-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007857-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/urn:x-wiley:14651858:media:CD007857:CD007857-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_t/tCD007857-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Laboratory/pharmaceutical outcomes, Outcome 3 Ferritin: final or change (all patients)." data-id="CD007857-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Laboratory/pharmaceutical outcomes, Outcome 3 Ferritin: final or change (all patients). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/references#CD007857-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007857-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/urn:x-wiley:14651858:media:CD007857:CD007857-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_t/tCD007857-CMP-002-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Laboratory/pharmaceutical outcomes, Outcome 4 Transferrin saturation: final or change." data-id="CD007857-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Laboratory/pharmaceutical outcomes, Outcome 4 Transferrin saturation: final or change. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/references#CD007857-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007857-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/urn:x-wiley:14651858:media:CD007857:CD007857-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_t/tCD007857-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Laboratory/pharmaceutical outcomes, Outcome 5 Haematocrit." data-id="CD007857-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Laboratory/pharmaceutical outcomes, Outcome 5 Haematocrit.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/references#CD007857-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007857-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/urn:x-wiley:14651858:media:CD007857:CD007857-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_t/tCD007857-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Laboratory/pharmaceutical outcomes, Outcome 6 End of treatment or change in ESA dose." data-id="CD007857-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Laboratory/pharmaceutical outcomes, Outcome 6 End of treatment or change in ESA dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/references#CD007857-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007857-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/urn:x-wiley:14651858:media:CD007857:CD007857-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_t/tCD007857-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Laboratory/pharmaceutical outcomes, Outcome 7 eGFR end or change." data-id="CD007857-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Laboratory/pharmaceutical outcomes, Outcome 7 eGFR end or change.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/references#CD007857-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/media/CDSR/CD007857/image_n/nCD007857-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007857-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Patient‐centred outcomes for oral versus IV iron in adults and children with chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient‐centred outcomes for oral versus IV iron in adults and children with CKD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults and children with CKD<br/> <b>Setting:</b> Nephrology departments<br/> <b>Intervention:</b> IV iron<br/> <b>Comparison:</b> oral iron </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral iron</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IV iron</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death (all causes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1,000<br/> (19 to 58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.12<br/> (0.64 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1952 (11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 11/38 studies represented with only about 1/3 of patients.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular death</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1,000<br/> (8 to 142) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.71<br/> (0.41 to 7.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type of adverse event: allergic reactions/hypotension</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1,000<br/> (13 to 46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.56<br/> (1.88 to 6.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2607 (15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type of adverse event: all gastrointestinal adverse effects</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>319 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1,000<br/> (105 to 211) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.47<br/> (0.33 to 0.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1986 (14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type of adverse event: infection</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1,000<br/> (72 to 157) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.32<br/> (0.90 to 1.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>954 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Numbers of non‐dialysis patients needing to commence dialysis</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1,000<br/> (19 to 75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.81<br/> (0.41 to 1.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>743 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number requiring transfusion</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1,000<br/> (56 to 136) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.86<br/> (0.55 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>774 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>CKD:</b> chronic kidney disease; <b>IV:</b> intravenous; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for imprecision </p> <p><sup>2</sup> Downgraded one level for likely publication bias </p> <p><sup>3</sup> Downgraded one level for high heterogeneity </p> <p><sup>4</sup> Downgraded one level for publication bias </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Patient‐centred outcomes for oral versus IV iron in adults and children with chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/full#CD007857-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007857-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Laboratory and pharmaceutical outcomes for adults and children with chronic kidney disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Laboratory and pharmaceutical outcomes for adults and children with CKD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults and children with CKD<br/> <b>Setting:</b> Nephrology departments<br/> <b>Intervention:</b> IV iron<br/> <b>Comparison:</b> oral iron </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral iron</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IV iron</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number achieving target Hb or increase ≥1 g/dL</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>317 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>542 per 1,000<br/> (453 to 646) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.71<br/> (1.43 to 2.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2206 (13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of bias (ROB) downgraded as little info on random sequence generation (RSG) and allocation concealment. Heterogeneity 60% </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hb: final or change (g/dL)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean Hb level was 0.72 g/dL higher with IV iron compared to oral iron (0.39 to 1.05 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3373 (31)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/31 are at ROB for RSG &amp;/or allocation concealment. Heterogeneity 94%</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ferritin: final or change (µg/L)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean ferritin level was 224.84 µg/L higher with IV iron compared to oral iron (165.85 to 283.83 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3389 (33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/13 are at ROB for RSG or allocation concealment. Heterogeneity 60%.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSAT: final or change (%)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean TSAT was 7.69% higher with IV iron compared to oral iron (5.1 to 10.28 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3089 (27)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/27 only are at low risk of bias and heterogeneity is 97%.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HCT (%)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean HCT was 1.18% higher with IV iron compared to oral iron (2.17 lower to 4.52 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 4 studies in this analysis, all with unknown risk of selection bias. Heterogeneity 96%. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ESA dose: final or change</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The SMD for ESA dose was 0.72 lower with IV iron compared to oral iron (0.31 to 1.12 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>522 (11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ROB downgraded as little information on RSG and Allocation concealment. Heterogeneity 77% </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>eGFR: final or change (mL/min)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>the mean eGFR was 0.83 mL/min higher with IV iron compared to oral iron (0.79 lower to 2.44 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1052 (8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Half of the studies are at ROB for RSG &amp; allocation concealment.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>CKD:</b> chronic kidney disease; <b>eGFR:</b> estimated glomerular filtration rate; <b>ESA:</b> erythrocyte‐stimulating agent; <b>Hb:</b> haemoglobin; <b>HCT:</b> haematocrit; <b>IV</b> : intravenous; <b>RR:</b> Risk ratio; <b>TSAT:</b> transferrin saturation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for risk of bias </p> <p><sup>2</sup> Downgraded one level for inconsistency </p> <p><sup>3</sup> Downgraded one level for imprecision </p> <p><sup>4</sup> Downgraded one level for likely publication bias </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Laboratory and pharmaceutical outcomes for adults and children with chronic kidney disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/full#CD007857-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007857-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Laboratory outcomes in dialysis and chronic kidney disease participants</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% CI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Hb (g/dL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39 to 1.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 to 1.77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28 to 0.55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Ferritin (µg/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>224.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165.8 to 283.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1027</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>233.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>163.4 to 303.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>213.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>123.7 to 302.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>TSAT (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3089</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.10 to 10.28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.89 to 17.22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.67 to 7.97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Achieving target Hb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.43 to 2.04</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.52 to 2.66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CKD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 to 1.97</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CKD ‐ chronic kidney disease; Hb ‐ haemoglobin; TSAT ‐ transferrin saturation</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Laboratory outcomes in dialysis and chronic kidney disease participants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/full#CD007857-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007857-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Subgroup analysis and meta‐regression to examine heterogeneity in haemoglobin meta‐analyses</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total studies (N)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SMD (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Dose IV iron/study month </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 400 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17 (‐0.18 to 0.52)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 400 to 700 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.29 to 1.24)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 700 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.41 to 1.06)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Dose IV iron (mg total dose)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 1000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.25 to 0.66)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 to 1999 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48 (0.11 to 0.84)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.04 to 1.73)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Oral dose iron/study month</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 4000 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.37 to 1.38)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 4000 and &lt; 6000 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.28 to 0.64)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 6000 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.16 to 0.59)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Dose oral iron (mg total dose)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 12,000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.38 to 0.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1200 to 30,000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.29 to 1.03)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 30,000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45 (‐0.05 to 0.94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Any ESA use </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No EPO</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57 (0.05 to 1.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPO</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.32 to 0.78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>ESA timing of use </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Start of study</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.08 to 0.72)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Before study</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57 (0.28 to 0.85)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CKD stage </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 to 5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.26 to 0.50)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (5D)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.37 to 1.24)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Study duration </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 2 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.35 to 0.75)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2 to ≤ 4 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74 (0.28 to 1.19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 4 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.002 to 0.91)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Intervention aim </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase Hb</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.51 to 1.50)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maintain Hb</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.09 (‐0.53 to 0.36)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Pharmaceutical company sponsorship</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.40 to 1.23)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sponsored</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38 (0.28 to 0.48)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Imputed SD</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not imputed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.42 (0.02 to 0.81)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imputed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.35 to 0.76)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CKD: chronic kidney disease; EPO ‐ erythropoietin; ESA: erythropoiesis‐stimulating agent; Hb: haemoglobin; SD: standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Subgroup analysis and meta‐regression to examine heterogeneity in haemoglobin meta‐analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/full#CD007857-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007857-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Subgroup analysis and meta‐regression to examine heterogeneity in ferritin meta‐analyses   </span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total studies (N)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Dose IV iron/study month</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 400 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.59 (0.73 to 2.44)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.02</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 400 to 700 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.62 (1.41 to 1.83)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt;700 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32 (0.85 to 1.78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Dose IV iron (mg total dose) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 1000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.67 (1.03 to 2.30)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 to 1999 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.83 to 1.42)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.27 (0.55 to 3.99)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Oral dose iron/study month</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;4000 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.44 (0.77 to 2.11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.04</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 4000 to &lt; 6000 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.43 (1.16 to 1.69)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 6000 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.16 (1.18 to 3.14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Dose oral iron (mg total dose) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 12,000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.44 (1.05 to 1.83)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12000 to 30,000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.69 (1.05 to 2.34)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 30,000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.79 (1.15 to 2.43)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Any ESA use </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No EPO</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.46 to 2.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPO</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.62 (1.28 to 1.96)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>ESA timing of use </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Start of study</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.75 (0.88 to 2.62)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Before study</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.64 (1.22 to 2.06)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CKD stage</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 to 5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.70 (1.29 to 2.11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (5D)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50 (1.07 to 1.92)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Study duration</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 2 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (0.86 to 1.49)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2 to ≤ 4 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.64 (1.45 to 3.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 4 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.54 (1.05 to 2.04)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Intervention aim</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase Hb</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>336 (84 to 588)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maintain Hb</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>282 (177 to 261)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Pharmaceutical company sponsorship </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.84 (1.31 to 2.37)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sponsored</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.36 (1.02 to 1.71)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Imputed SD</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not imputed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> ‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (0.51 to 1.86)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imputed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.63 (1.31 to 1.94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CKD: chronic kidney disease; EPO ‐ erythropoietin; ESA: erythropoiesis‐stimulating agent; Hb: haemoglobin; SD: standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Subgroup analysis and meta‐regression to examine heterogeneity in ferritin meta‐analyses   </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/full#CD007857-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007857-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Subgroup analysis and meta‐regression to examine heterogeneity in transferrin saturation meta‐analyses</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total studies (N)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SMD (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Dose IV iron/study month</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 400 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.39 to 1.00)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 400 to 700 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.14 to 0.78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 700 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.00 (0.55 to 3.45)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Dose IV iron (mg total dose)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 1000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.34 to 0.90)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 to 1999 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41 (0.07 to 0.74)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.5 (‐1.46 to 8.39)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Oral dose iron/study month</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 4000 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56 (0.25 to 0.86)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 4000 to &lt; 6000 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54 (0.20 to 0.87)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 6000 mg/month</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.64 (0.69 to 2.59)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Dose oral iron (mg total dose)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 12,000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56 (0.41 to 0.72)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1200 to 30,000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56 (0.00 to 1.13)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 30,000 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.59 (0.55 to 2.63)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Any ESA use</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No EPO</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.36 to 1.31)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPO</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.42 to 1.03)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>ESA timing of use </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Start of study</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29 (‐0.42 to 1.00)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Before study</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.51 to 1.20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CKD stage</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 to 5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.35, 0.74)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dialysis (5D)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.75 to 1.80)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Study duration</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 2 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56 (0.41, 0.72)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2 to ≤ 4 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34 (0.32 to 2.35)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 4 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 (0.16 to 1.18)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Intervention aim</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase Hb</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.59 (4.07 to 17.11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maintain Hb</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.28 (‐3.73 to 40.30)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Pharmaceutical company sponsorship</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.52 to 1.62)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sponsored</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 (0.34 to 0.71)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Imputed SD</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not imputed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 (‐0.24 to 0.77)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imputed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 (0.47 to 0.97)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CKD: chronic kidney disease; EPO ‐ erythropoietin; ESA: erythropoiesis‐stimulating agent; Hb: haemoglobin; SD: standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Subgroup analysis and meta‐regression to examine heterogeneity in transferrin saturation meta‐analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/full#CD007857-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007857-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Patient centred outcomes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1952</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.64, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.41, 7.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of non‐dialysis patients needing to commence dialysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>743</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.41, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number requiring transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.55, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Type of adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Allergic reactions/hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.56 [1.88, 6.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>954</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.90, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 All gastrointestinal adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.33, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.18, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1625</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.47, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Nausea and vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.45, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 Taste disturbances</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.78 [0.84, 16.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8 Iron overload</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.58 [0.81, 53.51]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Patient centred outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/references#CD007857-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007857-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Laboratory/pharmaceutical outcomes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number achieving target haemoglobin or increase ≥ 1 g/dL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.43, 2.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Haemoglobin: final or change (all patients) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.39, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Ferritin: final or change (all patients) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>224.84 [165.85, 283.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Transferrin saturation: final or change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3089</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.69 [5.10, 10.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Haematocrit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [‐2.17, 4.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 End of treatment or change in ESA dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.72 [‐1.12, ‐0.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 eGFR end or change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [‐0.79, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Laboratory/pharmaceutical outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007857.pub3/references#CD007857-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007857.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD007857-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD007857-note-0008">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007857-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007857-note-0007">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD007857-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="hu#CD007857-note-0020">Magyar</a> </li> <li class="section-language"> <a class="" href="ja#CD007857-note-0006">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD007857-note-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD007857-note-0004">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD007857-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007857-note-0002">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD007857-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007857\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007857\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007857\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007857\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007857\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007857\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007857\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007857\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007857\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007857\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007857\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007857\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007857\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007857\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007857\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007857\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007857\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007857\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=77cjsSG8&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007857.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007857.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007857.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007857.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007857.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718527807"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007857.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718527811"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007857.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dd286cdcdf401',t:'MTc0MDcxODUyOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 